Filed
Pursuant to Rule 424(b)(4)
Registration
Statement 333-233929
PROSPECTUS
natuR
INTERNATIONAL CORP.
235,579,089
Shares
Common
Stock
This
prospectus relates to the offer and sale from time to time of up to an aggregate of 235,579,089 shares of our common stock by
several selling stockholders identified in this prospectus. These shares consist of shares of our common stock issuable under
shares of Series A Preferred Stock and Series G Preferred Stock and warrants that we issued to the purchasers of the preferred
stock pursuant to private placements of our securities.
This
prospectus describes the general manner in which the shares of common stock may be offered and sold by the selling stockholders.
If necessary, the specific manner in which shares of common stock may be offered and sold will be described in a supplement to
this prospectus.
We
are not offering any shares of common stock for sale under this prospectus, and we will not receive any of the proceeds from the
sale or other disposition of the shares of common stock offered hereby by the selling stockholders.
Our
common stock is listed on the OTCQB under the symbol “NTRU.” On November 1, 2019, the closing price of the common
stock on the OTCQB was $0.1130.
Investing
in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 5 for a discussion of information
that should be considered in connection with an investment in our securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus is November 1, 2019
TABLE
OF CONTENTS
We
may provide a prospectus supplement containing specific information about the terms of a particular offering by the selling stockholder,
or its transferees. The prospectus supplement may add, update or change information in this prospectus. If information in a prospectus
supplement is inconsistent with the information in this prospectus, you should rely on the information in that prospectus supplement.
You should read both this prospectus and the information incorporated by reference and, if applicable, any prospectus supplement
hereto. See the sections “Where You Can Find More Information” and “Incorporation by Reference” in this
prospectus for more information.
Unless
the context requires otherwise, in this prospectus Natur International Corp. (“Parent”), and its subsidiaries, the
principal one of which is Natur CBD, BV (“Natur” or “Subsidiary”), shall collectively be referred to as
“NIC”, “Natur”, “the Company”, “we”, “us”, and “our” unless
otherwise noted.
Some
of our trademarks, including our product logo, are used in this prospectus, which are intellectual property owned by the Company.
This prospectus also includes trademarks, trade names, and service marks that are the property of other organizations. Solely
for convenience, our trademarks and trade names referred to in this prospectus appear without the TM symbol, but those
references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our
rights, or the right of the applicable licensor to these trademarks and trade names.
We
have not, and the selling stockholder has not, authorized anyone to provide you with information different from that contained
or incorporated by reference in this prospectus or in any supplement to this prospectus, and neither we nor the selling stockholder
take any responsibility for any other information that others may give you. This prospectus is not an offer to sell, nor is it
a solicitation of an offer to buy, the securities in any jurisdiction where the offer or sale is not permitted. You should not
assume that the information contained in this prospectus or any prospectus supplement is accurate as of any date other than the
date on the front cover of those documents, or that the information contained in any document incorporated by reference is accurate
as of any date other than the date of the document incorporated by reference, regardless of the time of delivery of this prospectus
or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those
dates.
PROSPECTUS
SUMMARY
The
following summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the
information you should consider before investing in our common stock. You should carefully read this prospectus in its entirety
before investing in our common stock, including the sections entitled “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and
related notes included elsewhere in this prospectus.
Overview
The
Company commenced its business in 2015 with the objective of becoming a leader in the “hi-tech health” food and beverage
marketplace; achieved by responding to changing market needs and staying continuously ahead of emerging trends. The Company also
intends to address the demand of the consumer for knowledge about what he/she consumes with a greater level of supply chain transparency.
It
is the commitment of the Company to integrate new manufacturing technologies with standard practices for superior products and
yet remain Naturalicious (natural & delicious) to build out its value chain for the burgeoning market of nutritious beverages
and healthy snacks with and without hemp-derived supplements or other nutrient dense fusions. Our products have been delivered
in the Netherlands and the United Kingdom, with plans on expanding to additional locations in Europe and ultimately the United
States. Our understanding and application of the technological aspects of manufacturing assures a pathogen-free food and beverage
experience that preserves the nutrients and enzymes to the maximum level possible, while retaining the raw fresh nature of the
products. The result is what we believe to be the best tasting product with the maximum “goodness” and highest nutrient
density -- something the consumer seeks more and more in our target markets.
The
clear differentiator of the Company is the “natur” brand which is supported by its disruptive marketing. Yes, we are
branding nature. The Company finds that consumers are interested in “what we produce and how we voice this to the market”
more than how it is made. From an investment perspective, this is a fundamental component of our business model as we do not have
to commit very significant capex to building our own modern production and bottling facilities to deliver into the increasing
demand for our product.
In
the future we anticipate delivering documented nutrigenomic (precision nutrition) properties that we believe will be an aid to
personal weight management, increase energy, lower cholesterol, counter sleep disorders and boost immunity response. We believe
that these product aspects will position the Natur products at the top of the European market at a mid-market price point. This
profile will be accessible internationally, as we have already undertaken preliminary discussions with distributors in major international
markets outside Europe.
Our
market profile will be further enhanced with the new Natur personalized snacking/juicing experience that will accelerate the trend
towards “snackification” already present in more mature markets in the United States and Europe.
Through
third party contract manufacturers, we apply patented technology to proprietary nutrient dense blends of fruit and vegetables,
adding hemp-derived supplements. These are bottled or packed with technically advanced food and product safety measures and in
some cases cold high-pressure processing to bring fresh tasting fruit, vegetable and hemp-derived supplement blends to market
through more than fifteen product types. These newly innovated products are brought to market, in Europe, through Natur’s
distribution channels of direct-to-business, direct-to-consumer and through select distributors.
The
Company focus, however, is evolving. At the onset of 2019, our product line up centered on a range of cold pressed juices and
healthy snacks. Beginning in the fourth quarter of 2018, and throughout the first half of 2019, the Company began to shift its
dependence on the legacy fruit and vegetable juices and snacks toward innovating a new line of hemp-derived natural food and beverage
products and functional health &wellness products, validated supply chains and direct to consumer business models. The Company
product value proposition will be to provide affordable, culturally relevant, authentic, fresh fruit, vegetable and hemp-derived
supplement consumer products to democratize clean, healthy, eating and drinking occasions, with plans to address the growing needs
for products that address other personal needs in health, wellness and beauty care.
The
Company is also pursuing opportunities to acquire other businesses that it believes are complementary to its legacy and new line
of products and facilitate and expand its distribution. On July 25, 2019, the Company acquired a controlling position in Temple
Turmeric, Inc., a Delaware corporation (“Temple”). Founded in 2009, Brooklyn, New York based Temple’s mission
is to bring the highest quality turmeric to the world by pioneering the first Turmeric-based ready to drink beverage line. Temple
has driven consumer understanding and demand for Turmeric as it has become more and more widely consumed through this decade.
Temple now adds adaptogenic herbs and ancient super food formulations to beverages with a turmeric foundation. The Company has
also entered into two letters of intent to explore the acquisition of businesses that would expand its distribution capabilities
and add products that include based on hemp-derived CBD or cannabidiol. Both of these potential transactions are in the due diligence
and pre-documentary stages, and may not be concluded or if concluded may not be on the terms as currently contemplated by the
letters of intent. There is no assurance that the Company will conclude any potential transactions.
Corporate
Information
Natur
operated as a private enterprise in the Netherlands from its founding in 2015 through November 13, 2018, when it was acquired
as a wholly owned subsidiary in a share exchange transaction by Future Healthcare of America.
Future
Healthcare of America was formed on June 22, 2012, and its operations were in the field of providing home healthcare and health
care staffing services in Wyoming and Montana commenced in 2014 after several corporation reorganization actions. During 2018,
Future Healthcare of America began to discontinue its home healthcare services due to demographic changes in its market areas
while it was negotiating and preparing to acquire Natur. This discontinuation of its healthcare operations and final liquidation
of the legacy business of Future Healthcare of America is expected to be complete in the third quarter of 2019.
On
December 28, 2018, Future Healthcare of America changed its corporate name to Natur International Corp. The trading symbol on
The OTC Market, as of January 7, 2019, is “NTRU.”
In
May 2019, the Amsterdam District Court confirmed the closure of the Company’s Netherlands subsidiary companies Natur Holding
BV, Hi-Tech Juices BV, NL Juices Retail BV and NL Juices Online BV, as part of the Company’s corporate restructuring plan.
Natur BPS BV, a recently formed Netherlands subsidiary of the Company, assumed the Natur Holding BV legacy business to complement
its product portfolio of functional products. This court process allows the historical business of the Company’s beverage
business to be continued and eliminates a substantial amount of the liabilities of the Company. As a result of the Petition the
control of Natur International Corp. over Natur Holding B.V., the former subsidiary, terminated for financial reporting purposes
and Natur International Corp.’s investment in it was deconsolidated as of May 1, 2019.
Our
executive offices are located at Jachthavenweg 124, 1081 KJ Amsterdam, The Netherlands. Our telephone number is 011-31-20-578-7730.
Our website address is int.natur.eu. Information on our website is not incorporated by reference into this Prospectus.
THE
OFFERING
The
following is a brief summary of certain terms of this offering by the Company.
Shares
offered by the Selling Stockholders:
|
|
235,579,089
shares
|
|
|
|
Offering Price:
|
|
Determined at
the time of sale by the selling stockholders.
|
|
|
|
Use of Proceeds:
|
|
We will not receive
any proceeds from the sale of the shares of common stock by selling stockholders covered by this prospectus.
|
|
|
|
Common Stock
Outstanding Prior to the Offering:
|
|
322,230,038 shares,
which excludes the (i) 79,105,403 shares issuable on conversion of the Class A Preferred Stock, (ii) 180,291,808 shares issuable
on conversion of Class D through Class G Preferred Stock and (iii) 223,502,535 shares issuable on exercise of outstanding
warrants.
|
|
|
|
Risk Factors:
|
|
Investing in
our securities involves a high degree of risk. See the section entitled “Risk Factors” of this prospectus.
|
|
|
|
OTCQB Trading
Symbol:
|
|
NTRU
|
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus of the Company contains “forward-looking statements,” within the meaning of Section 27A of the Securities
Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”). Forward-looking statements relate to future events or future performance and include, without
limitation, statements concerning the Company’s business strategy, future revenues, market growth, capital requirements,
product introductions and expansion plans and the adequacy of the Company’s funding. Other statements contained in this
prospectus that are not historical facts are also forward-looking statements. The Company has tried, wherever possible, to identify
forward-looking statements by terminology such as “may,” “will,” “could,” “should,”
“expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates” and other comparable terminology.
The
Company cautions investors that any forward-looking statements presented in this prospectus, or that the Company may make orally
or in writing from time to time, are based on the beliefs of, assumptions made by, and information currently available to, the
Company. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends,
uncertainties and factors that are beyond the Company’s control or ability to predict. Although the Company believes that
its assumptions are reasonable, they are not a guarantee of future performance, and some will inevitably prove to be incorrect.
As a result, the Company’s actual future results can be expected to differ from its expectations, and those differences
may be material. Accordingly, investors should use caution in relying on forward-looking statements, which are based only on known
results and trends at the time they are made, to anticipate future results or trends. Certain risks are discussed in this prospectus
and also from time to time in the Company’s other filings with the Securities and Exchange Commission (the “SEC”).
This
prospectus and all subsequent written and oral forward-looking statements attributable to the Company or any person acting on
its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. The
Company does not undertake any obligation to release publicly any revisions to its forward-looking statements to reflect events
or circumstances after the date of this prospectus.
RISK
FACTORS
Investing
in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below,
together with all of the other information in this prospectus, including our consolidated financial statements and related notes,
before investing in our common stock. If any of the following risks materialize, our business, financial condition, operating
results and prospects could be materially and adversely affected. In that event, the price of our common stock could decline,
and you could lose part or all of your investment.
Risks
Related to Our Business
Because
our business and product marketing plans may be unsuccessful, we may not be able to continue operations as a going concern.
Our ability to continue as a going concern and expand our business is dependent upon our generating cash flow that is sufficient
to fund operations or finding adequate investment or borrowed capital to support our operations. Our business and product marketing
plans may not be successful in achieving a sustainable business and generating revenues. We have no arrangements in place for
sufficient financing to be able to fully implement our business plan. If we are unable to continue as planned currently, we may
have to curtail some or all of our business plan and operations. In such case, investors will lose all or a portion of their investment.
The
audit report for our financial statements have a “going concern” disclosure. At the time of the audit
report of our financial statements in March 2019, the Company concluded that its negative working capital and decreased cash flows
from operations are conditions that raised substantial doubt about the Company’s ability to continue as a going concern.
Since that date, the Company has sold a significant amount of equity securities and its financial position allows the management
to currently conclude that there is no going concern based on its operations and financial results set forth in the most recent
quarterly report. Notwithstanding the current financial position, the Company will need to raise additional funds for its operations
and expansion into various lines of business. There is no assurance that the Company will not continue to have a going concern
note or disclosure.
The
Company is undertaking a corporate reorganization and debt restructuring to reduce its debt burden, which if unsuccessful will
have a continuing material effect on its ability to raise capital and fund operations. The Company has taken steps to
restructure its debt, including the reorganization of a former subsidiary through a court sanctioned petition in The Netherlands,
and continuing negotiations to restructure retained and new debt into equity. The restructuring has included and will include
raising new capital. No assurance can be given that the Company will reorganize its debt sufficiently to improve its overall debt
position and be able to continue its business plan as currently structured and as it is hoped for the future.
Integrating
the acquisition of companies and their products into our product line will require substantial effort and expense. We
have completed an acquisition and are contemplating growth through future acquisitions. The potential acquisitions that are being
contemplated are subject to due diligence review, negotiation of definitive agreements and conclusion of various financial terms.
There is no assurance that the Company will concluded any contemplated acquisition. Any acquisition that may be concluded will
put additional time and financial demands on the personnel and resources of the Company. There is no assurance that the Company
overall will be able to meet these demands on a timely basis or at all, so as to achieve an integrated, consolidated operation.
If not, the Company will experience disruption and expense on which it may not achieve its expected return. As a result, the financial
results of the Company may be impaired.
Acquisitions
of existing businesses have many risks, many of which cannot be anticipated. Acquisitions of other businesses, assets
or products typically involve a number of special risks, including the diversion of management’s resources, issues related
to the assimilation of the operations and personnel of the acquired businesses, potential adverse effects on operating results
and amortization of acquired intangible assets. In addition, gross margins may be negatively impacted to the extent that gross
margins on acquired product lines are lower than our own product’s average gross margins. If we seek and find attractive
acquisition candidates, we may not be able to complete the transaction on acceptable terms, to successfully integrate the acquisition
into our operations, or to assure that the acquisition won’t have an adverse impact on our operations. Any plans to invest
in new markets or to consider additional acquisitions may cause us to seek additional financing that may be dilutive to current
investors or result in a higher debt-to-equity ratio than would otherwise be the case. Any financing we obtain may not be on terms
favorable to us, even if it is available.
Our
products are new to the marketplace, and may not achieve acceptance. All of our products are recent in their development
and conception. Therefore, we will need to spend substantial effort and resources on introducing them to the marketplace. Consumers
may not find our products acceptable and our sales objectives may not be achieved. The acceptance of any new consumer product
is speculative. If our products do not achieve market acceptance, we will suffer a significant loss and our financial position
will be adversely impacted.
Our
products have a limited shelf life. The Natur products generally are made with fresh ingredients; therefore those particular
products have a limited shelf life and must be transported and stored in cooled locations and consumer shelving. In order to maintain
our “day-of-production” flavor, we further restrict the shelf life of products through early expiration dates. The
restricted shelf life means that we don’t have any significant finished goods inventory and our operating results are highly
dependent on our ability to accurately forecast near term sales in order to adjust fresh fruit and vegetable sourcing and production.
We do not have a long history of forecasting product demands, and we may not be able to accurately forecast product demand in
the future. When we don’t accurately forecast product demand, we anticipate being either unable to meet higher than anticipated
demand or producing excess inventory that cannot be profitably sold.
Our
trade partners may have the right to return unsold products. Natur may enter into agreements with our trade partners that
provide a right to return unsold products. Due to the limited shelf life Natur might need to destroy the products because they
can’t be sold anymore. This right will reduce the income due to Natur for the destroyed products, which will have a negative
impact on its earnings.
Cost
sensitivity. Our profitability is highly sensitive to increases in raw materials, labor, shipping and other operating
costs. Unfavorable trends or developments related to inflation, raw material supply, labor and employee benefit costs, including
increases in hourly wage and minimum unemployment tax rates, rent increases resulting from the rent escalation provisions in our
leases, and the availability of employees may also adversely affect our results.
Typical
of smaller companies at the early stage of development, we expect our quarterly results to fluctuate. Due to our limited
scale and the need for expansion we expect that our results of operations will fluctuate on a quarterly basis and due to the total
size of the Company, which may have a large effect on our total financial results.
Claims
related to product liability. Because our products are not irradiated or chemically treated, they are perishable and contain
certain naturally occurring microorganisms. We may receive complaints from consumers regarding ill effects allegedly caused by
our products. These claims may result in monetary damages payable to persons that have had adverse reactions to our products.
Also, these claims may result in adverse publicity. Either of these outcomes could seriously harm our business, our business reputation,
sales and results of operations. Although we maintain product liability insurance, our coverage may not be sufficient to cover
the cost of defense or related damages in the event of a significant product liability claim.
Claims
related to our product assertions. Our products are sold as natural, cold pressed fruit and vegetable products containing
substantial amounts of various ingredients. We also make various other assertions about our products, such as no additives, no
sugar and no preservatives. Consumers and other consumer groups often challenge these types of claims. The law in the area of
what is natural and other aspects of our marketing our products is not settled and, in most cases, not statutory. In the U.S.,
there is a mixture of federal and state law that is not consistent. Therefore, we may be subject to various claims about our advertising
and our products from time to time, which may cause us to pay monetary damages, change our advertising or change our products.
Any of these actions may result in adverse consequences to our operations, our product placement and results of operations.
Sources
of raw materials. We depend upon the fruit and vegetable produced in various locations, with a current dependence on raw
materials from Spain and a few other countries. The farming locations and the agricultural production may be damaged or limited
as a result of windstorms, pests or plant disease. As our products are meant to be healthy options, our suppliers of raw materials
are not able to use many agricultural chemicals, and therefore, they may not be able to maintain production in the quantities
that we will need from time to time. Any decrease in the supply of fresh fruit and vegetables could have a material adverse effect
on our business and results of operations.
We
depend on one supplier for a significant amount of our raw materials and product development. We rely on one supplier
for a majority of our raw materials. We also are largely dependent on this supplier for important aspects of our product development.
This supplier is a significant shareholder of the Company. In the believed unlikely event that this supplier is unable to provide
us with the current level of raw materials and any increase in the raw materials due to an increase in our product requirements,
our business may be adversely impacted. Additionally, if we are not able to obtain the product development services that are currently
provided, our business development and the innovation of our products will suffer, which may have an adverse impact on or business.
We do not have any alternative suppliers or product developers from which we can obtain the quality or quantity of raw materials
and services.
Concentration
of production capacity. Virtually all of our juice production capacity is located at Murcia, Spain, which includes our
cold pressing, blending and bottling capability. Because currently we maintain minimal finished goods inventory at our production
location as part of our “day-of-production” production system, we could be challenged to continue to produce an adequate
supply of products in the event that production at or transportation from our production facility were interrupted by fire, flood
or other natural disasters, work stoppages, regulatory actions or other causes. Any significant interruption would seriously harm
our business and results of operations.
Currently,
our products are distributed in a limited geographic area. Our wholesale accounts and retail trade partners are located
in a few countries within the European Union. Most of our sales are in the metropolitan areas within that region. Due to this
concentration, natural disasters, economic downturns and other conditions affecting the region may adversely affect our product
distribution and our business generally, and our results of operations.
Brexit
may have an adverse impact on the Company. The consequences to the Company, if any, of Brexit cannot be determined at
this time. If there is an impact, it will depend on the quantity of products that are being sold by the Company to distributors
and consumers located in the United Kingdom, and what those sales represent of the overall sales and revenues of the Company.
Some of the consequences of Brexit may include (i) delays in the shipping and delivery of our products due to border conditions,
which delay may have an impact on the limited shelf life of our products, thereby limiting their marketability, (ii) increased
costs due to duties and other imposts imposed on the importation of goods into the United Kingdom, and (iii) other non-tariff
barriers that the United Kingdom may impose, such as changing regulations concerning our products that are different than those
of the European Union.
We
have a limited range of products and therefore have a limited diversification. Natur’s business is vertically integrated
and centered around a limited number of products, being all-natural super-premium beverages and healthy snacks, sold primarily
through our direct-store-delivery system and a limited number of distributors. Any significant disruption in our product supply
to the consumer and any decrease in the consumption of our products generally or specifically would have an adverse effect on
our business and results of operations.
Risks
related to outsourced product development. The Company obtains its finished products from third-party suppliers. Following
any anticipated or unanticipated change, shortages could result in an increase of the costs of goods, or adversely affect the
Company’s ability bring a product to market. Price increases due to inflationary pressures or supply side shortages from
a contract packer would directly affect the Company’s profitability if increases were not successfully passed on to customers.
Risks
related to expansion of our product lines and distribution. Our continued growth depends in part upon our ability to expand
into new geographic areas, either through internal growth or by acquisition. We are also beginning to expand into hemp-based products.
Overall, our growth in the range of products depends on having the necessary capital, being able to increase production, finding
raw materials that satisfy our criteria, expanding distribution channels, and securing consumers through our marketing efforts
and those of others. Due to the extent of our operating losses in recent years, we currently anticipate limited expansion in during
the next fiscal year and thereafter. There can be no assurance that we will expand into new product lines or geographic areas
or be able to invest in new markets. There can be no assurance that if expansion or investment is undertaken that it will be successful
or that expansion can be accomplished on a profitable basis. Demands on management and working capital costs resulting from the
perishable nature of our products may limit the ability, or increase the cost of, expansion into new regions. Furthermore, consumer
tastes vary by region, and there can be no assurance that consumers located in other regions will be receptive to our products.
Some
of our products will have hemp derived elements. As our product lines evolve, some of them will contain hemp derived elements.
These products are currently only being designed for distribution in Europe. The regulatory regime for products with these elements
is evolving. There is no comprehensive body of regulations at this time. It is currently possible to distribute these types of
products but there may be regulatory limitations in the future that restrict or eliminate the possibility of their distribution.
Regulation may be either EU wide or member state or locally legislated, and the regulation may be limited to only some kinds of
products and not others, such as limited to ingested products. If future regulation is enacted that affects any of our products,
we may have to discontinue their manufacture and distribution, in which case we would lose revenue and otherwise suffer financial
losses.
Competition.
We currently compete with the following products distributed in our current markets: Innocent, Naked Juice, Savsé,
Coolbest and a retailer’s own label. In the near future, we expect to expand into the German, Moldavian, French, Swiss,
and United States markets and we will encounter further competition from competitors that are active in those markets. New products
are introduced all the time, many of which will be directly competitive to our products or may be competitive on a tangential
basis, but in all cases likely diluting our place in the market as a provider of cold-pressed juice and other fruit and vegetable
products. There are efforts by large established companies, regional companies and local producers to address the healthy living
and aging consumer goods products, such as Odwalla and Naked Juice. We also face competition from local outlets selling smoothie
products and other fresh squeezed products and white label products offered by chain outlets. While we believe that we compete
favorably with our competitors on factors including quality, nutritional integrity, food safety, merchandising, service, sales
and distribution, multiple flavors, brand name recognition and loyalty, our products are typically sold at prices higher than
most other competing beverage and bar products. Significant competitive pressure from these or other companies could negatively
impact our sales and results of operations.
Shifting
Consumer Tastes. Consumer acceptance and desire for existing and emerging healthy foods, snacks and beverages are continually
changing and are extremely difficult to predict. The Company is striving to be on the right side of this macro shift at all times.
Increased consumer concerns about nutrition, healthy diets (some known as Paleo, KETO, Whole30, and GAPS regimens) and food allergies
are ever changing. This brings to our business the risk that sales of our products may decline due to perceived health concerns,
changes in consumer tastes or other reasons beyond the control of the Company. The consumer acceptance and resulting success of
new products will be one of the keys to the success of the Company’s business plan. There can be no assurance that the Company
will succeed in the development of any new products or that any new products developed by the Company will achieve market acceptance
or generate meaningful revenue for the Company.
Brand
Image. The Company’s success is tied to its ability to maintain the brand image and product quality for the Company’s
existing products, new products and brand extensions. The Company can give no assurance that the Company’s advertising,
marketing and promotional programs will have the desired impact on its products’ brand image and on consumer preferences.
Real or imagined product quality issues or contaminations, even if blatantly false, could adversely affect to the Company’s
profitability and brand image. There is no assurance that the Company will not be party to product liability litigation. If the
Company experiences product liability claims, the Company’s financial condition and business operations could be materially
adversely affected.
Marketing
Costs. Adequate retail authorization, distribution and shelf space for product availability, particularly in hypermarkets,
are required for success in marketing health food, snack and beverage products. These authorizations can require additional marketing
support spending to obtain additional shelf space. In general, this is a competitive condition the Company will meet, or choose
otherwise. The Company may incur significant shelf space or other promotional costs as a necessary condition of entering into
competition or maintaining market share in particular markets or stores, and, if incurred, such costs may materially affect the
Company’s financial performance.
Our
products may be contaminated, tainted or damaged by third parties acting beyond our control. Third parties, acting on
behalf of the Company, manufacture and physically distribute the Company’s products. Therefore, our products could become
contaminated, tainted or damaged by these other parties whose actions are beyond the control of the Company. The third parties
that we engage for manufacturing and distributing our product and the retail outlets for our products must take adequate precautions
not to contaminate, taint or damage the Company’s products. Although we have established handling protocols and we believe
our manufacturer, distributors and retailers will follow these protocols and use good commercial sense in handling a perishable
product, the Company cannot be certain that the its products will not be damaged in the ordinary course of business. In the event
the Company’s products are damaged, contaminated or tainted, the Company may experience an adverse financial effect due
to lost sales, the cost of a product recall, and product liability damages and an adverse business effect due to reputational
damage and reluctance of consumers to trust our products. The Company, at this time, cannot estimate any cost or liability amounts
that the Company might incur in connection damaged, contaminated or tainted products.
We
are dependent on the continued services and on the performance of our senior management and other key personnel. The loss
of the services of any of our executive officers, such as Paul Bartley, our Chief Executive Officer, or Ruud Huisman, our Chief
Financial Officer, or other key employees could have a material adverse effect on our business, operating results and financial
condition. We also depend on our ability to identify, attract, hire, train, retain and motivate other highly skilled technical,
managerial, sales, operational, business development and customer service personnel. Competition for such personnel is intense,
and there can be no assurance that we will be able to successfully attract, assimilate or retain sufficiently qualified personnel.
The failure to attract and retain necessary skilled personnel could have a material adverse effect on our business, operating
results and financial condition.
If
the protection of trademark, brands and other proprietary rights is inadequate, we could lose our proprietary rights and experience
a loss of revenues. We rely on a combination of copyright, trademark, trade dress and trade secret laws, employee and
third-party non-disclosure and invention assignment agreements and other methods to protect our proprietary technology. Despite
these precautions, it may be possible for unauthorized third parties to obtain and use information that we regard as proprietary.
In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the United
States. There can be no assurance that the steps taken by us to protect our proprietary rights will be adequate or that third
parties will not infringe or misappropriate our trademarks, copyrights and similar proprietary rights. If we resort to legal proceedings
to enforce our IP rights, those proceedings could be expensive and time-consuming and could distract our management from our business
operations.
Intellectual
property claims against us can be costly and could impair our business. We cannot predict whether third parties will assert
claims of infringement against us, or whether any future assertions or prosecutions will harm our business. Although we take significant
steps to make sure that our products do not infringe on the rights of others, there is always the possibility that another person
or company may assert that we infringed on their proprietary rights. If we are forced to defend against any such claims, whether
they are with or without merit or are determined in our favor, we may face costly litigation, diversion of management, or product
launch delays, any of which could adversely impact our business. As a result of such a dispute, we may have to enter into royalty
or licensing agreements. Such royalty or licensing agreements, if required, may be unavailable on terms acceptable to us, if at
all. If there is a successful claim of intellectual property infringement against us and we are unable to license the infringed
or similar IP on a timely basis, our business could be impaired.
Government
regulations may increase our costs of doing business. The adoption or modification of laws or regulations relating to
our business could harm our operating results and financial condition by increasing our costs and administrative burdens. Laws
and regulations directly applicable to our business are becoming more diverse and prevalent in all the markets where we are likely
to distribute our products. We must comply with regulations in Europe, the United States, as well as any other regulations adopted
by other countries where we do business. Compliance with any newly adopted laws or regulations may prove difficult for us and
may harm our business, operating results and financial condition.
We
will require additional capital in the future, which may not be available on terms acceptable to us, or at all. Our future
liquidity and capital requirements will depend upon numerous factors, including the success of our products and market developments.
We will to need to raise funds through public or private financings, strategic relationships or other arrangements. There can
be no assurance that such funding, will be available on terms acceptable to us, or at all. If funds are raised through the issuance
of equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution
in net book value per share, and such equity securities may have rights, preferences or privileges senior to those of the holders
of our existing capital stock. Furthermore, any debt financing, if available, may involve restrictive covenants that may limit
our operating flexibility with respect to certain business matters. If adequate funds are not available on acceptable terms, we
may not be able to continue to develop or enhance our products, take advantage of future opportunities or respond to competitive
pressures, any of which could have a material adverse effect on our business, operating results and financial condition.
Risks
Related to Ownership of Our Common Stock
There
is not an active market for our common stock. There has been no sustained activity in the market for our common stock
and we cannot provide any assurances that an active market for our common stock will ever develop. Investors should understand
that there may be no alternative exit strategy for them to recover or liquidate their investments in our common stock. Accordingly,
investors must be prepared to bear the entire economic risk of an investment in the Company for an indefinite period of time.
If an active market ever develops for our common stock, we anticipate that our then financial condition and product offerings
will greatly impact the market value of our common stock. The market value at any point in time may not reflect the value of our
business or our business prospects.
We
are subject to the reporting requirements of the United States securities laws, which will require expenditure of capital and
other resources. We are a public reporting company subject to the information and reporting requirements of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and other federal securities laws, including, without limitation,
compliance with the Sarbanes-Oxley Act (“Sarbanes”). The costs of preparing and filing annual and quarterly reports,
proxy statements and other information with the SEC and furnishing audited reports to stockholders will cause our expenses to
be substantially higher than they would otherwise be if we were privately-held. It will be difficult, costly, and time-consuming
for us to develop and implement internal controls and reporting procedures required by Sarbanes, and we will require additional
staff and third-party assistance to develop and implement appropriate internal controls and procedures.
Because
we are subject to the “penny stock” rules as our shares are quoted on an over-the-counter market, the level of trading
activity in our stock may be reduced. If an active trading market does develop for our stock, it is likely that our stock
will be subject to the regulations applicable to penny stocks. The regulations of the SEC promulgated under the Exchange Act that
require additional disclosure relating to the market for penny stocks in connection with trades in any stock defined as a penny
stock. The SEC regulations define penny stocks to be any non-exchange equity security that has a market price of less than $5.00
per share, subject to certain exceptions. Unless an exception is available, those regulations require the broker-dealer to deliver,
prior to any transaction involving a penny stock, a standardized risk disclosure schedule prepared by the SEC, to provide the
customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson
in the transaction, monthly account statements showing the market value of each penny stock held in the purchaser’s account,
to make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s
written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity,
if any, in the secondary market for a stock that becomes subject to the penny stock rules. Consequently, these penny stock rules
may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage market investor
interest in and limit the marketability of our Common Stock.
In
addition to the “penny stock” rules promulgated by the Securities and Exchange Commission, the Financial Industry
Regulatory Authority, Inc. (“FINRA”) has adopted rules that require that in recommending an investment to a customer,
a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending
speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain
information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations
of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for
at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our
Common Stock, which may limit an investor’s ability to buy and sell our stock.
We
may not be able to attract the attention of major brokerage firms or securities analysts in our efforts to raise capital.
In due course, we plan to seek to have our common stock quoted on a national securities exchange in the United States. There can
be no assurance that we will be able to garner a quote for our common stock on an exchange. Even if we are successful in doing
so, security analysts and major brokerage houses may not provide coverage of us. We may also not be able to attract any brokerage
houses to conduct secondary offerings with respect to our securities.
Because
future sales by our stockholders could cause the stock price to decline, our investors may lose money on their investment in our
common stock. No predictions can be made of the effect, if any, that market sales of shares of our common stock or the
availability of such shares for sale will have on the market price prevailing from time to time. Nevertheless, sales of significant
amounts of our common stock could adversely affect the prevailing market price of our common stock, as well as impair our ability
to raise capital through the issuance of additional equity securities.
Risks
Relating to this Offering
Without
a successful offering, we may not be able to fully implement our business plan. We need to sell the shares being sold
in this offering in order to fully implement our business plan of restructuring. If we do not sell a sufficient number of shares,
we may have to curtail aspects of our business plan or abandon them altogether. Revising the business plan may result in our not
being able to continue in business as planned.
This
offering is being made without an underwriter; therefore, it is possible that we will not sell all the shares offered. The
offering is self-underwritten. This means we will not engage the services of an underwriter to sell the shares. We intend to sell
the shares through the efforts of one of our officers, and we will not pay him any commissions. Without the services of a professional
finance firm, it is possible that we will not sell all the shares offered. If we do not sell the full number of shares being offered,
we may have to modify ours business plan, which may adversely affect our financial condition.
This
offering is being made without any escrow of investor funds or provisions to return funds. When investors purchase our
common stock, the purchase price will not be placed in any escrow account and will become a general asset of the Company. There
is no minimum offering amount. Sales will be made on a rolling basis. There are no investor protections for the return of invested
monies.
Because
there is no minimum offering requirement, early investors in this offering bear a disproportionate risk of the Company being able
to implement its business plan on the basis of shares actually sold. This offering is made on a rolling basis with no
minimum amount having to be raised. Therefore, early investors will participate in the offering with no assurance that a sufficient
amount of shares will be sold for the Company to fully implement its business plan. If an insufficient number of shares are sold
in this offering, we may have to limit the extent to which we will be able to implement our business plan, but investors will
not be able to get their investment funds back.
Our
officers will have broad discretion in the use of proceeds from this offering. Although we intend to use the net cash
proceeds from this offering for working capital and other general corporate purposes, the use of any cash funds received can be
changed by management at any time. The amount allocated to a use also may be changed depending on management’s determination
about the best use of the funds at a particular time. Therefore, investors must rely entirely on the business judgment of management
in the use of the offering proceeds and to determine how and what portions of the business plan will be implemented.
USE
OF PROCEEDS
We
will not receive any proceeds from the sale of shares of common stock by the selling stockholders.
If
the selling stockholders exercise their warrants for cash, the Company will receive up to approximately $4,632,000. Any funds
received from the exercise of these warrants will be used for working capital.
SELLING
STOCKHOLDER
2018
Private Placement Financing
On
September 21, 2018, the Company entered into a Securities Purchase Agreement (the “SPA”) pursuant to which it sold
to Alpha Capital Anstalt (“Alpha”) 2,469.131 shares of non-voting, convertible Series A Preferred Stock, each share
convertible into approximately 33,000 shares of Common Stock at the rate of $.030303 per share. Alpha also purchased two warrants,
one pursuant to the SPA that is exercisable for 33,000,000 shares of Common Stock at an exercise price of $.060606 per share and
one pursuant to a debt cancellation agreement exercisable for 6,000,000 shares of Common Stock at an exercise price of $.15 per
share. The aggregate purchase price for the Series A Preferred Stock and the two warrants was $2,000,000 in cash and conversion
of approximately $769,000 of principal debt and interest due to Alpha from the Company under a prior loan agreement. Subsequently,
Alpha converted a number of its shares of Series A Preferred Stock and the Company and Alpha negotiated to reduce the exercise
price on 16,500,000 of the shares underlying the original 33,000,000 share warrant to $.0304 per share.
In
connection with the SPA, the Company and Alpha also entered into a registration rights agreement providing for the registration
for re-sale by Alpha of the Common Stock issuable upon conversion of the Series A Stock and upon exercise of the two warrants.
We were committed to file the registration statement no later than January 11, 2019 and to cause the registration statement to
become effective no later than the 60th calendar day following the filing date (or, in the event of a “full review”
by the Securities and Exchange Commission (“SEC”), the 90th calendar day following the filing date). We are also committed
to maintain as current the registration statement for the resale by Alpha of the registered Common Stock. The registration rights
agreement provides for liquidated damages upon the occurrence of certain events, including our failure to file the registration
statement or cause it to become effective by the deadlines or to maintain it as a current registration statement. The amount of
liquidated damages payable to Alpha would be 2% of the aggregate amount invested by Alpha for each 30-day period, or pro rata
portion thereof, during which the default continues, up to a maximum amount of 10% of the aggregate amount invested by Alpha.
We filed this registration statement of which this prospectus is a part with the SEC pursuant to the registration rights agreement.
June
2019 Private Placement Financing
In
June 2019, the Company entered into several Securities Purchase Agreements (the “June SPA”) pursuant to which it sold
Mr. Ranny Davidoff, Arcade Dynamic Event Fund Ltd., and Atlantic Global Fund B.V. of an aggregate of 58,736.843 of Series G Preferred
Stock which is convertible into 58,736,843 shares of common stock and warrant to purchase 58,736,843 shares of common stock. The
aggregate purchase price was $2,232,000 for the securities, for an effective conversion rate per share of $0.038. The warrants
are exercisable at a per share price of $0.038. In connection with the June SPA, the Company also entered into a registration
rights agreement with the purchasers providing for the registration for re-sale of the common stock issuable upon conversion of
the Series G Stock and upon exercise of the warrants issued to the purchasers.
Selling
Stockholder Table
The
following table sets forth for the selling stockholder, the name, the number and percentage of shares of common stock beneficially
owned as of October 21, 2019, the maximum number of shares of common stock that may be offered pursuant to this prospectus and
the number and percentage of shares of common stock that would be beneficially owned after the sale of the maximum number of shares
of common stock, and is based upon information provided to us by the selling stockholder for use in this prospectus. The information
presented in the table is based on 322,230,038 shares of our common stock outstanding on October 21, 2019.
|
|
Shares Beneficially Owned Before Offering(1)
|
|
|
Maximum Number of
Shares to be Sold
|
|
|
Shares Beneficially Owned After the Sale of the Maximum Number of Shares
|
|
NAME OF SELLING STOCKHOLDER
|
|
Number
|
|
|
Percentage
|
|
|
Hereunder
|
|
|
Number
|
|
|
Percentage
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpha Capital Anstalt(2)
|
|
|
118,105,403
|
|
|
|
9.99
|
%
|
|
|
118,105,403
|
|
|
|
0
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ranny Davidoff
|
|
|
52,631,580
|
|
|
|
15.66
|
%
|
|
|
52,631.580
|
|
|
|
0
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arcade Dynamic Event Fund Ltd.
|
|
|
23,578,948
|
|
|
|
6.81
|
%
|
|
|
23,578,948
|
|
|
|
0
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Atlantic Global Fund B.V.
|
|
|
17,684,210
|
|
|
|
5.20
|
%
|
|
|
17,684.210
|
|
|
|
0
|
|
|
|
*
|
|
|
*
|
Represents
beneficial ownership of less than one percent.
|
|
(1)
|
Beneficial
ownership and percentage ownership are determined in accordance with the rules of the Securities and Exchange Commission. In calculating
the number of shares beneficially owned and the percentage ownership of a selling stockholder, shares underlying convertible securities
held by the selling stockholder that are either currently convertible or exercisable or convertible or exercisable within 60 days
are deemed outstanding.
|
|
(2)
|
Alpha
holds 2,397.131 shares of Series A Preferred Stock which are currently convertible into an aggregate of 79,105,403 shares of common
stock. Alpha also holds two warrants to acquire up to 39,000,000 shares of common stock. The total number of shares of common
stock that Alpha is able to acquire is 118,105,403 shares. Under the terms of the Series A Preferred Certificate of Designation
and the terms of the warrants, the holder thereof may not own in excess of 9.9% of the common stock of the Company. The address
for Alpha Capital Anstalt is Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein. Konrad Ackermann holds voting and dispositive
power over such shares.
|
|
(3)
|
Mr.
Davidoff holds 26,315.790 shares of Series G Preferred Stock which are currently convertible into an aggregate of 26,315,790
shares of common stock and a warrant to acquire up to 26,315,790 shares of common stock. The total number of shares of common
stock that Mr. Davidoff is able to acquire is 52,631,580 shares. The address for Mr. Davidoff is, 5 Park Place, Rue de la Impasse,
98000 Monaco.
|
|
(4)
|
Arcade
Dynamic event Fund Ltd. holds 11,789.474 shares of Series G Preferred Stock which are currently convertible into an aggregate
of 11,789,474 shares of common stock. The fund also holds a warrant to acquire up to 11,789,474 shares of common stock.
The total number of shares of common stock that the fund is able to acquire is 23,578,948 shares. The address for the fund is
Building 2, Caves Village, Nassau, The Bahamas, and Alessandro Russo holds voting and dispositive power over such shares.
|
|
(5)
|
Atlantic Global Fund
B.V. holds 8,842.105 shares of Series G Preferred Stock which are currently convertible into an aggregate of 8,842,105
shares
of common stock. The fund also holds a warrant to acquire up to 8,842,105 shares of common stock. The total
number
of shares of common stock that the fund is able to acquire is 17,684,210 shares. The address for the fund is Pareraweg 45,
Willemstad, Curacao, Dutch Antilles
and
Mr. Eric Andersen holds voting and dispositive power over such shares.
|
PLAN
OF DISTRIBUTION
Each
selling stockholder, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares
of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of its shares of common stock on
any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may
be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying
prices determined at the time of sale, or at negotiated prices.
Each
selling stockholder may use any one or more of the following methods when disposing of shares or interests therein:
|
●
|
ordinary brokerage transactions and transactions
in which the broker-dealer solicits purchasers;
|
|
●
|
block trades in which the broker-dealer will
attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
|
|
●
|
purchases by a broker-dealer as principal and
resale by the broker-dealer for its account;
|
|
●
|
an exchange distribution in accordance with
the rules of the applicable exchange;
|
|
●
|
privately negotiated transactions;
|
|
●
|
short sales effected after the date the registration
statement of which this prospectus is a part is declared effective by the SEC;
|
|
●
|
through the writing or settlement of options
or other hedging transactions, whether through an options exchange or otherwise;
|
|
●
|
broker-dealers may agree with the selling stockholder
to sell a specified number of such shares at a stipulated price per share; and
|
|
●
|
a combination of any such methods of sale.
|
Each
selling stockholder may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned
by it and, if it defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the
shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3)
or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee
or other successors in interest as a selling stockholder under this prospectus. Each selling stockholder also may transfer the
shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be
the selling beneficial owners for purposes of this prospectus.
In
connection with the sale of our common stock, each selling stockholder may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. Each selling stockholder may also sell shares of our common stock short and deliver these securities to close out
its short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. Each selling
stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or the creation
of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).
The
aggregate proceeds to each selling stockholder from the sale of the common stock offered by it will be the purchase price of the
common stock less discounts or commissions, if any. Each selling stockholder reserves the right to accept and, together with its
agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through
agents. We will not receive any of the proceeds from the sale of common stock by the selling stockholder.
Each
selling stockholder also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under
the Securities Act of 1933, provided that they meet the criteria and conform to the requirements of that rule.
Each
selling stockholder and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests
therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions,
concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities
Act. Any selling stockholder who is an “underwriter” within the meaning of Section 2(11) of the Securities Act will
be subject to the prospectus delivery requirements of the Securities Act.
To
the extent required, the shares of our common stock to be sold, the name of each selling stockholder, the respective purchase
prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with
respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective
amendment to the registration statement that includes this prospectus.
In
order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only
through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has
been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied
with.
We
have advised each selling stockholder that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales
of shares in the market and to the activities of the selling stockholder and its affiliates. In addition, to the extent applicable,
we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholder
for the purpose of satisfying the prospectus delivery requirements of the Securities Act. Each selling stockholder may indemnify
any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities
arising under the Securities Act.
We
have agreed to indemnify each selling stockholder against liabilities, including liabilities under the Securities Act and state
securities laws, relating to the registration of the shares offered by this prospectus.
BUSINESS
Company
mission and overview
Natur’s
vision is for technology to be the force of our innovation as we build culturally relevant consumer products that nurture the
human body. The mission of Natur is to deliver 100% natural products that are good for everyone and for nature, with an aim to
sell products that meet or exceed consumer expectations for health, wellness and good taste. Natur specially selects plant-based
ingredients, including Hemp Cannabidiol (CBD), fruits and vegetables, committing not to use concentrates, preservatives, stabilizers
or additives in our products. Natur further invests in sustainability projects to reduce the environmental impact of our own activities.
Business
Overview
The
Company commenced its business in 2015 with the objective of becoming a leader in the “hi-tech health” food and beverage
marketplace; achieved by responding to changing market needs and staying continuously ahead of emerging trends. The Company also
intends to address the demand of the consumer for knowledge about what he/she consumes with a greater level of supply chain transparency.
It
is the commitment of the Company to integrate new manufacturing technologies with standard practices for superior products and
yet remain Naturalicious (natural & delicious) to build out its value chain for the burgeoning market of nutritious beverages
and healthy snacks with and without CBD or other nutrient dense fusions. Our products have been delivered in the Netherlands and
the United Kingdom, with plans on expanding to additional locations in Europe and ultimately the United States. Our understanding
and application of the technological aspects of manufacturing assures a pathogen-free food and beverage experience that preserves
the nutrients and enzymes to the maximum level possible, while retaining the raw fresh nature of the products. The result is what
we believe to be the best tasting product with the maximum “goodness” and highest nutrient density -- something the
consumer seeks more and more in our target markets.
The
clear differentiator of the Company is the “natur” brand which is supported by its disruptive marketing. Yes, we are
branding nature. The Company finds that consumers are interested in “what we produce and how we voice this to the market”
more than how it is made. From an investment perspective, this is a fundamental component of our business model as we are not
having to commit very significant capex to building our own modern production and bottling facilities to deliver into the increasing
demand for our product.
In
the future we anticipate delivering documented nutrigenomic (precision nutrition) properties that we believe will be an aid to
personal weight management, increase energy, lower cholesterol, counter sleep disorders and boost immunity response. We believe
that these product aspects will position the Natur products at the top of the European market at a mid-market price point. This
profile will be accessible internationally, as we have already undertaken preliminary discussions with distributors in major international
markets outside Europe.
Through
third party contract manufacturers, we apply patented technology to proprietary nutrient dense blends of fruit and vegetables,
adding hemp-derived supplements. These are bottled or packed with technically advanced food and product safety measures and in
some cases cold high-pressure processing to bring fresh tasting fruit, vegetable and hemp-derived supplement blends to market
through more than fifteen product types. These newly innovated products are brought to market, in Europe, through Natur’s
distribution channels of direct-to-business, direct-to-consumer and through select distributors.
The
Company focus, however, is evolving. At the onset of 2019, our product line up centered on a range of cold pressed juices and
healthy snacks. Beginning in the fourth quarter of 2018, and throughout the first half of 2019, the Company began to shift its
dependence on the legacy fruit and vegetable juices and snacks toward innovating a new line of hemp-derived natural food and beverage
products. The Company product value proposition will be to provide affordable, culturally relevant, authentic, fresh fruit, vegetable
and hemp-derived supplement consumer products to democratize clean, healthy, eating and drinking occasions, with plans to address
the growing needs for products that address other personal needs in health, wellness and beauty care and pet care.
Cannabidiol
(CBD) is the non-psychoactive cannabinoid of the cannabis plant, often known as hemp. CBD is not the THC cannabinoid of the plant
that is an intoxicating substance which is illegal in many jurisdictions. CBD however, extracted and separated from specific varieties
of the industrial hemp plant, is legal worldwide. Although CBD can be found in other plants, it is the hemp plant that is used
because of its abundance in the plant, typically representing up to 40% of its extracts. When separated into its pure form, it
cannot provide the intoxication effects of THC. CBD is typically used for health reasons. Although there is much research to be
done in the field, it is believed that there are a wide range of health benefits. CBD products may be used for wellness purposes
such as to aid sleep, or for pain or anxiety management: they do not require a prescription.
On
July 25, 2019, the Company acquired a controlling position in Temple Turmeric, Inc., a Delaware corporation (“Temple”).
Founded in 2009, Brooklyn, New York based Temple’s mission is to bring the highest quality turmeric to the world by pioneering
the first Turmeric-based ready to drink beverage line. Temple has driven consumer understanding and demand for Turmeric as it
has become more and more widely consumed through this decade. Temple now adds adaptogenic herbs and ancient super food formulations
to beverages with a turmeric foundation.
On
June 30, 2019, the Company expressed its interest in pursuing a transaction with SIH. The contemplated transaction would be an
acquisition of assets and companies that together will operate a consumer distribution and logistics supply business. The identification
of assets and companies has yet to be done. The terms of a potential acquisition have yet to be negotiated and finalized. The
overall transaction will in all events be subject to many conditions precedent. There may be conditions to the transaction that
cannot be satisfied. Therefore there is no certainty that any transaction with SIH will be finalize or that if finalized will
be consummated.
The
Company” has entered into a letter of intent to acquire a majority position of Infinite Product Company LLP (“IPC”),
a Colorado based limited liability partnership, manufacturing and selling products using the research related to the characteristics
of CBD or cannabidiol and the endocannabinoid system. IPC formulates a wide range of products including topicals, ingestibles,
oils, beauty and pet products. The IPC products have not been evaluated by the United States Food and Drug Administration and
are not intended to treat, cure or prevent any disease or illness. The purchase price for the majority position will be paid in
installments over several months at and from the closing of the transaction in an amount equal to $6,120,000, and then a further
maximum amount of $5,000,000, based on IPC meeting specified EBITDA targets in fiscal year 2010. The parties have agreed that
the Company will have the right to purchase the balance of the partnership under terms and conditions to be agreed, and determined
at a later time. The letter of intent is only an expression of the parties’ intent to pursue a transaction. The parties
must still conduct due diligence on the other, draft acquisition documentation, verify the terms of the letter of intent and purchase
price determinations and otherwise commence the transaction beyond the stage of the letter of intent. There is no assurance, therefore,
that a transaction will be concluded, or if concluded on the terms set forth in the letter of intent.
Corporate
Management
The
Company and Natur have gathered a top team of experienced management and consultants in the field of food and beverage, who have
an in-depth knowledge of the market arena for our products and yet have the right fit of discipline and entrepreneurial vision
and drive.
The
Natur non-executive board has top industry relevant experience and has a hands-on drive to make the company successful and to
gain a leadership position in the healthy product food and beverage market place through the offering of a palette of products
that not only are natural and delicious but with functional beneficial properties and can also be supplied as organic. Their expertise
and insights in the digital world will also help drive the Natur to embrace these new delivery frontiers.
Natur
has five persons in management positions and twenty other employees.
From
Farm to Functional
Natur
markets “farm-to-functional” organic and/or all-natural plant-based consumer products. The product portfolio has recently
been expanded to include full-spectrum cannabinoids (CBD)-based consumer products including cosmetic, beauty, pet care, nutraceuticals
and other products in the health and wellness sector. Natur applies technologically advanced solutions to both product development
and consumer enjoyment as a true and certified “breed to brand” experience, available anytime, anyplace, anywhere.
Natur is building a leading-edge, safe and transparent supply chain for all customers, making it well positioned and able to establish
its market share and partner with the major international distribution leaders.
Products
The
Company divides its products in seven categories: (1) beverages, snacks and other products infused with CBD, (2) not from concentrate,
fruit and vegetable juice blends, 250ml sized, mildly pasteurized, with a 180 day shelf life, 3) not from concentrate fruit smoothies,
250ml sized, mildly pasteurized, with a 180 day shelf life, 4) fruit and vegetable blend juices, 250ml sized, cold pressed, high
pressure processed, with a shelf life between 50 and 120 days, 5) fruit and vegetable blend shots, 100 ml sized, cold pressed,
high pressure processed with a shelf life between 50 and 120 days, 6) innovative snacking options low in calories and high in
daily requirements for fruits and vegetables and 7) the Temple products. Below is a product description within the categories.
Beverages,
snacks and other products infused with Cannabidiol (CBD)
Our
product line consists of the following categories:
|
o
|
NFC Juices shelf life 180 days
|
|
o
|
HPP Juice shots shelf life 90-120 days
|
|
o
|
Bio Chocolate Bars, vegan
|
|
o
|
Tinctures of varying strengths
|
|
o
|
CBD Bio-Cellulose Facial Mask
|
|
o
|
Pet Tincture 1 oz. 250mg broad spectrum oil
|
|
o
|
Diverse Vape Cartridges
|
Not
From Concentrate, Fruit and Vegetable Juice Blends, 250ml, Mildly Pasteurized, with a 180 Day shelf life
|
●
|
natur. Rocket Fuel 12x 250ml NL/UK
|
|
●
|
Rocket Fuel is a fruit and vegetable blend of
apple, coconut water, beetroot, raspberry, and persimmon. Vitamin B1 & C activate the natural energy while vitamin A,
B6, B12 and selenium contribute to the normal function of the immune system. Vitamin E contributes to the protection of cells
from oxidative stress.
|
|
●
|
natur. Body Guard 12x 250ml NL/UK
|
|
●
|
Body Guard is a fruit and vegetable blend of
apple, carrot, orange, coconut water, peach, passion fruit and persimmon. Vitamin B1 & C activate the natural energy while
vitamin A, B6, B12 and selenium contribute to the normal function of the immune system. Vitamin E contributes to the protection
of cells from oxidative stress.
|
|
●
|
natur. Power Plant 12x 250ml NL/UK
|
|
●
|
Power Plant is a fruit and vegetable blend of
apple, coconut water, pear, spinach, cucumber and persimmon. Vitamin B1 & C activate the natural energy while vitamin
A, B6, B12 and selenium contribute to the normal function of the immune system. Vitamin E contributes to the protection of
cells from oxidative stress.
|
Not
From Concentrate Fruit Smoothies, 250ml, Mildly Pasteurized, with 180 Days shelf life
|
●
|
natur. Goji Galore 12x 250ml NL/UK
|
|
●
|
Goji Galore is a fruit and vegetable smoothie
with coconut water, strawberry, raspberry, goji, apple, kaki and blackcurrant. Vitamin B1 & C activate the natural energy
while vitamin A, B6, B12 and selenium contribute to the normal function of the immune system. Vitamin E contributes to the
protection of cells from oxidative stress.
|
|
●
|
natur. Matcha Madness 12x 250ml NL/UK
|
|
●
|
Matcha Madness is a fruit and vegetable smoothie
with coconut water, pear, cucumber, spinach, banana, kaki, apple, spirulina and matcha. Vitamin B1 & C activate the natural
energy while vitamin A, B6, B12 and selenium contribute to the normal function of the immune system. Vitamin E contributes
to the protection of cells from oxidative stress.
|
|
●
|
natur. Turmeric Tiger 12x 250ml NL/UK
|
|
●
|
Turmeric Tiger is a fruit and vegetable smoothie
with coconut water, banana, turmeric, pineapple, apple, lime and kaki. Vitamin B1 & C activate the natural energy while
vitamin A, B6, B12 and selenium contribute to the normal function of the immune system. Vitamin E contributes to the protection
of cells from oxidative stress.
|
Fruit
and Vegetable Blend Juices, 250ml, Cold Pressed, High Pressure Processed with 50 Days shelf life
|
●
|
natur. Spicy Greens 6x 250ml NL/UK HPP ‘Grab
and Go’
|
|
●
|
Spicy Greens is a savory blend of cucumber,
kale, spinach, lime, mint and ginger on an apple and pear base. The juice is high in vitamin C which activates the natural
energy and contributes to the immune system.
|
|
●
|
natur. The Force 6x 250ml NL/UK HPP ‘Grab
and Go’
|
|
●
|
The Force is a savory blend of beetroot, carrot,
cucumber, apple, acerola, blueberries, lime and ginger. The juice is high in vitamin C which contributes to the normal function
of the immune system.
|
|
●
|
natur. Pearfection 6x 250ml NL/UK HPP ‘Grab
and Go’
|
|
●
|
Pearfection is a fresh blend of apple, pear
and acerola. Pearfection contains potassium which is a mineral that contributes to the proper functioning of your muscles.
|
|
●
|
natur. Berrylicious 6x 250ml NL/UK HPP ‘Grab
and Go’
|
|
●
|
Berrylicious is a sweet juice of mixed forest
fruits and apple. The juice is high in vitamin C which supports the natural defense mechanism.
|
|
●
|
natur. Fountain of Youth 6x 250ml NL/UK
|
|
●
|
Fountain of Youth is based on carrot and mango
with a touch of passion fruit and turmeric. The juice is high in vitamin A which nurtures the skin. Fountain of Youth also
contains turmeric which is a natural painkiller with a powerful anti-inflammatory effect.
|
|
●
|
natur. Emperor of the Sun 6x 250ml NL/UK
|
|
●
|
Emperor of the Sun is a juice made from oranges
with the highest nutritional values. This bottle contains more than 60% of the daily intake of vitamin C which supports the
firmness of the skin.
|
|
●
|
natur. Vitamin Sea 6x 250ml NL/UK
|
|
●
|
Vitamin Sea is a juice made from oranges and
kiwis with the highest nutritional values. This bottle contains more than 60% of the daily intake of vitamin C which supports
the firmness of the skin.
|
|
●
|
natur. Strawberry Sunrise 6x 250ml NL/UK
|
|
●
|
Strawberry Sunrise is a juice made from oranges
and strawberries with the highest nutritional values. This bottle contains more than 60% of the daily intake of vitamin C
which supports the firmness of the skin.
|
Fruit
and Vegetable Blend Shots, 100ml, Cold Pressed, High Pressure Processed with 50 Days shelf life
|
●
|
natur. The Charger 8x 100ml NL/UK HPP ’Shots’.
The Charger is a savory blend of fennel, kale, spinach, cucumber, coriander, apple and lime. The juice is high in vitamin
C which contributes to the reduction of tiredness and fatigue and increases iron absorption.
|
|
●
|
natur. The Clean 8x 100ml NL/UK HPP ’Shots’.
The Clean is a savory blend of apple, beetroot, carrot, spinach, celery and lemon. The shot is high in vitamin C which contributes
to the protection of cells and oxidative stress.
|
|
●
|
natur. The Glow 8x 100ml NL/UK HPP ’Shots’.
The Glow is a blend based on carrot and mango with a touch of passion fruit and turmeric. The shot is high in vitamin A which
nurtures the skin. It also contains turmeric which is a natural painkiller with a powerful anti-inflammatory effect.
|
Innovative
Snacking options
Filling
the consumer need for guilt free products, the Company has formulated an innovation without any known equal. These are available
in 3 flavor variants. Research has revealed these are fully on trend, with 100% fruit & vegetables, 100% natural, no additives,
and rich in fiber.
In
close conjunction with a third-party manufacturer in 2018, the Company has invested heavily in New Product Development (NPD).
Consequently, the Company is proud to announce its innovation in Snacking: ‘Natur Break’. The product portfolio extension
consists of three variants:
|
●
|
Natur. Mango-Carrot-Pumpkin Break
|
|
●
|
Natur. Strawberry-Raspberry-Beetroot Break
|
|
●
|
Natur. Apple-spinach-Avocado break
|
The
delicious ‘better-for-you snack’ line:
|
●
|
100% fruit & veggies (225gr)
|
|
●
|
Crunchy separately packaged topping with nuts
and seeds (20gr)
|
|
●
|
100% natural, no additives
|
|
●
|
One serving contains 33% of vegetables- and
50% fruit of the Recommended Daily Intake (RDI)
|
The
introduction is fully on trend:
|
●
|
Increasing demand for healthy and honest food.
|
|
●
|
Increasing awareness about fructose sugars in
fruit.
|
|
●
|
Opportunities for combining vegetables and fruit.
|
|
●
|
Growth of convenience and healthy ‘on-the-go’
solutions
|
This
new range is in perfect complementary harmony with the vision and existing portfolio of Natur. Based on conducted extensive qualitative
consumer panel research in January 2019 and initial trade response and acceptance, the Company believes this addition to the portfolio
has the potential to add value to the category.
Temple
product line
The
temple product line consists of the following two categories:
|
●
|
VITALITY SUPERBOOST SHOTS with Symphonic adaptogens
that enhance the bioavailability of cumin:
|
|
o
|
Turmeric Shot: Hawaiian turmeric, holy basil,
ashwagandha, yerba mate.
|
|
o
|
Fire Shot: Raw apple cider vinegar, ghost pepper,
cinnamon, vanilla.
|
|
o
|
Red Ginger Shot: Elderberry, white turmeric,
ginger, apple cider vinegar.
|
|
●
|
VITALITY SUPERTONICS with adaptogens and natural
caffeine (Adaptogens are healing herbs that work vigorously with your body to optimize total stress response.)
|
Product
Development
Beverages
and snacks with Functional Nutraceuticals
The
Company’s mission is to leverage technology as the driving force of innovation to build culturally relevant natural and/or
organic consumer products that are beneficial to the human body and improve general wellbeing. Putting this into practice, the
Company is developing new product line extensions by putting functionality in food & beverages making them more relevant to
today’s health conscious consumer.
|
o
|
Enhanced waters with new flavor twists or ingredients
added to the benefits of hydration
|
|
o
|
Enhanced beverages can have a (coconut) water
base with fruit / vegetable and or other plant derived additives to provide more nutrition
|
|
o
|
Sparkling waters with functional ingredient
|
|
o
|
Functional F&B and health & wellness
products may have other ingredient features including low sugar options, carbonation or fermentation.
|
|
o
|
Non Dairy nut milks / non allergenic (alternative)
nut milks
|
|
o
|
Plant proteins such as Duckweed, pea, and fava
bean
|
|
o
|
Nutrigenomics: Nutrigenomics is the study of
the interaction between nutrients and genes, or how the foods we eat can modulate the activity of our genes and, therefore,
influence our state of health. Incorporating nutrigenomics will enable Natur to enhance its product line of juices, waters
and snacks with additional function from among seven efficacies: energetic metabolism, immunity strengthening, stress management,
sleep quality, detoxication, bone metabolism and appetite control. The initial product line will consist of:
|
|
o
|
Expanding our CBD line to include “Dutch
heritage” products such as liquorice and stroopwafels (caramel waffles)
|
Furthermore,
the Company is developing and commercializing medicinal and health-focused Functional Natural Cannabis and hemp products that
will embrace production transparency GMP product quality standards and novel technologies.
Primary
Markets
The
fruit juices market was valued globally at $71.31 billion in 2016 and is expected to grow at a CAGR of 6.14% during the forecast
period, to reach an expected value of $121 billion by 2025. The global fruit and vegetable blends market was valued at $51.5 billion
in 2016 and is expected to grow at a CAGR of 6.3% during the forecast period, to reach an expected value of $89.2 billion by 2025.
The vegetable juices market was valued at $31.37 billion in 2016 and is expected to grow at a CAGR of 4.63% during the forecast
period, to reach an expected value of $46.86 billion by 20251.
Europe’s
cannabis market is estimated to be worth up to €123b by 2028 and will likely become the world’s largest legal market
over the next five years. Home to more than 740 million people, a population more than double that of the United States and Canada
combined, Europe is set to become the world’s largest legal cannabis market over the next five years. Over the last twelve
months, the European cannabis industry has grown more than it has in the last six years. The retail value of Europe’s health
and wellness market was estimated to be worth some €180 billion in 2018, a rise in value from €151 billion in 2013.
Figures for the Canadian market for health products suggest that CBD products account for an estimated 0.05% of the health and
wellness market value and we would expect the European CBD market to account for a similar, if not larger share of the region’s
wellness market value by 2028. This growth is attributable to growing health literacy across Europe with people becoming better-versed
in how to improve their health through changes in lifestyles and supplementation As a result, people are taking greater responsibility
for their mental health and physical well-being. Figures published by the WHO estimate that some 25% of Europe’s population
suffers from depression or anxiety, and given the mood-enhancing benefits of CBD, demand for CBD-based products that can boost
mental health will experience strong growth. Segment performance will be further propelled by growing availability of CBD consumer
goods through ingredient innovation from big brands in mainstream consumer goods markets. Nearly 7% of adults in a U.S. survey
reported using CBD as a supplement (conducted by Cowen n = ~2,500). This strong consumer interest is validated by the growing
number of brands and form factors that are now available through increasingly divers retail channels, including Amazon, Sephora
and Neiman Marcus. The launch of CBD-infused beverages, for example, will help drive value sales of CBD products higher. Furthermore,
as food and drinks trends often filter into other consumer goods markets, Prohibition Partners predicts that sales will also be
bolstered by rising demand for CBD-infusions in beauty products and possibly even household products in future. In addition, the
lack of a regulated market has helped drive demand for CBD products in Europe as the only legal means to access the therapeutic
properties of cannabis. Furthermore, legal markets in the US show a high demand for high CBD and minimal THC recreational cannabis
and Europe is expected to follow a similar trend. Europe’s cultivation capacity and processing infrastructure will quickly
put the region on par with the North American market for hemp CBD products.
Legislation
Six
countries have announced new legislation and over €500m have been invested in European cannabis businesses. Governments and
their legislative arms are already becoming increasingly pro-cannabis. The debate over cannabis in Europe has also matured as
politicians, healthcare professionals and entrepreneurs have followed the growth of the industry in the United States and Canada.
In all aspects of legislation and standardization, the EU bloc’s governments, industries and citizens have excelled at finding
innovative solutions. The cannabis debate has already reached the European Union legislative level, where last summer the European
Parliament’s Environment Public Health and Food Safety Committee called on the European Commission to create an EU-wide
policy for medical cannabis. The versatility of cannabis also will have a significant impact across multiple sectors, including
beauty and wellbeing, leisure, manufacturing, textiles, and food and beverage. Widespread applications for cannabis, coupled with
high consumption rates and exclusive pricing indicate a potential market worth up to €123b by 2028. Europe’s burgeoning
legal cannabis industry represents an exciting green-field opportunity, provided stakeholders take a knowledge-based and considered
approach.
1
Source: Grand View Research 2018 - WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews.
We
believe that the opportunity for the Natur products can be summarized as follows:
|
●
|
globally there is a generic shift towards a
healthier lifestyle and healthier foods that is already well established in the more advanced North American and European
markets;
|
|
●
|
there is a fast-growing European market for
healthy natural juices and snack foods that are suited to the needs of a modern lifestyle;
|
|
●
|
illustrating these trends, within the Benelux
and UK fruit juice market for example, there is a continuing shift to more complex and more expensive premium juices;
|
|
●
|
a steadily increasing number of consumers are
willing to pay a premium for niche brands with superior quality, functional outcomes and special drinking experiences;
|
|
●
|
the major European retailers (including supermarket
chains) are evaluating how they can differentiate their respective offerings and enhance consumer experience to attract customers;
and
|
|
●
|
governments are legislating against carbonated
soft drinks with added sugar reinforcing consumers’ negative opinions of these products and accelerating a shift to
raw/fresh natural drinks for all family members.
|
In
addition to the above characteristics of the market in which we operate, we believe there are other consumer trends that we need
to take into consideration. These include the following:
|
●
|
increased availability of vegetarian and vegan
products
|
|
●
|
demand for healthy and responsible snacks
|
|
●
|
increase of alternative ingredients from nature
|
|
●
|
‘pure nature’ provides ‘feeling
good’ to the consumer
|
The
consumer trends also suggest that persons are wanting healthier products generally. Typically, the following factors are taken
into consideration:
|
●
|
untreated products that do not use artificial
coloring, flavors or preservatives;
|
|
●
|
products that are better for the environment;
|
|
●
|
more demand for gluten-free, halal or Kosher
products (‘free from’)
|
Consumers
not only consume for taste, but also for the function of food. Natur is addressing these new factors in its products and marketing.
Craftsmanship
and Artisanship
|
●
|
more demand for artisan and fresh products
|
|
●
|
discovery to new flavors and ethnic origin
|
|
●
|
signature from the craftsman
|
|
●
|
hero products and story telling
|
Sharing
Online - Products should look visually attractive to share on social media.
Sustainable
|
●
|
consumers are spending more on sustainable products
every year
|
|
●
|
no waste, from either the packaging or the product
itself
|
Clean
Labels
|
●
|
honesty about the ingredients (‘from field
to fork’)
|
|
●
|
simple: less ingredients
|
|
●
|
simple: ingredients that do what they have to
do
|
|
●
|
who makes the product, where and how?
|
More
Eating Occasions - with smaller and healthier portions
Blurring
|
●
|
sports drinks become mainstream. Reducing difference
between on-the-go and retail
|
|
●
|
food service becomes an important trigger
|
More
Direct Consumption - new eating occasions
Premiumization
- food is lifestyle. Increasing demand for premium variants.
Convenience
- the consumers are increasingly rushing and are looking for solutions.
Differentiated
Packaging - smaller production batches in alternative packaging
Online
Shopping - continued rapid growth. Regular grocery shopping shifting to online
Tailored
Offers - personal advantage e.g. consumer loyalty card
Super
Powders - maca, matcha, turmeric, spirulina, kale
Technology
- shelf life extension without additives
The
Company believes there is now mainstream acceptance in the Netherlands, UK and throughout Europe of ordering food over the internet
supported by a well-established fulfillment infrastructure for local delivery; there is no current significant competition from
large international players in either the Netherlands or UK, nor wider European markets, in the cold-pressed natural juices market
to the best of our knowledge. In the NFC market segment, there is no other brand that can match Natur’s Super NFC line in
nutrient density, with ambient delivery possibilities for up to four weeks while retaining the organoleptic properties and a shelf
life of up to six months.
Customer
Sales Authorizations
The
Company markets its products through five distinct channels in Europe – chain grocery, petrol and other smaller retail stores,
direct to consumer/business through e-commerce, caterers, and wholesalers (who reach independent retailers and Food Service locations).
The
Company is building the brand through a combination of permanent shelf space and promotional rotational spaces. Over the past
two years, in the Netherlands, these have included presence in the 700-store chain Albert Heijn, the oldest organization owned
and operated by the Dutch supermarket operator Ahold, which dominates the food grocery market with a 34.7% market share, the progressive
all-natural retailer Marqt (18 stores), and Plus Supermarkets (256 stores), to name a few. In the petrol sector, the Company conducts
business for example with the BP, Total and Avia petrol chains.
In
the UK, during the past two years, the Company served hundreds of independent natural food stores through direct relationships
from a staff of several sales and marketing personnel, while undertaking a branded takeover of WHSmith transportation retailers
in a large-scale rotational promotion. The Company has streamlined the market development for the UK and is resetting its strategies
for a distributor-oriented expansion. The Company’s extended shelf life technologies will support the anticipated slowing
at the border of a non-deal Brexit.
With
distribution in several hundred Dutch retailers and with a new distribution agreement with one of the UK’s most customer-centric
natural foods distributors, the Company is poised for expansion to new authorizations in existing and new markets. An example
of such expansion is an authorization pending with the 600-store chain Jumbo, the second largest food grocery retailer with a
19,.1% market share, which is expected to place Natur products in 60 of its ‘on the go’ stores in 2019.
In
2018 HMS Host and Albert Heijn each represented more than ten percent of the Company’s revenues, together representing 58%
of our revenues. In 2017 no one customer represented more than ten percent of the Company’s revenues.
Direct
to Consumer & Businesses
The
Company has invested in an e-commerce platform from the https://nl.natur.eu/ buy now page that provides an end to end solution
to direct-to-consumer sales as well as shipments to businesses. This meets the expanding need for healthy snacking where consumers
live and work. Customers have the option to select a two-hour time window for when they want to receive their order. For these
customers the Company is using an external logistics company providing warehousing and order fulfillment. For business direct
customers the Company is using Leen Menken as logistics partner for the Netherlands.
Wholesale
Through
wholesalers like Lekkerland (€13 billion turnover in 2017), Sligro (€3 billion turnover in 2017) and Bidfood (€700
million turnover in 2017), the Company is distributing its products to a large variety of smaller outlets in both on- and off-trade
channels. From cafe to caterer, canteen to health care institution and from hotel to restaurant.
Catering
The
Company pursues the catering category with the goal of prestigious availability for brand building and commercial interest. The
Company is selling to multiple sport clubs, offices, schools and many other public locations. This channel also includes airline
catering companies. The Company is in final negotiations with a larger Dutch provider in this channel. This channel also includes
outreach to convention centers where the Company has in place an agreement with RAI Amsterdam (largest in The Netherlands), exposing
the brand to 1.6 million visitors each year. Through our partner Absolute Taste, the Company has provided healthy juices to The
Ryder Cup, several Formula 1 races, Association of Tennis Professionals Finals and The Shard in London.
Festivals
and Events
The
Netherlands are famous for their festivals. Natur is attending the main dance festivals offering this crowd healthy refreshments,
while also selling through regular bars and via mobile sales and sampling teams. Through the customers like Absolute Taste, the
company delivers to international large festivals.
Anticipated
new business authorizations
The
Company is expanding its business to Bulgaria and other Eastern European countries and is evaluating expansion into the United
States over the next 6 to twenty-four months.
The
Company is also in discussions with a distributor for France, which is expected to start in the fourth quarter of 2019.
Also,
the Company is looking to extend the addressable market for its products with large distribution partners and/or retailers in
Germany, Austria, Israel and the Middle East.
In
2019, the Company acquired a controlling interest in Temple. Temple’s mission is to bring the highest quality turmeric to
the world by pioneering the first Turmeric-based ready to drink beverage line. Temple has driven consumer understanding and demand
for Turmeric as it has become more and more widely consumed through this decade. Temple now adds adaptogenic herbs and ancient
super-food formulations to beverages with a turmeric foundation. The company is working on a calculated expansion plan, beginning
with the markets highest indexing in the development of healthy eating and drinking products. New York City is one such market,
along with Los Angeles, San Francisco and Central Texas. The United States market is highly reliant on distribution agreements;
and those distribution agreements are struck most easily when large natural foods chains authorize the Company’s product
lines. The Company plans to rely heavily on innovation to foster success in the United States where working with functional supplements
and innovating snacking allow for disruption and competitive advantage.
Distribution
The
Company employs the practice of distributing product through independent, third party routes to market. In the Netherlands, the
Company deploys product to market through a contract relationship with Leen Menken Food Service Logistics who delivers greater
than 10% of the Company’s total Netherlands volume. This professional contract provider, from its distribution center in
Zoetermeer, is centrally located in the Randstad, close to the port of Rotterdam and Schiphol Airport. With 15,000 pallet spaces,
the Company’s relationship is scalable and efficient for refrigerated storage and transportation. Leen Menken applies work
automation according to the latest technical development. On the other hand, for certain activities, dedicated human attention
is needed, provided by a workforce of more than fifty people. Menken is certified, and the distribution center works according
to the quality requirements of ISO 9001, BRC, SKAL, Lean and Green & AEO.
Production
The
Company relies on more than 10% of its salable product from its relationship with contract packer and investor AMC Group. This
special contribution to the strategic business plan represents a high barrier to entry for any potential competing participant,
as the scale and breadth of AMC’s operations are unmatched in Europe. Further, it is the platform on which the Company’s
plans for the European market will be delivered.
The
Company has an integrated product offering primarily using unique cold-pressed juices as a basis for (functional) supplements,
boosters and natural snacks. The products are considered as “safe foods” due to our Pure Pulse (PEF 2.0) and High-Pressure
Processing (HPP) processes. Pathogens receive a 5+Log reduction while all the goodness, minerals, nutrients and enzymes remain
intact. Also, thanks to the extended shelf life and consumption period of the Company’s products the process produces less
waste. The Company will deploy unique patented PEF 2.0 technology which creates a product that is not only cold pressed, but also
actually enhances the natural flavors. The PEF processing technology allows the Company to be extremely price competitive as less
factory workers are needed for this line production technology and, unlike with HPP production, no expensive refrigerated working
environment is needed.
For
products not produced by AMC, representing a very small percentage of current volume, the Company is working with other leading
Dutch and European contract manufacturers.
Sourcing
of Raw Materials
The
Company relies on the expertise of the AMC Group for sourcing fruit and vegetable juice. The AMC processes begin with proprietary
breeds of fruits and vegetables, taking the most advanced and many times patented proprietary extraction methods. Further, they
have pioneered proprietary methods for shelf life extension with the greatest retention of enzymes, nutrient density and natural
taste.
AMC
Group accounted in the aggregate for more than 10.3% of the current accounts payable at December 31, 2018, and the AMC Group companies
accounted for more than 21.5% of accounts payable at December 31, 2017.
Government
Regulations
There
are many food related regulations found in the laws of the different markets in which our products are distributed. The regulatory
regime is likely to expand and become more complicated over time in each of our markets. Two principal governing bodies provide
guidance and / or regulation in the human consumption food and beverage industry.
Europe’s
European Food Safety Authority (EFSA), under Regulation (EC) No 178/2002 (General Food Law Regulation) lays down the general principles
and requirements of food law, establishing the EFSA and laying down procedures in matters of food safety. The basic rule is that
no food shall be placed on the market that is unsafe, injurious to health or unfit. Under Regulation (EC) No. 852/2004 there are
additional food safety regulations based on the HACCP system, and businesses must maintain records of where the raw materials
for their products originated. The basic food labeling law is found in Regulations (EU) 1169/2011 and 1924/2006, which set out
the information that must be provide to consumers and indicates what can be provide as nutrition and health claims.
Member
States of the EU also have locally applicable laws and regulations covering aspects of public health, product safety, fair trading
and adequate information. Currently, because the products of the Company are sold in the Netherlands and the United Kingdom, the
Company has to comply with those laws in addition to the EU regulations. As the Company sells products in other Member States,
it will have to comply with any additional locally applicable laws.
Food
that is not compliant with the food safety requirements of the EU or a Member State will be subject to recall for destruction.
Retailers and distributors must help with the withdrawal of unsafe food and pass on information necessary to trace it. Consumers
and regulators are to be notified about recalled foods. The recall is typically at the expense of the product producer and typically
it can be very costly, not only in terms of monetary expense but also in terms of the reputation of a product.
While
not applicable at this time, should the Company enter the United States market with natural, wholesome better for you food and
beverages, it will be governed by the U.S. Food and Drug Administration, and to some extent the United States Department of Agriculture.
In addition, state regulation may apply to our products and their distribution. Additionally, in the United States, there is a
substantial body of government regulation and case law that will impact what is deemed “natural” and other aspects
of the content of our products, product recalls, food safety and labeling.
The
failure to comply with any of the material provisions of the various applicable laws, regulations and other legal requirements
may result in fines, product recalls, or termination of our ability to manufacture and distribute our products. Contaminated products
may result in product liability claims. The result of these may have an adverse impact on our business reputation and our financial
position. We do not believe that any business insurance that we may hold will be adequate to recompense us for our financial damages.
Competition
The
Company has entered the very competitive space of better-for-you food and beverage products. There are a considerable number of
competitors comprised of a select few multi-national beverage and food conglomerates and a greater number of upstart independent
brands, many limited to specific markets.
The
multi-nationals with which the Company competes head to head are PepsiCo with their beverage product line Naked distributed broadly
in the United States and the European Union, and the Coca Cola Company, with their beverage line Innocent Drinks in the European
Union and Odwalla in the United States. The Company’s ability to be swift to respond to market opportunity is a competitive
advantage over the slower moving larger corporations. Also, retailers’ own label beverages are considered as competition.
Typically, at a lower price point, the products offered are extensive and widely available.
The
smaller, more nimble competitors in the beverage arena include the UK’s Savsé, Coolbest, grocery retailer private
labels brands, and countless start up beverage labels in the UK, Netherlands, and Switzerland. In the near future, the Company
expects to expand into the German, Moldavian, Bulgarian, Italian, French, Swiss, and United States markets, and we will encounter
further competition from competitors that are active in those markets. New products are introduced all the time, many of which
will be directly competitive to our products or may be competitive on a tangential basis, but in all cases likely diluting our
place in the market as a provider of cold-pressed juice and other fruit and vegetable products.
We
also face competition from local outlets selling smoothie products and other fresh squeezed products. While we believe that we
compete favorably with our competitors on factors including quality, nutritional integrity, food safety, merchandising, service,
sales and distribution, multiple flavors, brand name recognition and loyalty, our products are typically sold at prices higher
than most other competing beverage and bar products. Significant competitive pressure from these or other companies could negatively
impact our sales and results of operations.
In
the emerging CBD food, beverage, snacks, health & beauty and animal products categories the competition consists of many small
players, all vying for leadership positions. The major food and beverage companies remain on the sidelines with experimental efforts
but not full-scale rollouts.
Property
The
Company leases office space in Amsterdam, The Netherlands. There is adequate alternative office space available at competitive
rates in Amsterdam. The Company does not own manufacturing or warehouse facilities, as it uses contract facilities in Europe.
The Company, through its partially owned subsidiary, Temple Turmeric, Inc. leases office and manufacturing facilities in Brooklyn,
New York.
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Fiscal
Year 2018 Compared to Fiscal Year 2017
|
1.
|
Financial condition, changes in financial
condition and results of operations
|
In
2015/2016 the Company developed together with related partner AMC Juices a range of cold-pressed juices and in the fourth quarter
2016 the first entry to the market was achieved. In 2017 the range of products was extended by adding a range of nearly not heated
juices and coconut water-based smoothies with a shelf life of 180 days (SNFC). This with the aim of providing products at a lower
price point and offering a product that can be shipped ambient for a certain period of time. We further extended our HPP line
with shots, lemonades and breakfast drinks. The current product offering of juices includes 38 different products of which 18
are pro-actively offered to the market, after the company performed in 2019 a rationalization of its product offering to minimize
waste.
The
company is aiming to further expand its portfolio with additional functional juices infused with all-natural functional ingredients
such as CBD and plant-based protein and nutrigenomics. These additions to our products are aimed for personalized health, which
is fully on trend in the European Market.
Also,
an additional range of snack offerings has been developed in 2018. The Company aims for adding those to its portfolio in the second
quarter of 2019.
During
2018, management of the company was heavily involved in the negotiations with management and shareholders of Future Healthcare
of America. A lack of free cash has limited the company to grow significantly in its home market (the Netherlands). As a consequence,
management has been focused on cost cutting measures, that were effective in the short term to mitigate and control the cost development.
As
part of the Company’s strategy to operate in a lean and mean manner, the Company has decided to centralize all support functions
in the headquarters in the Netherlands and to support global account management centrally. For that reason, effective November
30, 2018, the Company has closed down the London office. The existing support functions have been transferred to the headquarters
in Amsterdam as part of the centralization of support staff initiative. A distributor for the UK has been engaged, who will deliver
to our current local customer base.
In
the table below, the profit and loss account for the periods ended 31 December 2017 and 31 December 2018 is displayed:
|
|
December 31,
2018
|
|
|
December 31,
2017
|
|
Revenues
|
|
|
1,675,160
|
|
|
|
526,339
|
|
Gross Margin
|
|
|
622,086
|
|
|
|
93,434
|
|
Sales, general and Admin
|
|
|
6,132,779
|
|
|
|
7,499,295
|
|
Operating loss
|
|
|
(5,510,693
|
)
|
|
|
(7,405,861
|
)
|
Revenues
for continued operations increased compared to prior year by 218% on a full year basis. At the same time, economies of scale and
supply chain efficiency improvements have resulted in an improved margin. During 2018, various measures has been taken to mitigate
the loss-making from operational activities, leading to a sharp decrease of our losses during the first 9 months of 2018. Wages
and salaries have been under strict control by utilizing digital and automated solutions for our support functions. Due to cash
restrictions we have not been able to invest in the marketing and activation of our products in the various channels. Nevertheless,
we have exceeded our prior year revenues by $1.2 million. We have used guerilla marketing techniques and active sales to achieve
this.
We
will build our international presence from a solid position in the Dutch market place, and in parallel, expand the UK market,
the French market and other European markets, to provide the Company with a good international platform and a blueprint for its
further European roll-out.
Management
of the Company is aware that the auditor expressed an opinion on the matter of going concern; management is continuously streamlining
the operations, whilst at the same time increasing revenue by introducing new products and attracting new customers. The relative
share of costs against this increase in revenue is significantly lower which has a positive effect on the development of the gross
margin and cash flow from operations. Based on global developments and following the success of companies in the USA and Canada,
the company also defined new growth objectives with complementary products based on CBD as a new revenue model. For this, the
Company established a new sister company to Natur Holding BV, Natur CBD BV, which is wholly owned by Natur International Corp.
and is seeking additional capital, that may be either equity or debt, or both. However, potential investors require a debt restructuring
and therefore management developed a corporate restructuring program and started negotiations with the current debtholders of
Natur Holding BV to convert their debt into equity of Natur International Corp. The main pillar of such a restructuring plan is
the transfer of certain assets and liabilities from Natur Holding BV to Natur CBD BV at arm’s length conditions and subsequently
liquidate Natur Holding BV. As the intended restructuring is guided and controlled by legal specialists, management is reasonably
assured that a to-be appointed trustee by the applicable Court in the Netherlands will accept the assets and liability transaction.
The execution of the intended restructuring program is conditional upon the ability of the Company to raise additional capital
prior to the implementation of the restructuring plan in order to supply the buying entity of the assets and liabilities
with sufficient funds for the asset transaction and the financing of the daily operations. If this condition is not met, the restructuring
will fail, and management will be forced to seek legal protection against its creditors and debtholders.
There
are a number of risks associated with the restructuring. These include the following:
1.
Because the restructuring requires funding of Natur CBD BV, there is the risk that the Company will not be able to secure the
amount necessary to fund the acquisition of the assets and accept the liabilities in the reorganization, in which case the restructuring
will not result in the corporate objective sought, which is to reduce the debt of the Company on a consolidated basis.
2.
Once the trustee has been appointed, there is no ability for the Company to terminate the restructuring process as described above.
The trustee could take decisions that were not anticipated in respect of the assets and liabilities of Natur Holding, which may
have an adverse impact on the restructuring and therefore on the entire Company. The trustee may even reject in its entirety the
proposed restructuring plan.
3.
If either because Natur CBD BV cannot complete its acquisition of the assets and acceptance of designated continuing liabilities,
or there is objection to the restructuring by third parties, or the trustee on its own initiative rejects the restructuring plan,
the trustee will have wide discretion in how to proceed. The trustee may sell the assets in a public sale, in which case the Company
would lose the assets, including their value to the creditors of Natur Holding and the ability to use the assets. In this event,
the Company would most likely not be able to continue its operations as a producer of its products and have to terminate operations.
In the event of no operations, the investors in the company would lose the entirety of their investment.
4.
There can be no assurance given that the trustee will discharge the debts that are sought to be terminated in the reorganization.
Therefore, the Company may retain more debt obligations than anticipated and not be able to service the debt. If the debt on the
Company is not reduced sufficiently, there is the risk that the Company will not be able to operate profitably or be able to continue
its operations.
5.
The planned restructuring is anticipated to expunge all the debt other than certain trade obligations, tax obligations and other
general obligations of the operations in the Netherlands amounting to approximately $ 800,000. The Company anticipates being able
to service this amount of assumed liabilities after the reorganization, but there can be no assurance that it will be able to
do so. In such event, the Company may again face a reorganization or have to otherwise change its business plan or cease operations.
6.
Although management and the board of directors believes that the restructuring will ultimately benefit the Company, there is no
certainty that the restructuring will result in the required improvement to the financial condition of the overall Company or
make operational funding available. The Company will continue to need to raise working capital and obtain funding in the future,
for which no assurance can be given that the company will be able to find such funding on acceptable terms or at all.
|
2.
|
Liquidity and capital resources
|
Total
net cashflow for the year 2018 amounted to -$0.9 million. The 2018 operating loss before depreciation and currency translation
differences was $5.3 mio. This was partly financed by Efficiency Life Fund and NL Life Sciences, who provided several loans to
cover for these losses ($1.6 mio and $1.4 mio) to ensure continuity. The recapitalization and issuance of preferred shares at
the close of the reversed merger lead to a further investment of $2.0 mio.
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
|
|
|
|
|
|
|
Net increase/(decrease) of cash position
|
|
|
(913,352
|
)
|
|
|
954,370
|
|
|
|
|
|
|
|
|
|
|
Cash position beginning of period
|
|
|
1,082,734
|
|
|
|
144,842
|
|
Cash for discontinued operations
|
|
|
(41,018
|
)
|
|
|
36,775
|
|
Cash position end of period
|
|
|
128,364
|
|
|
|
1,082,734
|
|
|
3.
|
Unusual events that materially affected
or are expected to materially affect income
|
As
a start-up company, the first two years were mainly focused on developing the products, building a relationship with key-suppliers
and contracting distributors. Whilst the global market for our key products developed according to the vision management had at
the start, the capital requirements for this type of business appeared to be steeper than anticipated and the market adaptation
to our products was less than we expected. The new product range that we launched at the end of 2017 made our general consumer
base larger.
As
a result, management of the company sought for a strategic partnership to strengthen the business model and to secure additional
capital if and when needed. This search led to a series of discussions and meetings with management and shareholders of Future
Healthcare of America. These activities distracted management significantly from the commercial and operational tasks and responsibilities.
Since November 13, 2018 Future Healthcare of America and Natur Holding BV operate as one company, allowing management to refocus
their attention on developing and growing the key business of the company.
June
30, 2019 Compared to June 30, 2018
During
the three months ended June 30, 2019, Natur recorded revenues of $8,134, a 98% decrease over revenues of $414,716 for the same
period in 2018. The decrease in 2019 is attributed to the decision the Company made to discontinue selling to less profitable
customers while developing its new culturally relevant product lines. It should be noted that in Q2 2018, revenues were generated
by two large customers. Both of these customers proved to be less beneficial to the business than planned and by the beginning
of Q1 2019 sales to these customers were discontinued.
With
the lower revenues in the quarter, cost of goods sold included unleveraged warehousing, inventory reduction and product discard
costs and totaled $4,919, a 99% decrease as compared to $283,400 in the comparable period of 2018. Natur posted a gross profit
of $3,215 during the second quarter 2019, versus a gross loss of $131,316 for the second quarter of 2018.
Six
Months Ended June 30, 2019 Compared to June 30, 2018
During
the six months ended June 30, 2019, Natur recorded revenues of $72,553, a 92% decrease over revenues of $942,433 for the same
period in 2018. The decrease in 2019 is attributed to the decision the company made to discontinue selling to less profitable
customers while developing its new culturally relevant product lines. It should be noted that in first half of 2018, the introduction
of two large customers generated initial opening orders, filling the supply chain. Both of these customers proved to be less beneficial
to the business than planned and by the beginning of Q1 2019 sales to these customers were discontinued.
With
the lower revenues in the six-month period, cost of goods sold included unleveraged warehousing, inventory reduction and product
discard costs and totaled $99,696, an 82% decrease as compared to $557,152 in the comparable period of 2018. Natur posted a gross
loss of $27,143 during the first half of 2019, versus a gross profit of $385,281 for the first half of 2018.
Natur
continued to make year over year improvements in some controllable costs while recording total operating expenses of $3,294,333
during the first half of 2019, a 14% increase as compared to operating expenses of $2,895,729 in the same period of 2018. Wages
& Salaries showed a strong improvement, totaling $373,064 in the first half of 2019 versus $792,679 in the first half of 2018,
a decrease of 53% driven by significantly streamlined head-count compared to 2018. An additional strong contributing factor is
the discontinuation of retail store activities in both the UK and the Netherlands. Selling, General & Administrative costs
increased to $2,645,471 from $2,019,466 when comparing the first half of 2019 versus 2018, or 31%. This was driven mainly by an
increase in the overall costs incurred by the business due to the administration costs of maintaining a public listing such as
legal, board and accountancy fees. The Company also introduced a stock option scheme in 2019 with no similar such costs in the
first half of 2018 with costs totaling $1,088,206 for 2019 . Amortization depreciation and impairment costs increased to $275,798
from $83,584 when comparing the first half of 2019 versus 2018, or 230%. This was driven mainly by the Company taking a prudent
measure to write down all assets in the retail stores (approximately $200,000) to Nil. As the Company could not comfortably assume
we would receive any proceeds for these assets it will therefore only take gains on disposal in future periods should they be
realized. These assets are now with the Curator pursuant to the Petition who is dealing with the liquidation of Natur Holding
B.V.
Natur’s
net loss available to common shareholders was $1,551,207 for the first half of 2019. This represents a 58% decrease from our net
loss of $3,669,410 in the first half of 2018. The decrease in the loss was partially offset due to the liquidation of the UK business
and a number of the subsidiaries in the Netherlands which allowed a gain on disposal of $1,891,985 to be realized.
Three
Months Ended June 30, 2019 Compared to June 30, 2018
During
the three months ended June 30, 2019, Natur recorded revenues of $8,134, an 87% decrease over revenues of $64,419 for the preceding
period. The decrease against the quarters was driven by the fact that the companies focus for the quarter was on restructuring
and seeking funding that would allow the business to continue as a going concern. The focus moving forward into the second half
of the year is to engage revenues as part of the Company’s new strategic focus.
For
the quarter ended June 30, 2019, cost of goods sold totaled $4,919, a 91% decrease as compared to $94,777 in the preceding period
of 2019. This reflects the costs associated with the overall reduction of revenue and due to the reduction in sales the Company
had experienced higher marginal costs for our warehousing in the first quarter which have now been largely reduced. We also experienced
higher disposal costs due to the perishable nature of our products in the first quarter of 2019. Natur posted a gross profit of
$3,215 during the second quarter 2019, versus a gross loss of $30,358 for the preceding quarter of 2019.
Natur
recorded total operating expenses of $1,355,005 during the second quarter of 2019, a 30% decrease as compared to operating expenses
of $1,939,328 in the preceding period. Wages & Salaries totaled $108,335 in the second quarter of 2019 versus $264,729 in
the preceding quarter a decrease of 59% driven by significantly streamlined head-count compared to the first quarter. An additional
strong contributing factor is the discontinuation of retail store activities in both the UK and the Netherlands. Selling, General
& Administrative costs decreased to $1,243,061 from $1,402,410 when comparing the preceding quarter, or 11%. This was driven
mainly by a decrease in the overall costs incurred by the business due to the administration costs of maintaining a public listing
as processes have been strengthened and we have undertaken less advisory work in the quarter. The was slightly offset by the fact
that the Company also introduced a stock option scheme in 2019 with higher costs in the second quarter due to the termination
agreement with Ms. Ellen Berkers. Amortization depreciation & impairment costs decreased to $3,609 from $272,189 when comparing
the second quarter of 2019 versus the first quarter of 2019, or 99%. This was driven mainly by the Company taking a prudent measure
to write down all assets in the retail stores (roughly $200k) to Nil in the first quarter. As the Company could not comfortably
assume we would receive any proceeds for these assets it will therefore only take gains on disposal in future periods should they
be realized. These assets are now with the Curator pursuant to the Petition who is dealing with the liquidation of the company.
Natur’s
net profit available to common shareholders was $196,324 for the second quarter of 2019. This represents a strong improvement
from our net loss of $1,747,531 in the first quarter of 2019. The gain was partially by the corporate restructuring and the decision
to close the UK business and a number of the company’s subsidiaries in the Netherlands which allowed a gain on disposal
of $1,891,985 to be realized.
Restructuring
Activities
Debt
restructuring - Effective June 30, 2019 the Company and most of its debtholders have agreed and executed contracts to settle the
amounts owed by the Company to the holders under individual the debt agreements, including principle, interest expenses, penalties
and other charges of whatsoever nature, all in an amount equal to $6,754,575 in exchange for and in consideration of the issuance
to by the Company of an aggregate of 161,149,309 shares of Common Stock.
Corporate
restructuring - In line with the objective to secure the continuity of the Company, it was decided in late 2018 to extend the
product line with the addition of functional extracts (Nutrigenomics, hemp-derived extracts). For this, the Company established
Natur CBC B.V. at March 13, 2019, wholly owned by Natur International Corp. Based on global developments and following the success
of companies in the USA and Canada, the Company defined new growth objectives with complementary products based on hemp-derived
extracts as a new revenue model. Additional funding was sought in the market, but it became apparent that the willingness of new
investors to provide the company with funding in debt or equity was dependent on the restructuring of the existing debt of the
Company. As most of this debt exists at the level of Natur Holding B.V., it was decided to develop a restructuring plan to: establish
an asset transfer from Natur Holding B.V. to Natur CBD B.V., optimizing the proceeds for these assets and subsequently liquidate
Natur Holding B.V. and continue the business in Natur CBD B.V. with an extended portfolio of functional products, including food
and beverages infused with hemp-derived extracts and deliver the objectives as set by the Board.
In
May 2019 we reached agreements with most of the debtholders to convert their debt to equity and effectively May 1, 2019 the asset
transfer between Natur Holding B.V. and its sister company Natur Functionals B.V. was executed and Natur Holding B.V. and its
wholly owned subsidiaries were declared bankrupt by the Court in Amsterdam, the Netherlands. The total Debt that was converted
to Shares to be issued is $6,754,575.
In
June we reached agreement with private investors for the sale of Preferred Stock and Warrants. At June 30, 2019 agreements were
signed for a total of $2,064,756 against 65,621.283 of to be issued Preferred Shares.
CHANGES
IN REGISTRANT’S CERTIFYING ACCOUNTANT
December
2018 Change
On
December 10, 2018, the Company notified Sadler, Gibb & Associates, L.L.C. (“SGA”) that it had dismissed SGA as
its independent certifying accountant. The dismissal of SGA was approved by the board of directors of the Company (the “Board”).
SGA
did not review any audited financial statements of the Company, as there was no required report to be filed by the Company during
their period of engagement that required an audit report. During the Company’s period of engagement of SGA from July 16,
2018, through December 10, 2018, there were no disagreements with SGA on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure, which if not resolved to SGA’s satisfaction would have caused it to
make reference thereto in connection with its reports on the financial statements for such years. During the Company’s period
of engagement of SGA from July 16, 2018, through December 10, 2018, there were no events of the type described in Item 304(a)(1)(v)
of Regulation S-K.
On
December 10, 2018, the Company engaged Malone Bailey LLP (“Malone”), located at 9801 Westheimer Rd, Houston, TX 77042,
as its new independent registered public accounting firm. The engagement of Malone was approved by the Board.
During
the fiscal years ended December 31, 2017 and 2016 and through December 10, 2018, the Company did not consult with Malone with
respect to any matter whatsoever including without limitation with respect to any of (i) the application of accounting principles
to a specified transaction, either completed or proposed; (ii) the type of audit opinion that might be rendered on the Company's
financial statements; or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation
S-K) or an event of the type described in Item 304(a)(1)(v) of Regulation S-K.
The
Company has provided SGA with a copy of the foregoing disclosure and requested that it furnish the Company with a letter addressed
to the SEC stating whether it agrees with the statements made therein. A copy of the letter, dated December 10, 2018, was filed
as Exhibit 16.1 to the Current Report filed with the SEC on December 11, 2018.
July
2018 Change
On
July 16, 2018, the Company, with the approval of its Audit Committee, terminated the services of its independent registered public
accounting firm, Gregory & Associates, LLC (“Gregory”), effective immediately and retained the services of Sadler,
Gibb & Associates, L.L.C. (“Sadler”) as its independent registered public accounting firm.
Gregory’s
reports on the financial statements of the Company for the fiscal years ended December 31, 2017 and December 31, 2016 did not
contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting
principles, except that its report for the fiscal years ended December 31, 2017 and 2016 contained notes regarding the Company’s
ability to continue as a going concern. During the Company’s fiscal years ended December 31, 2017 and 2016 and through the
date hereof, there were no disagreements (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K) with Gregory on any
matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which disagreements,
if not resolved to Gregory’s satisfaction, would have caused them to make reference to the subject matter in connection
with their report on the Company’s consolidated financial statements for such periods. Furthermore, no reportable events
occurred within the periods covered by Gregory’s reports on the Company's financial statements, or subsequently up to the
date of Gregory’s dismissal. As used herein, the term “reportable event” means any of the items listed in paragraphs
(a)(1)(v)(A)-(D) of Item 304 of Regulation S-K.
The
Company provided Gregory with a copy of the foregoing disclosures and requested that Gregory provide a letter addressed to the
SEC stating whether it agrees with the statements made therein. Attached as Exhibit 16.1 to the Current Report on Form 8-K, filed
with the SEC on July 17, 2018, is a copy of Gregory’s letter addressed to the SEC relating to the statements made by the
Company in the Current Report.
During
the Company’s two most recent fiscal years ended December 31, 2017 and December 31, 2016, and through the date hereof, neither
the Company nor anyone on its behalf consulted Sadler regarding (i) the application of accounting principles to a specified transaction,
either completed or proposed; or the type of audit opinion that might be rendered on the consolidated financial statements of
the Company or (ii) any matter that was either the subject of a disagreement or a reportable event as described above.
MANAGEMENT
Executive
Officers and Directors
Set
forth below is information regarding the current directors and executive officers of the Company as of the date of this Prospectus.
Directors are to be elected each year by our stockholders at an annual meeting. Each director holds his office until his successor
is elected and qualified or resignation or removal. Executive officers are appointed by our board of directors. Each executive
officer holds his office until he resigns or is removed by the board of directors or his successor is appointed and qualified.
Name
|
|
Age
|
|
Title
|
Paul Bartley
|
|
50
|
|
Chief Executive Officer and Director
|
Rudolf Derk Huisman
|
|
69
|
|
Chief Financial Officer and Director
|
Anthony Joel Bay
|
|
63
|
|
Director
|
Nina Storms
|
|
65
|
|
Director
|
Frans van der Minne
|
|
71
|
|
Director
|
Mark Simmonds
|
|
55
|
|
Director
|
Boaz Wachtel
|
|
60
|
|
Director
|
Paul
Bartley has been the Chief Executive Officer and a director of the Company since July 2019. Mr. Bartley has been employed
by a private group of family-owned businesses for over 25 years in many aspects of food and beverage production, manufacturing,
packaging, equipment, distribution, exporting, importing and ecommerce businesses. From January 2014 to June 2019, Mr. Bartley
served as the managing director of Delori Foods, a specialty markets distributor of niche food, beverage and alcohol brands in
the United States, Asian and other markets. Mr. Bartley has been instrumental in establishing and integrating into the Delori
Group its China operations, including packaging, production, bottling, co-packing and distribution operations. Delori production
includes several nationally-distributed brands throughout the greater China and USA markets, including award-winning FMCG brands
in the food, beverage and dairy industries. Mr. Bartley also has transformed the Delori Foods components and equipment division
into developing transformative packaging and processing solutions to serve the hemp industries with functional edibles, vape,
and processing technologies. In 2016, Mr. Bartley also established a venture under the name “YHT Technology” to develop
SHARE as the next generation of software systems and affiliate marketing channel technologies for a direct-to-consumer (D2C) business
model capable of displacing and disrupting the retailer marketplace’s stranglehold on consumer choices and brand access.
SHARE’s initial launch platform focuses on the China direct-to-consumer influencer-driven marketing channels. The SHARE
mission is to ensure consumers around the world are free to access value-driven quality-of-life experiences in selecting and purchasing
the world’s next generation of authentic healthy and functional brands. Mr. Bartley has been appointed as a director of
the Company for his knowledge of the Company’s day-to-day operations as Chief Executive Officer.
Rudolf
Derk Huisman has been Chief Financial Officer of the Company since June 2019 and a director since January 2019. Mr. Huisman
is the strategic advisor of Arbor Media, a Dutch based leading supplier of audio and video conferencing and archiving solutions
and a strategic consultant for risk management. From May 2015 to September 2018, Mr. Huisman was the Global Transition Lead at
FEDEX/TNT, responsible for the transition of 14 finance and non-finance processes from 53 countries to a BPO provider. From 2011
to March 2015, Mr. Huisman was the Finance Director of the BA Decorative Paints of AkzoNobel, where he was responsible for the
development and successful implementation of a turn-around program of the European business. Mr. Huisman has been appointed as
a director of the Company for his financial experience within the corporate context as a chief financial officer and for his familiarity
with corporate governance structures and requirements. Additionally, he has experience in emerging entrepreneurships and in turn-around
situations.
Anthony
Joel Bay has been a director of the Company since his appointment in January 2019. Since April 2017, Mr. Bay has served as
the CEO and Chairman of UPROAR Global Media, a global streaming platform operating from London, UK and Seattle, Washington. Prior
to this, Mr. Bay was the Global Head of Digital Video for Amazon.com in Seattle, Washington, and served in senior executive positions
with Microsoft and Apple. Mr. Bay has been appointed as a director of the Company for his knowledge and experience in technology,
electronic commerce, digital media and supply chain logistics and for his experience as a senior executive at three of the most
valuable technology companies in the world. In addition, his roles as a director of private and public companies brings strength
in corporate governance and board oversight.
Nina
Storms has been a director of the Company since her appointment in January 2019, and was interim-CEO from June 2019 to July
2019. Ms. Storms is a well-known entrepreneur having led technology and telecommunication companies in Europe and has served as
Advisory Board Member of Natur Holding B.V. from January 2014 to January 2019. In 1994 Mrs. Storms founded World Online, which
became one of the largest Pan-European Internet telecommunication companies. By 2000, World Online was listed on the stock exchange
with an enterprise value greater than EUR 12 billion. Afterwards, she invested in numerous media and internet companies. Mrs.
Storms, who holds a PhD, is a published author on the subject of creative accounting / fraudulent reporting co-written with published
Profs. Rob Kamerling and Henk Langendijk. Mrs. Storms has been appointed as a director of the Company for her role as a co-founder
of Natur Holding B.V. and her knowledge of the Company’s operations and expansion in Europe and the UK. She is the primary
strategist and innovator of the Company.
Frans
van der Minne has been a director of the Company since his appointment in March 2019. Mr. van der Minne has been serving in
a strategic advisory role to Heineken NV from 2009 until his retirement in 2103. Prior to that role, Mr. van der Minne spent 35
years with Heineken NV in a series of increasingly responsible roles, including Chief Executive Officer of Heineken USA, Inc.
from 2000 to 2006. Mr. van der Minne has been appointed as a director of the Company for his knowledge of consumer goods development,
commercialization and probability.
Mark
Simmonds has been a director of the Company since August 2019. Mr. Simmonds was a Conservative Party politician and Member
of Parliament from 2001 to March 2015. He was also a Minister in the UK Foreign and Commonwealth Office from September 2012 to
August 2014. Between 2015-2018, Mr. Simmonds has been a Senior Advisor to Kroll Inc, since April 2015 he has been the Chairman
of the Advisory Board of the Global Investment platform Invest Africa, from 2015 to 2016 he has been the Chairman of Fincomeco,
a company providing business and technological solutions aimed at food security and economic diversity for Africa and a non-exec
director of Bloc Commodities since November 2014 an Advisory Board Member of the Commonwealth Investment Council, and since 2017
a Board Member of Engender Health, a women’s health organization. Since 2018 he has also been chairman of GIG technology
He became an associate of the Royal Institution of Chartered Surveyors in 1987. He worked as a surveyor for Savills from 1986
to 1988 and was a partner in Strutt & Parker from 1988 to 1996. He was a director of Hillier Parker from 1997 to 1999 and
a chairman of Mortlock Simmonds Brown from 1999 until becoming an MP in 2001.
Boaz
Wachtel has been a director of the Company since September 2019. Mr. Wachtel was the founder and has been chairman of CresoPharma,
an Australian publically traded CBD based nutraceutical company. Between 2015 and 2016, Mr. Wachtel was the co-founder and managing
director of Phytotech Medical, which is Australia’s first publically traded medical cannabis company. Mr. Wachtel has been
a lecturer at various universities in the world, and is a frequent speaker at events related to medical cannabis and cannabis
regulations. Mr. Wachtel received his bachelor’s degree from Hebrew College in Boston, Massachusetts and his master’s
degree in management and marketing from University of Maryland.
Board;
Committees of the Board of Directors
The
Company is not required to have and currently does not have an Audit Committee. The Company’s Board of Directors performs
the same functions of an Audit Committee, including recommending a firm of independent certified public accountants to audit the
financial statements; reviewing the auditors’ independence, the financial statements and their audit report; and reviewing
management’s administration of the system of internal accounting controls.
Although
the Company does not have and is not required to have an Audit Committee, the Board has determined that Mr. Huisman qualifies
as an “audit committee financial expert” as a result of his past business experience and education.
The
Board of Directors currently does not have and is not required to have a compensation or a nominating committee. The directors
believe that it is not necessary to have such committees at this time, because the functions of such committees can be adequately
performed by the Board.
Code
of Ethics
Management
of the Company upholds a set of basic values to guide their actions and management is committed to maintaining the highest standards
of business conduct and corporate governance. Management has adopted a Code of Business Conduct and Ethics for directors, officers
(including the principal executive officer and principal financial officer) and employees. Copies of the Code of Ethics and Business
Conduct may be obtained free of charge by written request to Natur International Corp., Jachthavenweg 124, 1081 KJ Amsterdam,
The Netherlands, attention: Chief Financial Officer.
Conflict
of Interest
The
Company has not adopted any set policies or procedures for the review, approval, or ratification of any transaction between the
Company and any executive officer, director, nominee to become a director, 10% shareholder, or family member of such persons,
required to be reported under paragraph (a) of Item 404 of Regulation S-K promulgated by the SEC. The board of directors does,
however, consider conflicts of interest in the approval of matters put to the board and will follow the legal requirements of
the State of Wyoming and general practices of good governance.
Limitation
of Liability of Directors and Indemnification of Directors and Officers
Section
17-16-851 of the Wyoming Business Corporation Act provides that a corporation may indemnify a director against liability incurred
in a proceeding if:
(i)
(A) the director conducted himself in good faith; and
(B)
he reasonably believed that his conduct was in or at least not opposed to the corporation’s best interests; and
(C)
in the case of any criminal proceeding, the director had no reasonable cause to believe his conduct was unlawful; or
(ii)
the director engaged in conduct for which broader indemnification has been made permissible or obligatory under a provision of
the articles of incorporation, as authorized by Section 17-16-202(b)(v) of the Wyoming Business Corporation Act.
A
director’s conduct with respect to an employee benefit plan for a purpose the director reasonably believed to be in the
interests of the participants in and beneficiaries of the plan is conduct that satisfies the requirement of subparagraph (a)(i)(B)
of Section 17-16-851.
The
termination of a proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent is
not, of itself, determinative that the director did not meet the standard of conduct described in Section 17-16-851.
Unless
ordered by a court under Section 17-16-854(a)(iii) of the Wyoming Business Corporation Act, a corporation may not indemnify a
director under Section 17-16-851:
(i)
In connection with a proceeding by or in the right of the corporation, except for reasonable expenses incurred in connection with
the proceeding if it is determined that the director has met the standard of conduct under subsection (a) of Section 17-16-851;
or
(ii)
In connection with any proceeding with respect to conduct for which he was adjudged liable on the basis that he received a financial
benefit to which he was not entitled, whether or not involving action in the director’s capacity.
Section
17-16-852 of the Wyoming Business Corporation Act requires that a corporation indemnify a director who was wholly successful,
on the merits or otherwise, in the defense of any proceeding to which the director was a party because he was a director of the
corporation against reasonable expenses incurred by the director in connection with the proceeding.
Under
Section 17-16-853 of the Wyoming Business Corporation Act, a corporation may, before final disposition of a proceeding, advance
funds to pay for or reimburse the expenses incurred in connection with the proceeding by an individual who is a party to a proceeding
because that individual is a member of the Board of Directors if he delivers to the corporation:
(i)
A written affirmation of his good faith belief that the standard of conduct described in Section 17-16-851 has been met by the
director or that the proceeding involves conduct for which liability has been eliminated under a provision of the articles of
incorporation as authorized by Section 17-16-202(b)(iv); and
(ii)
His written undertaking to repay any funds advanced if the director is not entitled to mandatory indemnification under Section
17-16-852 and it is ultimately determined under Section 17-16-854 or 17-16-855 that he has not met the standard of conduct described
in Section 17-16-851.
Article
IX of the Company’s Articles of Incorporation provides for the indemnification of our directors and officers to the fullest
extent permitted by law.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors and officers pursuant
to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.
EXECUTIVE
COMPENSATION
Summary
Compensation Table
The
following table sets forth the compensation awarded to, earned by or paid to those persons who were the Company’s Chief
Executive Officer and Chief Financial Officer in 2017 and 2018 (collectively, the “Named Executive Officers”). There
were no other executive officers of the Company whose total salary and bonus exceeded $100,000 for the periods presented.
Name
and Principal Position
|
|
Year
|
|
Earnings
|
|
|
Option
Awards
|
|
|
All
Other
Compensation
|
|
|
Total
Compensation
|
|
Ellen Berkers(1)
|
|
2018
|
|
$
|
21,562
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
21,562
|
|
Chief Executive and
Chief
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christopher Spencer(2)
|
|
2018
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Chief Executive Officer
|
|
2017
|
|
$
|
50,000
|
(3)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John Busshaus(4)
|
|
2018
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Chief Financial Officer
|
|
2017
|
|
$
|
50,000
|
(5)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
50,000
|
|
|
(1)
|
Ms.
Berkers was appointed Chief Executive Officer and Chief Financial Officer on November 13, 2018. On February 6, 2019, Ms. Berkers
resigned as Chief Executive Officer in connection with the appointment of Robert Paladino to that office who subsequently resigned
on July 31, 2019. Mr. Paul Bartley was appointed to the office of the Chief Executive Officer. On June 24, 2019, Ms. Berkers
resigned as Chief Financial Officer in connection with the appointment of Ruud Huisman to such office.
|
(2)
|
Mr. Spencer resigned as Chief Executive Officer
effective November 13, 2018.
|
|
|
(3)
|
Earned but not paid as of December 31, 2017.
The salary amounts due as of November 13, 2018 were settled by the issuance of an aggregate of 1,011,781 shares of common
stock to Mr. Spencer.
|
|
|
(4)
|
Mr. Busshaus resigned as Chief Financial Officer
effective November 13, 2018.
|
|
|
(5)
|
Earned but not paid as of December 31, 2017.
The salary amounts due as of November 13, 2018 were settled by the issuance of an aggregate of 1,011,781 shares of common
stock to Mr. Busshaus.
|
Employment
Arrangements
Mr.
Spencer, the former Chief Executive Officer and director of the Company, provided services to the Company under a consulting arrangement
to help in the winding down of the operations of the Company prior to the acquisition of Natur Holding BV and facilitate the transition
requirements of the acquisition by the Company. Mr. Spencer was paid a monthly amount of $2,000, until his resignation at May
31, 2019.
Mr.
Paul Bartley, the current Chief Executive Officer, is employed on a full time basis at a monthly salary of €18,000. The Company
anticipates that it will enter into an employment agreement with Mr. Bartley in due course.
Mr.
Rudolf Derk Huisman, the current Chief Financial Officer, is employed on a full-time basis at a monthly salary of €15,000.
The Company has entered into a management agreement with Mr. Huisman as of July 1, 2019. See Certain Relationships and Related
Party Transactions, below, for a description of the contractual arrangements between Mr. Huisman and the Company.
Mr.
Anthony Joel Bay is compensated as a director through his personal service company. See Certain Relationships and Related Party
Transactions, below, for a description of these contractual arrangements.
Mr.
Mark Simmonds is compensated as a director through his personal service company. See Certain Relationships and Related Party transactions,
below, for a description of this contractual arrangements.
Mr.
Boaz Wachtel is compensated as a director under a service agreement. See Certain Relationships and Related Party transactions,
below, for a description of this contractual arrangements.
Outstanding
Equity Awards at Fiscal Year 2018 End
There
were no equity awards outstanding for the Named Executive Officers as of December 31, 2018.
Grants
of Plan-Based Awards for Fiscal Year 2018
There
were no plan-based equity awards made to the Named Executive Officers during fiscal 2018.
Option
Exercises and Stock Vested at Fiscal Year 2018 End
There
were no option exercises and restricted stock that vested during fiscal 2018 for the Named Executive Officers.
Pension
Benefits
As
of December 31, 2018, the Company does not have any plans that provide for payments or other benefits at, following, or in connection
with retirement.
Nonqualified
Deferred Compensation
The
Company does not have a Deferred Compensation Plan for its executive officers.
Other
Potential Post-Employment Payments for Fiscal Year 2018 End
As
of December 31, 2018, there were no Named Executive Officers with employment contracts that require or required severance or other
post-employment payments.
Summary
Information about Equity Compensation Plans
The
Company currently has a stock option plan to incentivize those that contribute to the development and operations of the Company.
This plan is available for employees, consultants, officers and directors or similarly positioned persons of the Company. 16,240,000
shares currently have been allocated to equity award plans or similar arrangements; it is contemplated that approximately 40,000,000
shares of common stock will additionally be allocated to such plans or arrangements. The terms of any equity award plan or arrangement
and the terms of specific awards are determined by the Board of Directors after having satisfied the requirements of any tax laws,
national exchange requirements and corporate requirements.
Director
Compensation
We
reimburse directors for out-of-pocket expenses they incur when attending meetings of the Board either directly or through their
personal service company arrangements. Salaried or otherwise compensated executives who serve as directors do not receive any
compensation for their services as directors. As of December 31, 2018, there were no stock options outstanding that were granted
to any of our directors.
The
directors of Natur, when appointed or otherwise taking office, will be compensated at a rate to be determined by the Board of
Directors of Natur, with the approval of the Board of Directors of the Company. The compensation arrangement may be through a
wholly owned personal service company of the director in certain cases.
DIVIDEND
POLICY
We
have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future
earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable
future, if at all.
MARKET
INFORMATION FOR COMMON STOCK
Market
Information
Until
January 7, 2019, our common stock traded on the OTCQB under the symbol “FUTU,” when it was changed to “NTRU”
to reflect the change in the corporate name to Natur International Corp. On January 18, 2019, our common stock began trading on
the Pink Open Market until April 26, 2019, when it recommenced trading on the OTCQB. Any over-the-counter-market quotations reflect
inter-dealer prices, without retail mark-up, mark-down or commissions and may not necessarily represent actual transactions.
Holders
We
have approximately 347 stockholders of record. This figure doesn’t include an indeterminate number of stockholders who hold
their shares in “street name”.
Dividends
We
have not declared and paid any dividends since inception, and it is anticipated that the Board of Directors will not declare any
dividends in the future, electing to retain funds for the expansion of its business..
CERTAIN
RELATIONSIHPS AND RELATED PARTY TRANSACTIONS
Parent
Corporation
On
July 19, 2019, the Company entered into a letter of intent with Share International Holdings B.V., a corporation formed under
the laws of the Netherlands (“SIH”), indicating the Company’s interest in pursuing a business arrangement with
SIH, the terms of which are to be negotiated after a period of due diligence by each company about the other. Mr. Paul Bartley,
the Company’s Chief Executive Officer and a director, is a principal of SIH. In connection with the exploration of a business
arrangement, the Company lent $250,000 to SIH under a promissory note, due January 4, 2020. The note bears interest at the rate
of 10%. The repayment obligation under the Note will be cancelled if no business arrangement is concluded due to a breach by the
Company of any agreement for the business arrangement that is concluded in the future, either party to the Note experiences a
material adverse change, or the business arrangement is not approved by the stockholders or owners of the respective parties to
the extent that approval is required. The Note also has other standard default provisions under which the Company may declare
a default.
The
Company had a consulting arrangement with Christopher Spencer, the former Chief Executive Officer and director of the Company,
payable at the monthly rate of $2,000.
Subsidiary
Corporation – Natur Holding BV Reorganization
During
the fiscal years ended December 31, 2017 and 2018, the following transactions were carried out in which Natur Holding BV, a discontinued
wholly owned subsidiary of the Parent Company, was or is to be a participant and the amount involved exceeds $120,000 or one percent
of the average of the Company’s total estimated revenues for full year 2018, and in which any related person had or will
have a direct or indirect material interest. In connection with the Company’s corporate restructuring plan, Natur Holding
BV was closed and Natur BPS BV assumed the Natur Holding BV legacy business in May 2019.
On
May 1, 2019, Natur Holding BV filed a Petition in the Netherlands Court for the District of Amsterdam (“Petition”)
for the liquidation of the company and the transfer of certain assets and retained liabilities to Natur BPS B.V., a wholly owned
subsidiary of Natur International Corp., which operates under the trade name Natur Functionals. This court process allowed the
historical business of the company, its beverage business, to be continued and eliminated a substantial amount of the liabilities
of the Company. As a result of the Petition the control of the Parent Company over Natur Holding B.V. for financial reporting
purposes ended, and its investment in it was deconsolidated as of May 1, 2019.
AMC
Innova and AMC Novel Technologies has been the supplier of the juices that the Company is selling. Both AMC-companies are directly
affiliated with SFI Gestion de Participaciones Minoritarias, a significant shareholder of the Company. Total purchased juices
from AMC for the 12 months ended December 31, 2017 and December 31, 2018 were $0.9 million and $1.4 million, respectively, including
inventory.
Efficiency
Life Fund (“ELF”) provided loans to Natur Holding BV during the fiscal years 2017 and 2018. As of December 31, 2018,
the loans aggregated $11,671,743. No interest was charged to Natur Holding BV on the loans. Natur Holding BV has entered into
a Debt Conversion and Extinguishment Agreement where the Company converts $3,000,000 of the aggregate balance into a long-term
loan, due at December 31, 2022. For the remainder of the loan 78,832.399 shares of class Series C Preferred Stock will be issued
at a current conversion rate being at $0.1122. These preferred shares were converted into shares of Common Stock on July 3, 2019.
The agreement is pursuant to a “topping up” anti-dilution provision, which may result in a maximum of 213,092,756
additional shares of Common Stock being issued, the current conversion rate being at $.1122 per share of common stock and the
maximum conversion rate being at $.030303 per share of common stock.
Employment
Arrangements Through Subsidiary
Rudolf
Derk Huisman, the Company’s Chief Financial Officer, and a director of the Company, is paid through through Pas Beheer BV,
his personal service company in the Netherlands. Pas Beheer BV entered into an agreement the Company for all his services to the
Company. The agreement complies with the corporate service agreement provisions of Netherlands law and is governed by the law
of that jurisdiction. Pas Beheer will be paid €180,000 per annum, monthly, reimbursed for expenses in providing the services,
and was issued a six-year option to purchase an aggregate of 7,319,321 shares of common stock of the Company. The agreement also
has typical intellectual property, non-competition, and confidentiality provisions for the benefit of Natur and the Company. The
option granted by the Company provides for equal quarterly vesting of the shares commencing March 31, 2019, over three years ending
December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time until March 31, 2025, the sixth-year
anniversary. The option provides for cashless exercise and may be registered for resale at the election of the Company. If the
service agreement is terminated for a breach thereof, all vested and unvested options will terminate, but if the service agreement
is otherwise terminated, then only then vested options will continue to be exercisable for the full term. Any unvested options
will accelerate if there is a change of control through the sale of 90% or more of the equity of the Company. The agreement assumes
a number of standard hours to be worked.
Mark
Simmonds is compensated under an Agreement to Render Independent Board Member Services, under which he will be paid an annual
fee of €24,000, payable monthly, and an additional €1,000 per day for every day that he devotes to preparation and physical
attendance for his board duties and other activities requested of the board, up to a maximum of €15,000 per month. It is
explicitly agreed that services as committee member or other additional projects or services are included in this fee arrangement.
Additionally, the Company will grant MS Ltd the right, which right MS Ltd may accept at its sole discretion, to acquire a number
of shares equal to approximately 1 percent of shares in the issued and outstanding capital of NIC, each with a nominal value of
$.038.
Boaz
Wachtel Mr. Wachtel is compensated under an Agreement to Render Independent Board Member Services, under which he will be paid
an annual fee of €24,000, payable monthly, and an additional €1,000 per day for every day that he devotes to preparation
for his board duties, up to a maximum of €15,000 per month. The per diem includes compensation for services as a committee
member and working on other projects or services for the board of directors and Company. The Company has offered to Mr. Wachtel
an option grant for the right to purchase up to approximately 1% of the issued and outstanding capital of the Company, at a purchase
price per share of $0.038.
Anthony
Joel Bay, a director of the Company, through La Bay Ventures Inc., his personal service company in the United States, has entered
into a four-year agreement with Natur Holding BV (that was assumed by Natur CBD BV in May 2019) for all his services to it and
the Company. The agreement complies with the corporate service agreement provisions of Netherlands law and is governed by the
law of that jurisdiction. La Bay Ventures will be paid € 24,000 per annum, monthly, reimbursed for expenses in providing
the services, and will be issued a six-year option to purchase an aggregate of 7,319,321 shares of common stock of the Company.
The agreement also has typical intellectual property, non-competition, and confidentiality provisions for the benefit of both
Natur and the Company. The option granted by the Company provides for equal quarterly vesting of the shares commencing March 31,
2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time until
March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at the
election of the Company. If the service agreement is terminated for a breach thereof, all vested and unvested options will terminate,
but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable for the full
term. Any unvested options will accelerate if there is a change of control through the sale of 90% or more of the equity of the
Company. The agreement assumes a number of standard hours to be worked. For any additional work performed beyond the director’s
agreement, a separate consulting agreement will be established.
Nina
Storms, a director of the Company, is compensated through her personal service company with an annual payment of €24,000
and reimbursement of her expenses. Furthermore, it has been agreed that Ms. Storms can invoice the Company for specific consulting
activities for an amount of €15,000 per month.
Ellen
Berkers, the Company’s former Chief Financial Officer and director resigned in June 2019 and through Montrose Executive
Management BV, her personal service company in the Netherlands, has entered into a termination agreement with the Company. The
agreement stipulates that Mrs. Berkers will be paid for her services until June 30 2019 and that the 5,800,000 granted options
will vest immediately. The underlying shares will be transferred to her personal service company before the end of September 2019.
PRINCIPAL
STOCKHOLDERS
Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The
following table sets forth information regarding beneficial ownership of the Company’s Common Stock as of the date of this
prospectus (i) by our executive officers and directors; (ii) by all executive officers and directors as a group; and (iii) by
each person who is known by us to beneficially own more than 5% of the common stock.
Name of Beneficial Owner
|
|
Amount and Nature of
Beneficial Ownership(1)
|
|
|
Percentage(2)
|
|
|
|
|
|
|
|
|
Executive Officers and Directors
|
|
|
|
|
|
|
Paul Bartley
|
|
|
-
|
|
|
|
-
|
|
Rudolf Derk Huisman(3)
|
|
|
-
|
|
|
|
-
|
|
Anthony Joel Bay(4)
|
|
|
-
|
|
|
|
-
|
|
Nina Storms
|
|
|
-
|
|
|
|
-
|
|
Frans van der Minne
|
|
|
-
|
|
|
|
-
|
|
Mark Simmonds (5)
|
|
|
-
|
|
|
|
-
|
|
Boaz Wachtel (6)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Directors and executive officers as a group (7 persons)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Five Percent Stockholders
|
|
|
|
|
|
|
|
|
Alpha Capital Anstalt (7)
|
|
|
2,376,145
|
|
|
|
4.99
|
%
|
|
|
|
|
|
|
|
|
|
SFI Gestion de Participaciones Minoritarias, SL (8)
|
|
|
82,450,133
|
|
|
|
25.60
|
%
|
|
|
|
|
|
|
|
|
|
NL Life Sciences Holding B.V. (9)
|
|
|
82,450,133
|
|
|
|
25.60
|
%
|
|
|
|
|
|
|
|
|
|
Efficiency Investment Fund – 6th Wave SP (10)
|
|
|
103,112,399
|
|
|
|
32.00
|
%
|
|
|
|
|
|
|
|
|
|
Stichting Apollo Investments Management (11)
|
|
|
18,492,520
|
|
|
|
5.07
|
%
|
|
|
|
|
|
|
|
|
|
Ranny Davidoff (12)
|
|
|
52,631,580
|
|
|
|
15.66
|
%
|
|
|
|
|
|
|
|
|
|
Arcade Dynamic Event Fund Ltd. (13)
|
|
|
23,578,948
|
|
|
|
6.81
|
%
|
|
|
|
|
|
|
|
|
|
Atlantic Global Fund B.V. (14)
|
|
|
17,684,210
|
|
|
|
5.20
|
%
|
|
(1)
|
Unless
otherwise indicated, each person has sole investment and voting power with respect to the shares indicated, subject to community
property laws, where applicable. Includes any securities that such person has the right to vote or acquire within sixty (60) days
of October 21, 2019, pursuant to options, warrants, conversion privileges or other rights.
|
|
(2)
|
Based
on 322,230,038 shares of Common Stock issued and outstanding.
|
|
(3)
|
Excludes
shares of Common Stock that are subject to a director compensatory option held by a personal service company for Mr. Huisman for
an aggregate of 7,319,321 shares of Common Stock that vests quarterly over the three years commencing March 31, 2019 and is exercisable
commencing January 1, 2022.
|
|
(4)
|
Excludes
shares of Common Stock that are subject to a director compensatory option held by the personal service company for Mr. Bay for
an aggregate of 7,319,321 shares of Common Stock that vests quarterly over the three years commencing March 31, 2019 and is exercisable
commencing January 1, 2022.
|
|
(5)
|
Excludes
shares of Common Stock that Mr. Simmonds, through is personal service company, may acquire in an amount up to 1% of the issued
and outstanding shares of the Company at a purchase price per shares of $0.038, under an option agreement connected to his employment
as a director.
|
|
(6)
|
Excludes
shares of Common Stock that Mr. Wachtel may acquire in an amount up to 1% of the issued and outstanding shares of the Company
at a purchase price per share of $0.038 under an option agreement connected to his employment as a director.
|
|
(7)
|
Alpha
holds 2,397.131 shares of Series A Preferred Stock which are currently convertible into an aggregate of 79,105,402 shares of common
stock. Alpha also holds two warrants to acquire up to 39,000,000 shares of common stock. The total number of shares of common
stock that Alpha is able to acquire is 118,105,402 shares. Under the terms of the Series A Preferred Certificate of Designation
and the terms of the warrants, the holder thereof may not own in excess of 4.9% of the common stock of the Company, subject to
its ability to increase that ownership level to 9.9%, which 4.9% amount currently is equal to 16,079,278 shares of common stock.
The address for Alpha Capital Anstalt is Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein. Konrad Ackermann holds voting and
dispositive power over such shares.
|
|
(8)
|
The
address of this stockholder is Crta. Madrid – Cartagena, Km. 383, Espinardo, Murcia, Spain. Jose Miguel Uriona holds voting
and dispositive power over these shares.
|
|
(9)
|
The
address of this stockholder is Jachthavenweg 124, 1081 KJ Amsterdam, the Netherlands. Karen Brink holds voting and dispositive
power over these shares.
|
|
(10)
|
The
address of this stockholder is c/o Walkers Corporate Limited, Cayman Corporate Centre, 27 Hospital Road, Grand Cayman, KY1-9008
Cayman Islands. Tommaso Mingazzini and Stefano Zavaglia hold voting and dispositive power over these shares.
|
|
(11)
|
The
address of this stockholder is c/o Apollo Investments C.V., Jachthavenweg 124, 1081 KJ Amsterdam the Netherlands. Albert Brink
and Clayton Day hold voting and dispositive power over these shares. Albert Brink and Clayton Day hold voting and dispositive
power over these shares.
|
|
(12)
|
Mr.
Davidoff holds 26,315.790 shares of Series G Preferred Stock which are currently convertible into an aggregate of 26,315,790
shares of common stock and a warrant to acquire up to 26,315,790 shares of common stock. The total number of shares of common
stock that Mr. Davidoff is able to acquire is 52,631,580 shares. The address for Mr. Davidoff is 5 Park Place, Rue de la Impasse,
98000 Monaco.
|
|
(13)
|
Arcade
Dynamic Event Fund Ltd. holds 11,789.474 shares of Series G Preferred Stock which are currently convertible into an aggregate
of 11,789,474 shares of common stock. The fund also holds a warrant to acquire up to 11,789,474 shares of common stock.
The total number of shares of common stock that the fund is able to acquire is 23,578,948 shares. The address for the fund is
Building 2, Caves Village, Nassau, The Bahamas, and Alessandro Russo holds voting and dispositive power over such shares.
|
|
(14)
|
Atlantic
Global Fund B.V. holds 8,842.105 shares of Series G Preferred Stock which are currently convertible into an aggregate of 8,842,105
shares of common stock. The fund also holds a warrant to acquire up to 8,842,105 shares of common stock. The total
number of shares of common stock that the fund is able to acquire is 17,684,210 shares. The address for the fund is Pareraweg 45,
Willemstad, Curacao, Dutch Antilles
and
Mr. Eric Andersen holds voting and dispositive power over such shares.
|
DESCRIPTION
OF CAPITAL STOCK
Capital
Stock
Under
our Second Amended and Restated Articles of Incorporation, as further amended (collectively “Articles of Incorporation”),
we are authorized to issue 750,000,000 shares of common stock, par value $0.001 per share, of which 322,230,038 shares were issued
and outstanding as of October 21, 2019, and 5,000,000 shares of preferred stock, par value $0.001 per share, of which 182,688.938
shares have been classified as five different series of convertible preferred stock, of which 133,346.833 are issued and outstanding.
On
June 26, 2019, the Company filed an amendment to its Articles of Incorporation increasing the number of authorized shares of common
stock to 750,000,000 shares. As a result of the increase in the common stock capitalization, all of the issued and outstanding
shares of Series B Preferred Stock and Series C Preferred Stock automatically converted into 100,000,000 and 78,832,399 shares
of common stock, respectively, and those shares of preferred stock were returned to the status of authorized but unissued shares
of preferred stock.
Common
Stock
The
holders of our common stock are entitled to one vote per share on all matters submitted to a vote of the stockholders, including
the election of directors. Our Articles of Incorporation do not provide for cumulative voting in the election of directors. The
holders of our common stock will be entitled to cash dividends as may be declared, if any, by our Board of Directors from funds
available. Upon liquidation, dissolution or winding up of the Company, the holders of our common stock will be, subject to the
rights of the issued and outstanding shares of preferred stock, entitled to receive pro rata all assets available for distribution
to the holders of common stock. There are no pre-emptive, conversion, or redemption rights attached to our common stock.
Series
A Preferred Stock and Related Warrants
Our
Articles of Incorporation currently designate 2,397.131 shares of Series A Preferred Stock. Holders of Series A Preferred Stock
have the option to convert their shares into that number of shares of common stock equal to the stated value (i.e. $1,000), divided
by the conversion price of $0.030303 (subject to adjustment as set forth in the Articles of Incorporation). Currently, the Series
A Preferred Stock is convertible into 79,105,403 shares of common stock.
The
Series A Preferred Stock has no voting rights, other than as provided by law as to class matters. Holders of Series A Preferred
Stock are entitled to receive dividends as declared and paid on the Company’s common stock on an as-converted basis. Upon
liquidation, dissolution or winding-up of the Company, the holders of Series A Preferred Stock shall be entitled to receive an
amount equal to the stated value, plus any accrued and unpaid dividends thereon, for each share of Series A Preferred Stock before
any distribution or payment shall be made to the holders of common stock and subsequently issued shares of preferred stock.
Of
the shares of the Series A Preferred Stock, the common stock underlying 397.131 of those shares may also be sold as of the date
of this prospectus pursuant to Rule 144 on the basis of a holding period in excess of one year.
In
connection with the issuance of the Series A Preferred Stock, the Company issued two warrants to purchase up to 39,000,000 shares
of common stock, subject to adjustment for changes in the common stock of the Company. Of the warrant for 33,000,000 shares of
common stock, 16,500,000 of the shares may be purchased at $.0304 per share, and the balance, 16,500,000 shares, may be purchased
at $.06 per share, until October 21, 2021. The first shares to be issued under the warrant will have the lower exercise price.
The warrant for 6,000,000 shares may be exercised at a per share price of $.06, until November 13, 2022. The number of shares
and the exercise prices are subject to adjustment for changes in the common stock.
All
the shares of common stock issuable on conversion of the Series A Preferred Stock and underlying the warrants issued to the holder
of the Series A Preferred Stock have registration rights, which are satisfied in part by the registration statement of which this
Prospectus is a part. If the shares of common stock underlying the warrants are not registered for resale on an effective registration
statement at any time, then the warrants have the right of cashless exercise. The Company will reimburse the holder of the
Series A Preferred Stock and the related warrants for any buy-in penalties if it fails to timely deliver the shares of common
stock upon conversion or exercise.
Series
D, Series E and Series G Preferred Stock and Related Warrants
On
October 16, 2019, the Company filed Certificates of Amendment to its Certificate of Incorporation to create 15,789.473 shares
of Series D Preferred Stock (“Series D Preferred Stock”), 56,423.386 shares of Series E Preferred Stock (“Series
E Preferred Stock”), and 58,736.843 shares of Series G Preferred Stock (“Series G Preferred Stock”). These were
created in connection with the sale of preferred stock and warrants, in a private placement for an aggregate purchase price of
approximately $4,500,000 under securities purchase agreements concluded in June and July 2019 with several non-United States purchasers.
The
three classes of preferred stock have no voting rights, except as provided by law as to class matters. The liquidation preference
of each class is based on the purchase price of the shares of that particular class, and is subordinate to prior issued, outstanding
series of preferred stock and in preference to subsequent issued series of preferred stock. Each of the three series of preferred
stock is convertible into shares of common stock at the option of the holder until December 31, 2021, and if not then converted
will automatically convert into common stock on December 31, 2021. The conversion rate is subject to typical anti-dilution rights
for stock splits and reorganizations. The three classes of preferred stock may be converted into 130,949,703 shares of common
stock (subject to adjustment as set forth in the Articles of Incorporation).
In
connection with the issuance of the Series D Preferred Stock, Series E Preferred Stock and the Series G Preferred stock, the Company
issued a warrant to purchase shares of common stock. The warrant issued to the Series D Preferred Stock holder is the right to
purchase up to 20,000,000 shares of common stock at an exercise price of $.06 per share until 2021. The warrant issued to the
Series E Preferred Stock holder is the right to purchase up to 56,423,387 shares of common stock at an exercise price of $.0304
per share until 2021. The warrant issued to the Series G Preferred Stock holder is the right to purchase up to 58,736,843 shares
of common stock at an exercise price of $.076 per share until 2021. The warrant share number and exercise price is subject to
adjustment for changes in the common stock. The above warrants represent the right to purchase 130,949,703 shares of common stock
from time to time. The warrants do not have cashless exercise rights.
Only
the shares of common stock underlying the Series G Preferred Stock and warrants sold to the holder of the Series G Preferred Stock
were granted registration rights in connection with their purchase of the Company securities.
Series
F Preferred Stock
In
October 2019 the Company created a series of authorized but unissued preferred stock designated as the “Series F Preferred
Stock.” In total of 49,342.105 shares. The shares may be issued by themselves or as part of a unit, for cash or other consideration.
The Series F Preferred Stock will be convertible into 49,342,105 shares of common stock (subject to adjustment as set forth in
the Articles of Incorporation). The Company currently is in negotiations for an offering that will include the shares, but as
yet the Company has not concluded the sale.
The
Series F Stock does not have any dividend rights, a liquidation preference per share of $30.40, payable after satisfaction of
the liquidation preference of prior issued, outstanding preferred stock of the Company, the right to vote with the common stock
on an as converted basis, and optional conversion rights. The Series F Stock also has the right to vote as a separate class as
provided by law. It is also mandatorily convertible if at any time (a) the closing price of the Company’s common stock on
the trading market for the common stock exceeds $0.0608 (such dollar amount subject to appropriate adjustment in the event of
an adjustment of the conversion ratio of the Series F Preferred Stock) and (b) the dollar value of the common stock traded on
the Eligible Market (as defined) exceeds $200,000, provided that at such time there is a sufficient amount of authorized but unissued
Common Stock available to be issued upon conversion in full of all the shares of Series F Preferred Stock. The Company will reimburse
the holder for any buy-in penalties if it fails to timely deliver the shares of common stock upon conversion.
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock and the series of preferred stock is Issuer Direct. The transfer agent’s
address is 1981 East Murray-Holladay Road, Suite 100, Salt Lake City, UT 84117, and its telephone number is (801)-272-9294. The
global headquarters office if Issuer Direct is located at 500 Perimeter Park Drive, Suite D, Morrisville NC 27560 and its telephone
number is 1-919-481-4000
LEGAL
MATTERS
The
validity of the shares of common stock offered hereby will be passed upon for us by Golenbock Eiseman Assor Bell & Peskoe
LLP, New York, New York.
EXPERTS
The
audited financial statements of Natur International Corp. and its subsidiaries as of December 31, 2018 and 2017, incorporated
by reference in this prospectus and the registration statement, have been audited by Malone Bailey LLP, an independent registered
public accounting firm, as stated in their report. Such financial statements have been included in reliance upon the report of
such firm given upon its authority as an expert in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement on Form S-1, including exhibits and schedules, under the Securities Act with
respect to the shares of common stock to be sold in this offering. This prospectus, which constitutes a part of the registration
statement, contains all of the information set forth in the registration statement or the exhibits and schedules that are part
of the registration statement. For further information about us and our common stock, you may refer to the registration statement.
You
may read, without charge, and copy, at prescribed rates, all or any portion of the registration statement or any reports, statements
or other information in the files at the public reference room at the SEC’s principal office at 100 F Street NE, Washington,
D.C., 20549. You may request copies of these documents, for a copying fee, by writing to the SEC. You may call the SEC at 1-800-SEC-0330
for further information on the operation of its public reference room. Our filings, including the registration statement, will
also be available to you on the Internet website maintained by the SEC at http://www.sec.gov.
NATUR
INTERNATIONAL CORP.
AND
SUBSIDIARIES
INDEX
TO FINANCIAL STATEMENTS
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the members and Board of Directors of Natur International Corp.
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheets of Natur International Corp. and its subsidiaries (collectively, the
“Company”) as of December 31, 2018 and 2017, and the related consolidated statements of operations and comprehensive
loss, stockholders’ deficit, and cash flows for the years then ended, and the related notes (collectively referred to as
the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as December 31, 2018 and 2017, and the results of their operations and their cash flows for
the years then ended, in conformity with accounting principles generally accepted in the United States of America.
Going
Concern Matter
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency
that raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters
are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.
Basis
for Opinion
These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on
the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.
/s/
MaloneBailey, LLP
www.malonebailey.com
We
have served as the Company’s auditor since 2018.
Houston,
Texas
April
15, 2019
NATUR
INTERNATIONAL CORP.
CONSOLIDATED
BALANCE SHEETS
ASSETS
|
|
NOTE
|
|
December 31,
2018
|
|
|
December 31,
2017
|
|
|
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
|
128,364
|
|
|
|
1,082,734
|
|
Accounts receivable
|
|
|
|
|
42,744
|
|
|
|
39,165
|
|
Related party receivable
|
|
4
|
|
|
1,833
|
|
|
|
131,749
|
|
Inventories
|
|
|
|
|
179,072
|
|
|
|
269,469
|
|
Other current assets
|
|
5
|
|
|
99,535
|
|
|
|
360,590
|
|
Current assets held for disposal
|
|
14
|
|
|
377,628
|
|
|
|
401,747
|
|
Total Current Assets
|
|
|
|
|
829,176
|
|
|
|
2,285,454
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Current Assets
|
|
|
|
|
|
|
|
|
|
|
Intangible assets
|
|
|
|
|
37,353
|
|
|
|
85,694
|
|
Fixed assets
|
|
6
|
|
|
523,510
|
|
|
|
667,538
|
|
Other assets
|
|
7
|
|
|
201,160
|
|
|
|
224,560
|
|
Non-current assets held for disposal
|
|
14
|
|
|
51,165
|
|
|
|
61,719
|
|
Total Non-Current Assets
|
|
|
|
|
813,188
|
|
|
|
1,039,511
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
|
|
|
1,642,364
|
|
|
|
3,324,965
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
|
|
Accounts Payable
|
|
|
|
|
1,127,345
|
|
|
|
993,667
|
|
Accrued Expenses & other contingent liabilities
|
|
8
|
|
|
583,161
|
|
|
|
672,622
|
|
Related party other liabilities
|
|
9
|
|
|
2,032,705
|
|
|
|
1,195,627
|
|
Related party other notes
|
|
10
|
|
|
1,072,849
|
|
|
|
552,061
|
|
Convertible note payable
|
|
11
|
|
|
1,600,710
|
|
|
|
1,559,875
|
|
Related party convertible notes payable
|
|
12
|
|
|
11,671,743
|
|
|
|
11,031,512
|
|
Current liabilities held for disposal
|
|
14
|
|
|
887,126
|
|
|
|
252,841
|
|
Total Current Liabilities
|
|
|
|
|
18,975,639
|
|
|
|
16,258,205
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
|
|
18,975,639
|
|
|
|
16,258,205
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ Deficit
|
|
|
|
|
|
|
|
|
|
|
Common stock, $0.001 par value, 200,000,000 shares authorized, 129,049,192 and 115,759,999 issued and outstanding as of December 31, 2018 and December 31, 2017 respectively.
|
|
|
|
|
129,049
|
|
|
|
115,760
|
|
Preferred stock A, $0.001 par value, 2,469.131 shares authorized, 2,469.131 and $Nil issued and outstanding as of December 31, 2018 and December 31, 2017 respectively. Convertible to common stock at a 1:33 ratio.
|
|
|
|
|
2
|
|
|
|
-
|
|
Preferred stock B, $0.001 par value, 100,000 shares authorized, 100,000 and $Nil issued and outstanding as of December 31, 2018 and December 31, 2017 respectively. Convertible to common stock at a 1:1000 ratio.
|
|
|
|
|
100
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional paid in capital
|
|
|
|
|
5,174,269
|
|
|
|
3,316,560
|
|
Total Shareholders’ deficit
|
|
|
|
|
(22,299,570
|
)
|
|
|
(15,250,748
|
)
|
Accumulated other comprehensive loss
|
|
|
|
|
(337,125
|
)
|
|
|
(1,114,812
|
)
|
TOTAL SHAREHOLDERS’ DEFICIT
|
|
|
|
|
(17,333,275
|
)
|
|
|
(12,933,240
|
)
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ DEFICIT
|
|
|
|
|
1,642,364
|
|
|
|
3,324,965
|
|
The
accompanying notes are an integral part of these consolidated financial statements
NATUR
INTERNATIONAL CORP.
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|
December 31,
2018
|
|
|
December 31,
2017
|
|
|
|
|
|
|
|
|
REVENUE
|
|
|
1,675,160
|
|
|
|
526,339
|
|
|
|
|
|
|
|
|
|
|
COST OF GOODS SOLD – RELATED PARTY
|
|
|
935,156
|
|
|
|
302,595
|
|
COST OF GOODS SOLD
|
|
|
117,918
|
|
|
|
130,310
|
|
|
|
|
1,053,074
|
|
|
|
432,905
|
|
GROSS MARGIN
|
|
|
622,086
|
|
|
|
93,434
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES
|
|
|
|
|
|
|
|
|
Wages & Salaries
|
|
|
1,309,965
|
|
|
|
1,873,130
|
|
Selling, General & Administrative
|
|
|
4,613,549
|
|
|
|
5,455,188
|
|
Amortization & depreciation
|
|
|
209,265
|
|
|
|
170,977
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
6,132,779
|
|
|
|
7,499,295
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS
|
|
|
(5,510,693
|
)
|
|
|
(7,405,861
|
)
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
194,064
|
|
|
|
327,769
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
|
|
|
(5,704,757
|
)
|
|
|
(7,733,630
|
)
|
|
|
|
|
|
|
|
|
|
Income taxes
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM CONTINUING OPERATIONS
|
|
|
(5,704,757
|
)
|
|
|
(7,733,630
|
)
|
|
|
|
|
|
|
|
|
|
Discontinued operations (Note 14)
|
|
|
|
|
|
|
|
|
Loss on disposal of subsidiary
|
|
|
(56,762
|
)
|
|
|
-
|
|
Loss from operations of discontinued Component
|
|
|
(1,287,303
|
)
|
|
|
(1,416,010
|
)
|
|
|
|
|
|
|
|
|
|
NET LOSS
|
|
|
(7,048,822
|
)
|
|
|
(9,149,640
|
)
|
|
|
|
|
|
|
|
|
|
Earnings Per Share
|
|
|
(0.06
|
)
|
|
|
(0.08
|
)
|
Diluted Earnings Per Share
|
|
|
(0.06
|
)
|
|
|
(0.08
|
)
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
(7,048,822
|
)
|
|
|
(9,149,640
|
)
|
Other comprehensive income (loss)
|
|
|
777,687
|
|
|
|
(968,348
|
)
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE LOSS
|
|
|
(6,271,135
|
)
|
|
|
(10,117,988
|
)
|
The
accompanying notes are an integral part of these consolidated financial statements
NATUR
INTERNATIONAL CORP.
CONSOLIDATED
STATEMENTS OF SHAREHOLDERS’ DEFICIT
|
|
Common stock
|
|
|
Preferred A
|
|
|
Preferred B
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares
|
|
|
Amount
(.001 par)
|
|
|
Issued
shares
|
|
|
Amount
(.001 par)
|
|
|
Issued
shares
|
|
|
Amount
(.001 par)
|
|
|
Paid in
Capital
|
|
|
Retained
deficit
|
|
|
Accumulated
OCI
|
|
|
Total
|
|
Balance at December 31, 2016
|
|
|
115,759,999
|
|
|
|
115,760
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,316,560
|
|
|
|
(6,101,108
|
)
|
|
|
(146,464
|
)
|
|
|
(2,815,252
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9,149,640
|
)
|
|
|
|
|
|
|
(9,149,640
|
)
|
Other comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(968,348
|
)
|
|
|
(968,348
|
)
|
Balance at December 31, 2017
|
|
|
115,759,999
|
|
|
|
115,760
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,316,560
|
|
|
|
(15,250,748
|
)
|
|
|
(1,114,812
|
)
|
|
|
(12,933,240
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,048,822
|
)
|
|
|
|
|
|
|
(7,048,822
|
)
|
Recapitalization
|
|
|
13,289,193
|
|
|
|
13,289
|
|
|
|
2,469.131
|
|
|
|
2
|
|
|
|
100,000
|
|
|
|
100
|
|
|
|
1,857,709
|
|
|
|
|
|
|
|
|
|
|
|
1,871,100
|
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
777,687
|
|
|
|
777,687
|
|
Balance at December 31, 2018
|
|
|
129,049,192
|
|
|
|
129,049
|
|
|
|
2,469.131
|
|
|
|
2
|
|
|
|
100,000
|
|
|
|
100
|
|
|
|
5,174,269
|
|
|
|
(22,299,570
|
)
|
|
|
(337,125
|
)
|
|
|
(17,333,275
|
|
The
accompanying notes are an integral part of these consolidated financial statements
NATUR
INTERNATIONAL CORP.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
|
|
|
|
|
|
|
CASH FLOW FROM OPERATING ACTIVITIES
|
|
|
|
|
|
|
Net Loss
|
|
|
(7,048,822
|
)
|
|
|
(9,149,640
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities
|
|
|
|
|
|
|
|
|
Amortization & depreciation
|
|
|
209,265
|
|
|
|
170,977
|
|
Changes in:
|
|
|
|
|
|
|
|
|
- Accounts receivable
|
|
|
(3,579
|
)
|
|
|
95,287
|
|
- Related party receivable
|
|
|
129,916
|
|
|
|
(65,184
|
)
|
- Inventories
|
|
|
90,397
|
|
|
|
(216,017
|
)
|
- Other current assets
|
|
|
261,055
|
|
|
|
933,149
|
|
- Accounts payable
|
|
|
133,678
|
|
|
|
(765,934
|
)
|
- Accrued Expenses
|
|
|
22,749
|
|
|
|
1,195,627
|
|
- Accrued expenses – Related Parties
|
|
|
913,577
|
|
|
|
242,241
|
|
Net cash used by operating activities
|
|
|
(5,291,764
|
)
|
|
|
(7,559,494
|
)
|
Net cash provided from operating activities - Discontinued operations
|
|
|
620,074
|
|
|
|
26,141
|
|
|
|
|
|
|
|
|
|
|
CASH FLOW FROM INVESTING ACTIVITIES
|
|
|
|
|
|
|
|
|
Cash received for sale of property and equipment
|
|
|
6,504
|
|
|
|
-
|
|
Cash paid for purchase of property and equipment
|
|
|
-
|
|
|
|
(340,429
|
)
|
Net cash from/(used) in investing activities
|
|
|
6,504
|
|
|
|
(340,429
|
)
|
Net cash from/(used) in investing activities - Discontinued Operations
|
|
|
10,554
|
|
|
|
16,713
|
|
|
|
|
|
|
|
|
|
|
CASH FLOW FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
Related party loan repayments
|
|
|
-
|
|
|
|
(2,828,078
|
)
|
Related party loan additions
|
|
|
400,750
|
|
|
|
-
|
|
Cash received from acquisition
|
|
|
1,909,430
|
|
|
|
-
|
|
Convertible note payable
|
|
|
|
|
|
|
1,559,875
|
|
Related party convertible loan additions
|
|
|
1,145,452
|
|
|
|
11,031,512
|
|
Net cash provided from financing activities
|
|
|
3,455,632
|
|
|
|
9,763,309
|
|
Net cash from financing activities - Discontinued Operations
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Effect of foreign exchange rate changes on cash and cash equivalents
|
|
|
244,630
|
|
|
|
(968,348
|
)
|
|
|
|
|
|
|
|
|
|
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
|
|
(954,370
|
)
|
|
|
937,892
|
|
|
|
|
|
|
|
|
|
|
CASH AND CASH EQUIVALENTS beginning of period
|
|
|
1,082,734
|
|
|
|
144,842
|
|
CASH AND CASH EQUIVALENTS end of period
|
|
|
128,364
|
|
|
|
1,082,734
|
|
The
accompanying notes are an integral part of these consolidated financial statements
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – ORGANIZATION AND NATURE OF BUSINESS
Natur
International Corp was formerly named Future Healthcare of America. Future Healthcare of America was founded in 2012 and was traded
with stock ticker symbol FUTU. Future Healthcare of America was a provider of home healthcare services, including senior care,
occupational and speech therapy, and pediatric nursing services.
The
name change took place following the consummation of acquisition of Natur Holding B.V. and became effective Monday, January 7.
The stock ticker symbol has become NTRU. Currently the healthcare services are being wound down.
Natur
Holding B,V. (“we”, “our”, “the Company” or “Natur”) was founded in late 2015
and has its headquarters in Amsterdam, the Netherlands.
Our
current products include a range of cold pressed juices and healthy snacks. These products are currently sold either directly
or through distribution partners in the Netherlands and the United Kingdom.
Through
third party contract manufacturers, we apply patented technology to proprietary nutrient dense blends of fruit and vegetables.
These are bottled or packed with technically advanced food safety measures and cold high-pressure processing to bring fresh tasting
fruit and vegetable blends to market through more than fifteen product types. Natur’s distribution combines direct-to-business,
direct-to-consumer and through select distributors. We also operate our flagship branded store in the Amsterdam canal district
to operate as a consumer experiential environment.
The
Company products value proposition is to affordably provide the most authentic fresh fruit and vegetable juice experiences to
democratize clean, healthy, eating and drinking occasions.
Natur
operated as a private enterprise in the Netherlands from its founding in 2015 through November 13, 2018, when it was acquired
as a wholly owned subsidiary in a share exchange transaction by Future Healthcare of America on November 13, 2018, contemplated
by that certain Share Exchange Agreement, among the Company and the former shareholders of Natur Holding, B.V. (the “Share
Exchange Transaction”). In connection with the Share Exchange Transaction, the former shareholders of Natur received the
equivalent of 215,759,999 shares of the Common Stock (the “Common Stock”), which was issued in part as 115,760,000
shares of Common Stock and in part as 100,000 shares of voting, convertible Series B Preferred Stock (the “Series B Preferred
Stock”) representing 100,000,000 shares of Common Stock upon conversion. The Series B Preferred Stock will convert automatically
upon the Company increasing the number of shares of Common Stock of its authorized capital, which it plans to do promptly so as
to cause the conversion of the Series B Preferred Stock. Immediately after the Share Exchange Transaction, the former Natur shareholders
collectively own the controlling position among the shareholders of the Company
The
merger was accounted for as a reverse capitalization with Natur Holding BV being treated as the accounting acquirer. As such,
the historical information for all periods presented prior to the merger date relate to Natur Holding BV. Subsequent to the merger
date, the information relates to the consolidated entities of Natur with its subsidiary Natur Holding BV and the former subsidiaries
of Future Healthcare of America, that are currently in the process of being wound down and presented as discontinued operations.
In
connection with the acquisition, net cash received was $2,000,000 and costs incurred were $399,381 including professional fees
for legal, accounting services and finance commission.
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of presentation. The Company prepares its financial statements using the accrual basis of accounting in accordance with United
States generally accepted accounting principles (“US GAAP”).
Consolidation -
The financial statements presented reflect the accounts of Natur Holding B.V. and it’s direct or indirect subsidiaries.
All inter-company transactions have been eliminated in consolidation.
Use
of Estimates in Financial Statement Preparation. The preparation of financial statements in conformity with US GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent
assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
Customer
Concentration and Credit Risk. Two customers accounted for more than 58% of revenues from continuing operations for 2018.
One other customer exceeded 10% of revenues during the year ended December 31, 2017 accounting for 14% of revenue. No other customers
exceeded 10% of revenues during the year ended December 31, 2018. The Company believes it will continue to reduce the customer
concentration risks by engaging new customers and increasing activity of existing less active customers and smaller, newer customer
relationships. The Company is also utilizing its ability to sell its receivable debts to a third party to reduce the recoverability
risk of its larger accounts. While the Company continues to acquire new customers in an effort to grow and reduce its customer
concentration risks, management believes these risks will continue for the foreseeable future especially regarding revenue concentration.
Two
vendors accounted for more than 23% of accounts payable at December 31, 2018, and three vendors accounted for more than 22% of
accounts payable at December 31, 2017. No other vendors exceeded 10% of accounts payable at December 31, 2018 and December 31,
2017.
Cash
and Cash Equivalents. Cash equivalents include all highly liquid investments with original maturities of three months or less.
Accounts
Receivable. Accounts receivable are comprised of unsecured amounts due from customers. The Company carries its accounts receivable
at their face amounts less an allowance for bad debts. The allowance for bad debts is recognized based on management’s estimate
of likely losses per year, based on past experience and review of customer profiles and the aging of receivable balances. As of
December 31, 2018, and December 31, 2017, we did not record any allowance for bad debts. Selected account receivables are sold
to a factoring company with a transfer of risk of non-collectability.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
Inventory.
Inventory, consisting of raw materials, work in progress and finished goods, is valued at the lower of the inventory’s
costs or net realizable value, using the first in, first out method to determine the cost. Management compares the cost of inventory
with its net realizable value and an allowance is made to write down inventory to net realizable value, if lower.
Property
and Equipment. Property and equipment are valued at cost. Additions are capitalized and maintenance and repairs are charged
to expense as incurred. Gains and losses on dispositions of equipment are reflected in operations. Depreciation is provided using
the straight-line method over the estimated useful lives of the assets as follows:
Category
|
|
Estimated
Useful lives
|
Building and improvements
|
|
5
years
|
Machines and installations
|
|
5
years
|
Furniture and fixtures
|
|
7
years
|
Hardware and software
|
|
3
years
|
Intangible
Assets, and Long-Lived Assets. The Company recognizes an acquired intangible asset apart from goodwill whenever the intangible
asset arises from contractual or other legal rights, or when it can be separated or divided from the acquired entity and sold,
transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability.
Such intangibles are amortized over their useful lives. Impairment losses are recognized if the carrying amount of an intangible
asset subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.
The
Company’s long-lived assets, including intangibles, are reviewed for impairment whenever events or changes in circumstances
indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability
of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the
carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An
impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Long lived
assets were evaluated for impairment and no impairment losses were incurred during the years ended December 31, 2018 and 2017,
respectively.
Related
Party Transactions. The Board of Directors has adopted a Related Party Transaction Policy for the review of related person
transactions. Under these policies and procedures, the management reviews related person transactions in which we are or will
be a participant to determine if they are fair and beneficial to the Company. Financial transactions, arrangements, relationships
or any series of similar transactions, arrangements or relationships in which a related person has or will have a material interest
and that exceeds the lesser of: (i) $10,000, and (ii) one percent of the average of the Company’s total assets at year-end
for the last two completed fiscal years, in the aggregate per year are subject to the boards review. Any member of the board who
is a related person with respect to a transaction under review may not participate in the deliberation or vote requesting approval
or ratification of the transaction. Transactions that are subject to the policy include any transaction, arrangement or relationship
(including indebtedness or guarantees of indebtedness) in which the Company is a participant with a related person. The related
person may have a direct or indirect material interest in the transaction. It is Company policy that the board shall approve any
related party transaction before the commencement of the transaction. However, if the transaction is not identified before commencement,
it must still be presented to the board for their review and ratification. For more information regarding related party transactions,
see the applicable related party disclosure notes below.
Revenue
Recognition. Beginning on January 1, 2018, the Company recognizes revenue under ASC 606, Revenue from Contracts with Customers.
The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods
or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange
for those goods or services. The Company only applies the five-step model to contracts when it is probable that the Company will
collect the consideration it is entitled to in exchange for the goods and services transferred to the customer. The following
five steps are applied to achieve that core principle:
Step
1: Identify the contract with the customer
Step
2: Identify the performance obligations in the contract
Step
3: Determine the transaction price
Step
4: Allocate the transaction price to the performance obligations in the contract
Step
5: Recognize revenue when the company satisfies a performance obligation
The
Company’s performance obligations are satisfied at the point in time when products are received by the customer, which is
when the customer has title and the significant risks and rewards of ownership. Therefore, the Company’s contracts have
a single performance obligation (shipment of product). The Company primarily receives fixed consideration for sales of product.
The
Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers
contain no incentives or discounts that could cause revenue to be allocated or adjusted over time other than those discussed in
Note 8. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent
a fulfillment activity rather than a promised service to the customer. Revenue and costs of sales are recognized when control
of the products transfers to our customer, which generally occurs upon delivery to the customer. The Company’s performance
obligations are satisfied at that time.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
Revenues
do not include sales or other taxes collected from customers.
The
Company’s products are sold and distributed through various channels, which include selling directly to retail stores and
other outlets such as food markets, institutional accounts and independent outlets. The Company typically collects payment
from customers within 30 days from the date of sale. The following table presents our continued revenues disaggregated by geographical
region:
|
|
2018
|
|
|
2017
|
|
Netherlands
|
|
|
1,656,069
|
|
|
|
526,339
|
|
France
|
|
|
6,281
|
|
|
|
-
|
|
Iceland
|
|
|
12,810
|
|
|
|
-
|
|
Total
|
|
|
1,675,160
|
|
|
|
526,339
|
|
The
Company sells its products and extends credit, generally without requiring collateral, based on an ongoing evaluation of the customer’s
business prospects and financial condition. The Company evaluates the collectability of its trade accounts receivable based
on a number of factors, including the Company’s historic collections pattern and changes to a specific customer’s
ability to meet its financial obligations. The Company has established an allowance for doubtful accounts to adjust the recorded
receivable to the estimated amount the Company believes will ultimately be collected.
The
nature of the Company’s contracts does not give rise to variable consideration, such as prospective and retrospective rebates.
The
Company experiences customer returns primarily as a result of damaged or out-of-date product. At any given time, the Company estimates
less than 1% of bottle sales could be at risk for return by customers. As the company do not deem this amount to be material no
provision has been recorded for either the year ended 2018 or 2017. Returned product is recognized as a reduction of net sales.
Recent
Accounting Pronouncements
Compensation—Stock
Compensation: On June 20, 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718) - Improvements
to Nonemployee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to employees
and nonemployees. Under ASU No. 2018-07, the existing employee guidance will apply to nonemployee share-based transactions (as
long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution
of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods
or services. In addition, the contractual term will be able to be used in lieu of an expected term in the option-pricing model
for nonemployee awards. The adoption had no impact on the Company’s historic financial statements.
Leases:
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (ASU 2016-02). Under ASU No. 2016-2, an entity will
be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing
arrangements. ASU No. 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions.
Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user
of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies,
ASU No. 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim reporting periods
within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company adopted
this standard on January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company
expects to elect the ‘package of practical expedients’, which permits the Company not to reassess under the new standard
its prior conclusions about lease identification, lease classification and initial direct costs; the use of hindsight.; and all
of the new standard’s available transition practical expedients. While the Company continues to assess all of the effects
of adoption, the Company currently believe the adoption had no impact on the Company’s historical or future financial statements
based on their current operating activities.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
Income
Statement – Reporting Comprehensive Income: In February 2018, the FASB issued ASU No. 2018-02, “Income Statement
- Reporting Comprehensive Income (Topic 220)”, which amends the previous guidance to allow for certain tax effects “stranded”
in accumulated other comprehensive income, which are impacted by the Tax Cuts and Jobs Act (the “Tax Reform Act”),
to be reclassified from accumulated other comprehensive income into retained earnings. This amendment pertains only to those items
impacted by the new tax law and will not apply to any future tax effects stranded in accumulated other comprehensive income. This
standard is effective for fiscal years beginning after December 15, 2018 and allows for early adoption. The Company has completed
its evaluation of the impact of ASU No. 2018-02 and determined that there are no “stranded” tax effects in accumulated
other comprehensive income to be reclassified.
Revenue
from contracts with customers: In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic
606)”, which superseded previous revenue recognition guidance. ASU No. 2014-09 and its amendments were included in Accounting
Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers”. ASC 606 requires that a company
recognizes revenue at an amount that reflects the consideration to which the company expects to be entitled in exchange for transferring
goods or services to a customer. The Company adopted ASC 606 effective January 1, 2018, using the modified retrospective approach,
with no impact to the opening retained earnings. Results for periods beginning on or after January 1, 2018 are presented under
ASC 606, while prior periods are not adjusted and continue to be reported in accordance with the prior accounting guidance under
ASC 605, “Revenue Recognition”.
Foreign
Currency Translation. The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section
830-10-45”) for foreign currency translation to translate the financial statements from the functional currency, generally
the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the
functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books
of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities,
and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional
currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the
environment, or local currency, in which an entity primarily generates and expends cash.
The
financial records of the Company are maintained in its local currency, the euro (“EUR”), which is the functional currency.
Assets and liabilities are translated from the local currency into the reporting currency, U.S. dollars, at the exchange rate
prevailing at the balance sheet date. Revenues and expenses are translated at weighted average exchange rates for the period to
approximate translation at the exchange rates prevailing at the dates those elements are recognized in the consolidated financial
statements. Foreign currency translation gain (loss) resulting from the process of translating the local currency financial statements
into U.S. dollars are included in determining accumulated other comprehensive income in the consolidated statement of stockholders’
equity.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
Unless
otherwise noted, the rate presented below per U.S. $1.00 was the midpoint of the interbank rate as quoted by OANDA Corporation
(www.oanda.com) contained in its consolidated financial statements. Translation of amounts from EUR into U.S. dollars has been
made at the following exchange rates for the respective periods:
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
Balance Sheets
|
|
|
0.8734
|
|
|
|
0.8334
|
|
Statements of operations and comprehensive income (loss)
|
|
|
0.8464
|
|
|
|
0.8870
|
|
Equity
|
|
|
0.9037
|
|
|
|
0.9037
|
|
Cost
of Revenues. Cost of revenue includes all direct expenses incurred to produce the revenue for the period. This includes, but
is not limited to, costs for finished products, pick packing costs, storage costs and transportation costs. Cost of revenues are
recorded in the same period as the resulting revenue.
Employee
Benefits. Wages, salaries, bonuses and social security contributions are recognized as an expense in the year in which the
associated services are rendered by employees. For any unused portion of vacation leave, an accrual is recorded for carry over
to the following year.
Income
Taxes. The Company is subject to US corporation tax. The US combined federal and state corporate tax rate is 23%. The company’s
United States net operating losses totaled $3,483,928 as of December 31, 2017 and begin to expire in tax years 2032 and following.
Net losses from US operating totaled $157,386 for 2018 and may be carried forward indefinitely. The company is subject to US Internal
Revenue Code rules limiting the use of US net operating losses after the merger with Future Health Care of America during 2018
(described in Note 17). This limitation has no effect on the Company’s financial statements because the Company has recognized
no deferred tax asset with respect to its net operating loss carryforwards. The NOLs are the cumulative NOL’s per the Company’s
2017 federal income tax return. The 382 limit will not be factored in until the company has income and the limit is therefore
applicable.
Natur
Holding, the Dutch subsidiary of Natur International Corp is structured as a Dutch limited liability company. Tax on the result
is calculated based on the result before tax in the profit and loss account, taking into account losses available for set-off
from previous years (to the extent that they have not already been included in the deferred tax assets) and exempt profit components
and after the addition of non-deductible costs. Due account is also taken of changes which occur in the deferred tax assets and
deferred tax liabilities in respect of changes in the applicable tax rate.
The
corporate tax rate for profits above $238,812 (or €200,000) amounts to 25%. Below that amount the rate is 20%. Future profits
can be carried back to prior year losses for a maximum of 9 years for the full amount of losses incurred.
We
have the following Net Operating Losses that we will be able to offset against future profits with regards to corporation tax.
2016:
|
|
$
|
6,308,373
|
|
2017:
|
|
$
|
7,733,630
|
|
2018:
|
|
$
|
5,704,757
|
|
In
the financial statements of group companies, a tax charge is calculated on the basis of the accounting result. The corporate income
tax that is due by these group companies is charged into the current accounts of the company.
Because
of the compensable losses no deferred taxes are included in the financial statements. From incorporation of the company only the
Corporation Tax return of 2015/2016 has been filed. All years are still subject to examination.
Fair
Value of Financial Instruments. The carrying value of short-term instruments, including cash, accounts payable and accrued
expenses, and short-term notes approximate fair value due to the relatively short period to maturity for these instruments. The
long-term debt approximate fair value since the related rates of interest approximate current market rates.
Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on
the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use
of unobservable inputs.
The
Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.
Income
/(Loss) Per Share - The Company computes income (loss) per share in accordance with Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”) Topic 260 Earnings Per Share, which requires the Company to present basic
earnings per share and diluted earnings per share when the effect is dilutive (see Note 13).
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
3 GOING CONCERN
The
Company considered its going concern disclosure requirements in accordance with ASC 240-40-50. The Company concluded that its
negative working capital and decreased cash flows from operations are conditions that raised substantial doubt about the Company’s
ability to continue as a going concern. Without a successful plan in place from management these conditions could negatively impact
the Company’s ability to meets its financial obligations over the next year. In response, the Company has implemented a
plan to alleviate such reasonable doubt as follows: (i) the Company will continue to generate additional revenue (and positive
cash flows from operations) partly related to the Company’s expansion into new product lines during 2019 and partly related
to the Company wide sales initiatives already implemented; (ii) in addition cost saving initiatives and an organization restructuring
program that is almost completed, will have an additional positive impact on the cost-basis of the organization. Notwithstanding
the foregoing, the Company will seek capital as needed, which may be either equity or debt, or both. The Company does not have
any capital sources determined at this time, and capital may not be available when sought. The accompanying financial statements
have been prepared assuming that the company will continue as a going concern. The company is currently undertaking a corporate
restructuring exercise, which is further disclosed in Note 16 – subsequent events.
NOTE
4 RELATED PARTY RECEIVABLES
Receivables
of related parties at December 31, 2018 and December 31, 2017 consisted of the following:
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
NL Life Sciences B.V.
|
|
|
-
|
|
|
|
93,748
|
|
Flare Media B.V.
|
|
|
-
|
|
|
|
37,156
|
|
Other related party receivable
|
|
|
1,833
|
|
|
|
845
|
|
|
|
|
1,833
|
|
|
|
131,749
|
|
NOTE
5 OTHER CURRENT ASSETS
Other
current assets at December 31, 2018 and December 31, 2017 consisted of the following:
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
|
|
|
|
|
|
|
Value Added Tax receivable
|
|
|
67,388
|
|
|
|
162,687
|
|
Prepaid expenses
|
|
|
32,054
|
|
|
|
197,812
|
|
Other Receivables
|
|
|
93
|
|
|
|
91
|
|
|
|
|
99,535
|
|
|
|
360,590
|
|
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
6 FIXED ASSETS
Property
and equipment at December 31, 2018 and December 31, 2017 consisted of the following:
|
|
December 31,
2018
|
|
|
December 31,
2017
|
|
|
|
|
|
|
|
|
Building and improvements
|
|
|
491,847
|
|
|
|
515,432
|
|
Machines and installations
|
|
|
65,886
|
|
|
|
69,043
|
|
Furniture and fixtures
|
|
|
200,508
|
|
|
|
206,260
|
|
Hardware and software
|
|
|
80,163
|
|
|
|
46,090
|
|
|
|
|
838,404
|
|
|
|
836,825
|
|
|
|
|
|
|
|
|
|
|
Less: Accumulated Depreciation
|
|
|
(314,894
|
)
|
|
|
(169,287
|
)
|
|
|
|
523,510
|
|
|
|
667,538
|
|
Depreciation
expense for the period ended December 31, 2018 and the year ended December 31, 2017 was $179,600, and $157,534, respectively.
The other movement in cost is related to translation from operational currency to reporting currency.
NOTE
7 OTHER ASSETS
Other
assets are deposits for the head office rent and deposits for the shops in Amsterdam. They will be repaid upon expiration of the
lease.
|
|
December 31,
2018
|
|
|
December 31,
2017
|
|
|
|
|
|
|
|
|
Head office Rental deposit
|
|
|
103,614
|
|
|
|
105,119
|
|
Ferdinand Bolstraat store Rental deposit
|
|
|
34,651
|
|
|
|
35,154
|
|
Prinsengracht store Rental deposit
|
|
|
18,711
|
|
|
|
18,983
|
|
Credit card deposit
|
|
|
2,112
|
|
|
|
24,096
|
|
Hay Hill Rental deposit
|
|
|
34,364
|
|
|
|
34,862
|
|
Other
|
|
|
7,708
|
|
|
|
6,345
|
|
Total
|
|
|
201,160
|
|
|
|
224,560
|
|
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
8 ACCRUED EXPENSES & OTHER CONTINGENT LIABILITIES
Accrued
Expenses & other contingent liabilities at December 31, 2018 and December 31, 2017 consisted of the following:
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
|
|
|
|
|
|
|
Taxes payable
|
|
|
352,423
|
|
|
|
412,748
|
|
Invoices to be received
|
|
|
3,972
|
|
|
|
185,488
|
|
Holiday Allowance Payable
|
|
|
24,642
|
|
|
|
39,764
|
|
Other accrued expenses & other contingent liabilities
|
|
|
202,164
|
|
|
|
34,662
|
|
|
|
|
583,161
|
|
|
|
672,622
|
|
On
November 13, 2018, the Company financed the premium for directors’ and officers’ insurance. The Company borrowed
$71,703.90 at 6.20% interest, and the note will be repaid in 10 equal installments of $6,120.39 after a first payment of $10,500.
As of December 31, 2018, the balance of the note payable was $71,703.90.
NOTE
9 RELATED PARTY OTHER LIABILITIES
Related
party other liabilities at December 31, 2018 and December 31, 2017 consisted of the following:
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
|
|
|
|
|
|
|
NL Life Sciences B.V.
|
|
|
563,118
|
|
|
|
-
|
|
STB Family Offices SARL
|
|
|
200,234
|
|
|
|
185,012
|
|
STB Family Offices B.V.
|
|
|
661,432
|
|
|
|
-
|
|
Stichting Thank You Nature
|
|
|
16,913
|
|
|
|
-
|
|
Flare Media B.V.
|
|
|
25,458
|
|
|
|
-
|
|
AMC
|
|
|
325,382
|
|
|
|
789,148
|
|
Management
|
|
|
142,154
|
|
|
|
-
|
|
Yoomoo Limited
|
|
|
98,014
|
|
|
|
102,714
|
|
Other related party debt
|
|
|
-
|
|
|
|
118,753
|
|
|
|
|
2,032,705
|
|
|
|
1,195,627
|
|
For
the outstanding amount relating to AMC this transaction relates to the purchase of bottled juices for resale. Total purchases
relating to goods sold for the period ended December 31, 2018 and the year ended December 31, 2017 was $1,400,328, and $868,003,
respectively.
For
the loan from NL Life Sciences and STB Family Offices there is no repayment schedule in place. The interest rate is charged on
the basis of EURIBOR + 3% on the average balance of the loan.
The
other loans consist of the procurement of juices and consulting fees for the management team. No interest is being charged.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
10 RELATED PARTY OTHER NOTES
Loan
from other related parties at December 31, 2018 and December 31, 2017 consisted of the following:
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Efficiency Life Fund
|
|
|
400,750
|
|
|
|
-
|
|
TriDutch Holding B.V.
|
|
|
672,099
|
|
|
|
552,061
|
|
|
|
|
1,072,849
|
|
|
|
552,061
|
|
For
the loan from Tridutch Holding B.V., there is no repayment schedule in place. The interest rate is charged on the basis of EURIBOR
+ 3% on the average balance of the loan. In 2017 no additional amounts were drawn down and accrued interest of $17,243 was added
to the balance. In 2018 accrued interest of $17,249 was added to the balance and additional borrowings of $128,043 were drawn
down, partly offset by a positive exchange rate difference of $25,283. No repayments were made on the balance in either 2017 or
2018.
For
the loan from Efficiency Life Fund is a repayment schedule in place to repay the loan in 10 installments from July 2019 to April
2020. The entire balance of 400,750 was drawn down in 2018 with no repayments made on the balance to date.
NOTE
11 CONVERTIBLE NOTE PAYABLE
Convertible
loans payable at December 31, 2018 and December 31, 2017 consisted of the following:
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Convertible loan 1
|
|
|
629,750
|
|
|
|
599,952
|
|
Convertible loan 2
|
|
|
970,960
|
|
|
|
959,923
|
|
|
|
|
1,600,710
|
|
|
|
1,559,875
|
|
Loan
1
Party
for loan 1 has granted a loan facility in the principle amount of $581,058 or €500,000 with the right, but not the obligation
to convert the outstanding loan amounts into shares in the capital of Natur at a company valuation of $17.4 million or €15
million for a term from December 19, 2017, till the maturity date of December 31, 2018, at an interest rate of 10% per annum.
No further drawdowns were made on the loan in 2018 and the increased balance is due to the accrued interest as no repayment for
capital or interest have been made. As this date has now passed the loan is deemed to be in default but discussions are ongoing
around conversion or extension options.
Loan
2
On
October 20, 2017, an amount of $929,692 or €800,000 was advanced to the Company for a loan agreement that was drafted but
never signed. An interest rate of 5% per annum is calculated and the loan has a maturity date of February 28, 2018. The loan is
convertible to shares of Natur at a company valuation of $23.3 million or €20 million. The loan is in default and lender
has demanded payment and does not want to convert. No further drawdowns were made on the loan in 2018 and the increased balance
is due to the accrued interest as no repayment for capital or interest have been made.
NOTE
12 RELATED PARTY CONVERTIBLE NOTE PAYABLE
Related
party convertible note payable at December 31, 2018 and December 31, 2017 consisted of the following:
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Convertible loan Efficiency Life Fund
|
|
|
11,671,743
|
|
|
|
11,031,512
|
|
The
convertible loan has been converted. $8,671,743 of the balance was settled, using series C preferred shares and the remaining
$3,000,000 was converted into long term debt. Please refer to Note 16, subsequent events.
In
2017 an additional amount of $7,199,424 was drawn down on the loan and accrued interest of $304,873 was added to the loan balance.
$122,586 was repaid.
In
2018 an additional amount of $1,145,452 was drawn down on the convertible note payable and accrued interest of $Nil was added
to the loan balance and $Nil was repaid. The remaining movement in the balance of ($505,221) is related to exchange rate differences.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
13 – LOSS PER SHARE
At
December 31, 2018 the Company had 129,049,192 shares issues and outstanding at a nominal value of $.001. besides that, the Company
has 2,469.131 preferred A shares and 100,000 preferred B shares. Alpha capital Anstalt has two outstanding warrants issued
at November 13, 2018 with 4 years term. The first warrant has an exercise price of $0.0606 for 36,000,000 shares the second warrant
is 6,000,000 at $0.15 exercise price, the company has reserved 16,240,000 shares for management and Employee Stock Ownership Plan.
At December 31, 2017, the Company had 115,760,000 shares of common stock issued and outstanding.
NOTE
14 – DISCONTINUED OPERATIONS AND ASSETS/LIABILITIES HELD FOR DISPOSAL
Effective
November 30, 2018, the Company has closed down the London office and shops as part of the restructuring plan. Functionally the
operations were shut down before December 31, 2018 and therefore we have qualified it as discontinued operations the sale of assets
is in process. The existing support functions have been transferred to the headquarters in Amsterdam as part of the centralization
of support staff initiative. A distributor for the UK has been engaged, who will deliver to our current customer base. In accordance
with the guidance provided in ASC 205-20, the Company concluded that this sale qualified for presentation as discontinued operations.
The Company has no ongoing or future plans to start a new operating entity in the United Kingdom. Prior period income statement
balances applicable to the United Kingdom operations have been reclassified and are included under the Discontinued Operations
caption in the statements of operations while related assets and liabilities were reclassified to Assets Held for Disposal and
Liabilities Held for Disposal, respectively on the balance sheet.
Effective
August 31, 2018, Natur International Corp closed the offices of its Casper, Wyoming operations. The increase in costs coupled
with a decrease in business activity, lead to the decision to close the Casper, Wyoming operations. In closing the office, the
Company transitioned its clients to new service providers, and terminated employees as the transition happened. The month to month
lease was terminated with the landlord on August 31, 2018, and the office was closed the same day. We have one part-time employee,
working remotely, primarily on the collection of accounts receivable.
The
following table presents the carrying amounts of the major classes of assets and liabilities included in our discontinued operations
as presented on our Consolidated Balance Sheet as of December 31, 2018.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
14 DISCONTINUED OPERATIONS AND ASSETS/LIABILITIES HELD FOR DISPOSAL - continued
NATUR
INTERNATIONAL CORP
BALANCE
SHEET OF DISCONTINUED OPERATIONS
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
Current assets
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
-
|
|
|
|
40,881
|
|
Related party receivable
|
|
|
201,907
|
|
|
|
199,176
|
|
Accounts receivable
|
|
|
124,016
|
|
|
|
-
|
|
Inventories
|
|
|
-
|
|
|
|
69,370
|
|
Other current assets
|
|
|
51,706
|
|
|
|
92,321
|
|
Total current assets
|
|
|
377,629
|
|
|
|
401,748
|
|
|
|
|
|
|
|
|
|
|
Fixed Assets
|
|
|
|
|
|
|
|
|
Tangible fixed assets
|
|
|
27,547
|
|
|
|
46,473
|
|
Financial Fixed Assets
|
|
|
23,618
|
|
|
|
15,246
|
|
Total fixed assets
|
|
|
51,165
|
|
|
|
61,719
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
|
428,794
|
|
|
|
463,467
|
|
|
|
|
|
|
|
|
|
|
Short term debt
|
|
|
|
|
|
|
|
|
Accounts Payable
|
|
|
643,616
|
|
|
|
132,168
|
|
Cash at banks and in hand
|
|
|
-
|
|
|
|
-
|
|
Accrued expenses & other contingent liabilities
|
|
|
243,510
|
|
|
|
120,673
|
|
Total short-term debt
|
|
|
887,126
|
|
|
|
252,841
|
|
NATUR
INTERNATIONAL CORP
INCOME
STATEMENT OF DISCONTINUED OPERATIONS
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
|
|
|
|
|
|
|
REVENUE
|
|
|
314,822
|
|
|
|
568,975
|
|
|
|
|
|
|
|
|
|
|
COST OF GOODS SOLD
|
|
|
278,485
|
|
|
|
254,531
|
|
|
|
|
|
|
|
|
|
|
GROSS MARGIN
|
|
|
36,337
|
|
|
|
314,444
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES
|
|
|
|
|
|
|
|
|
Wages & Salaries
|
|
|
442,730
|
|
|
|
641,218
|
|
Selling, General & Administrative
|
|
|
862,869
|
|
|
|
1,072,523
|
|
Amortization & depreciation
|
|
|
17,135
|
|
|
|
16,713
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
1,322,734
|
|
|
|
1,730,454
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS
|
|
|
(1,286,397
|
)
|
|
|
(1,416,010
|
)
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(906
|
)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM DISCONTINUED OPERATIONS
|
|
|
(1,287,303
|
)
|
|
|
(1,416,010
|
)
|
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
15 – COMMITMENTS AND CONTINGENCIES
The
company has entered into a number of operating leases. Future minimum lease payments as of December 31, 2018 under non-cancelable
operating leases are as follows:
2019
|
|
|
436,657
|
|
2020
|
|
|
392,004
|
|
2021
|
|
|
146,759
|
|
2022
|
|
|
-
|
|
2023
|
|
|
-
|
|
Thereafter
|
|
|
-
|
|
Total
|
|
|
975,430
|
|
The
total rental expense relating to operating leases for the period ended December 31, 2018 and the year ended December 31, 2017
was $356,600, and $389,857, respectively.
Jachthavenweg
124. The lease relates to the rental of the head office in Amsterdam. The rental contract ends on 30th June 2021 with no early-exit
clause available. A Minimum notice period of 1-year before the contract end date is required otherwise the contract is extended
by 5 years.
Ferdinand
Bolstraat 65. The lease relates to the rental of retail space in Amsterdam. The rental contract ends on 31st December 2025
with an early-exit clause available on 31st December 2019. A Minimum notice period of 1-year is required before the lease is terminated.
Prinsengracht
455. The lease relates to the rental of retail space in Amsterdam. The rental contract ends on 31st December 2021 with an
early-exit clause available on 30th July 2019. A Minimum notice period of 1-year and a fine payment of $13,740 is required before
the lease is terminated.
Fiscal
unity
For
the corporate income tax, Natur Holding B.V., Naturalicious Rest of Europe B.V., Hi-tech Juices B.V., NL Juices Retail B.V., NL
Juices Online B.V., NFF Trading B.V. and The Force of Nature B.V. are a fiscal unity. Pursuant to the Collection of State Taxes
Act, the Company and its subsidiaries are severally and jointly liable for the tax payable by the combination.
For
the value added tax purposes, Natur Holding B.V., NL Juices Retail. B.V., Hi-tech Juices B.V., NL Juices Online B.V., NFF Trading
B.V. and The Force of Nature B.V. are a fiscal unity. Pursuant to the Collection of State Taxes Act, the Company and its subsidiaries
are severally and jointly liable for the tax payable by the combination.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
16 SUBSEQUENT EVENTS
Discontinued
operations
Effective
March 31, 2019, Natur International Corp closed the offices of its Billings, Montana operations. These operations were discontinued
during 2018. During 2018, the Company saw a continued decrease in the utilization of our home healthcare services in Billings,
Montana. Additionally, we have seen an increase in competition, specifically for Medicare service providers in 2018. Also, there
has been a shortage of Registered Nurses, Physical Therapists and management personnel, leading to higher costs due to having
to source the required talent from staffing companies. This increase in costs coupled with a decrease in business activity, lead
to the decision to close the Billings, Montana operations. In closing the office, the Company transitioned its clients to new
service providers, and terminated employees as the transition happened. The month to month lease will be terminated with the landlord
on March 31, 2019. We have one part-time employee, working remotely, primarily on the collection of accounts receivable.
Debt
restructuring
Effective
March 8, 2019 the Company and 6th Wave Efficiency Life Fund have agreed to settle a portion of the amounts owed by
the Company to the Holder under the Debt Agreement, including principle, interest expenses, penalties and other charges of whatsoever
nature, all in an amount equal to USD 8,846,208 (the “Converted Debt”) in exchange for and in consideration of the
issuance to Holder or its designees by the Parent Company of an aggregate of 78,832,399 shares of Class C Preferred Stock (“Debt
Repayment Shares”), convertible initially into the equivalent of 78,832,399 shares of Common Stock of the Parent Company
(the “Conversion Shares”). The condition precedent to the agreement, the issuance of the Debt Repayment Shares was
completed April 10, 2019.
The
Holder 6th Wave Efficiency Life Fund agrees that if it sells any of the shares of Common Stock it was directly or beneficially
issued by the Parent Company on November 13, 2018, either as shares of Common Stock or the Common Stock underlying the Class B
Preferred Stock, in exchange for its equity interest in the Company and any of the Conversion Shares (together the Common Stock,
the Common Stock underlying the Class B Preferred Stock and the Conversion Shares are referred to as the “Value Calculation
Shares”) at any time prior to December 31, 2022, and the gross proceeds to the Holder or its affiliates from the sale (or
deemed sale as provided herein) of any or all of the Value Calculation Shares exceeds USD $15,000,000, then the balance of the
Debt, equal to USD $3,000,000 as of the date hereof and any interest, expenses, penalties, and other charges of any nature due
thereon under the terms of the Debt Agreement (the “Debt Balance”), will be deemed fully paid, discharged and extinguished
and the Debt Agreement in all respects will be terminated and of no further effect.
On
March 19, 2019, the holder of the Series A Preferred Stock converted 72 of such shares with a stated value of $72,000 for 2,376,002
shares of common stock. The applicable conversion price was $0.030303. The company did not receive any payment on this conversion,
having received the consideration for the Series A Preferred Shares on November 12, 2018. There are remaining an aggregate of
2,397,131 shares of Series A Preferred Stock issued and outstanding. The shares of common stock issued on conversion are registered
for resale by the holder.
Corporate
restructuring
In
line with the objective to secure the continuity of the company, it was decided late 2018 to extend the product line with added
functional extracts (Nutrigenomics, CBD). For this, the company established a NewCo as sister company of Natur Holding BV at March
13, 2019, wholly owned by Natur International Corp. Based on global developments and following the success of companies in the
USA and Canada, the company defined new growth objectives with complementary products based on CBD as a new revenue model for
this NewCo. Additional funding was sought in the market, but it became apparent that the willingness of new investors to provide
the company with funding in debt or equity was dependent on the restructuring of the existing debt on the Balance Sheet of the
Company. As most of this debt is held on the Balance Sheet of Natur Holding BV, it was decided to develop a restructuring plan
to:
|
A.
|
Negotiate
with the debtholders a conversion of their debt to equity of Natur International Corp; We successfully concluded a conversion
of a large portion of the debt on 7 March, converting $ 8,846,208 of Debt into 78,832,399 preferred C shares. It is our intent,
to convert all of the remaining debt to equity and negotiations are on-going to determine the terms and conditions for the conversion;
|
|
B.
|
To
establish an asset transfer from Natur Holding BV to Natur CBD BV, optimizing the proceeds for these assets and subsequently liquidate
Natur Holding BV;
|
|
C.
|
Continue
the business in Natur CBD BV with an extended portfolio of functional products, including CBD infused food and beverages and deliver
the objectives as set by the Board
|
|
D.
|
Expeditiously
seek new funding in the form of (long-term) or convertible Debt or equity. Discussions with Third parties are on-going. The execution
of the intended restructuring program is conditional upon the ability of the company to raise additional capital prior to the
implementation of the restructuring plan in order to supply the buying entity of the assets and liabilities with sufficient funds
for the asset transaction and the financing of the daily operations. If this condition is not met, the restructuring will fail,
and management will be forced to seek legal protection against its creditors and debtholders.
|
We
expect to have finalized the intended actions before the midst of May 2019.
NATUR
INTERNATIONAL CORP.
NOTES
TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
17 - RECAPITALIZATION
As
discussed in Note 1 – Organization and nature of business, effective November 13, 2018, Future Healthcare of America entered
into a reverse capitalization transaction with Natur Holding BV. In conjunction with the transaction the Company was recapitalized,
resulting in the capital structure outlined below. The main purpose of the merger is to raise additional capital for the purposes
of growth. The historical number of common shares presented in our financial statements were converted to post merger shares on
a 1 to 112 basis. As part of the recapitalization net assets of $1.9 million.
The
following shares of common stock were issued subsequent to the reverse capitalization. Natur shareholders had a controlling voting
percentage of 94% subsequent to the reversed merger:
-
115,759,999 shares of common stock for the Natur shareholders.
-
2,023,562 shares of common stock for release of accrued salaries of management
-
2,469,131 shares of preferred A for a capital investment of $2,000,000 and a debt forgiveness of $1,010,000 and accrued interest
of $410,552. The preferred A shares will convert at a ratio of 1 preferred A share to 33 common shares.
-
100,000 shares of preferred B were issued for Natur shareholders. They will convert at a ratio of 1 preferred B share to 1,000
common shares.
NOTE
18 – STOCKHOLDERS’ DEFICIT
On
November 13, 2018, Future Healthcare of America (“Parent Company”) completed the transactions (the “Share Exchange
Transaction”) contemplated by that certain Share Exchange Agreement, among Parent Company and the former shareholders of
Natur Holdings, B.V., a Netherlands-based holding company (“Natur”). In connection with the Share Exchange Transaction,
the former shareholders of Natur received the equivalent of 215,759,999 shares of the Common Stock of Parent Company (the “Common
Stock”), which was issued in part as 115,760,000 shares of Common Stock and in part as 100,000 shares of voting, convertible
Series B Preferred Stock of Parent Company (the “Series B Preferred Stock”) representing 100,000,000 shares of Common
Stock upon conversion. The Series B Preferred Stock will convert automatically upon Parent Company increasing the number of shares
of Common Stock of its authorized capital in sufficient amount to permit the conversion of the Series B Preferred Stock, which
it plans to do promptly so as to cause the conversion of the Series B Preferred Stock. Immediately after the Share Exchange Transaction,
the former Natur shareholders collectively have a controlling position among the shareholders of Parent Company, and Natur has
become a wholly-owned subsidiary of Parent Company. At closing the number of common shares, issued and outstanding was 129,049,192.
On
September 21, 2018, Parent Company also executed a Securities Purchase Agreement (the “SPA”) by which it agreed to
privately issue and sell to Alpha Capital Anstalt (the “Alpha”) 2,469,131 shares of non-voting, convertible Series
A Preferred Stock, each share convertible into approximately 33 shares of Common Stock at the rate of $.030303. Alpha also purchased
two warrants, one pursuant to the SPA that is exercisable for 33,000,000 shares of Common Stock at $.060606 per share and one
pursuant to a debt cancellation agreement exercisable for 6,000,000 shares of Common Stock at $.15 per share. The aggregate purchase
price for the Series A Preferred Stock and the two warrants was $2,000,000 in cash and conversion of approximately $769,000 of
debt and interest due Alpha from Parent Company under a prior loan agreement. Prior to the acquisition of Natur, Alpha also cancelled
approximately $651,000 of debt principle and interest due from Parent Company. These transactions eliminated $1,420,000 of debt
principle and interest of Parent Company and improved its balance sheet. As part of the SPA transaction, Alpha has also agreed
to reimburse up to $100,000 of the liabilities of Parent Company existing at the closing date.
NATUR
INTERNATIONAL CORP.
CONSOLIDATED
BALANCE SHEETS
|
|
NOTES
|
|
(unaudited)
June 30,
2019
|
|
|
December 31, 2018
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
|
1,028,877
|
|
|
|
128,364
|
|
Accounts receivable
|
|
|
|
|
2,628
|
|
|
|
42,744
|
|
Related party receivable
|
|
|
|
|
-
|
|
|
|
1,833
|
|
Inventories
|
|
|
|
|
24,483
|
|
|
|
179,072
|
|
Other current assets
|
|
5
|
|
|
60,274
|
|
|
|
99,535
|
|
Current assets held for disposal
|
|
13
|
|
|
5,000
|
|
|
|
377,628
|
|
Total Current Assets
|
|
|
|
|
1,121,262
|
|
|
|
829,176
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Current Assets
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
|
|
|
|
|
37,353
|
|
|
|
37,353
|
|
Fixed asset
|
|
4
|
|
|
58,685
|
|
|
|
523,510
|
|
Other asset
|
|
|
|
|
-
|
|
|
|
201,160
|
|
Non-current assets held for disposal
|
|
13
|
|
|
-
|
|
|
|
51,165
|
|
Total Non-Current Assets
|
|
|
|
|
96,038
|
|
|
|
813,188
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
|
|
|
1,217,300
|
|
|
|
1,642,364
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND MEMBERS’ DEFICIT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
|
|
Accounts Payable
|
|
|
|
|
426,891
|
|
|
|
1,127,345
|
|
Accrued expenses & other contingent liabilities
|
|
6
|
|
|
106,387
|
|
|
|
583,161
|
|
Related party other liabilities
|
|
7
|
|
|
2,809,939
|
|
|
|
2,032,705
|
|
Related party other notes
|
|
8
|
|
|
2,984,017
|
|
|
|
1,072,849
|
|
Convertible note payable
|
|
9
|
|
|
1,202,849
|
|
|
|
1,600,710
|
|
Related party convertible note payable
|
|
10
|
|
|
-
|
|
|
|
11,671,743
|
|
Preferred Stock payable
|
|
|
|
|
2,064,736
|
|
|
|
-
|
|
Current liabilities held for disposal
|
|
13
|
|
|
170,469
|
|
|
|
887,126
|
|
Total Current Liabilities
|
|
|
|
|
9,765,288
|
|
|
|
18,975,639
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
|
|
|
|
9,765,288
|
|
|
|
18,975,639
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity
|
|
|
|
|
|
|
|
|
|
|
Common stock, $0.001 par value, 750,000,000 and 200,000,000 shares authorized as of June 30, 2019 and December 31, 2018, respectively. 310,597,593 and 129,049,192 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively.
|
|
|
|
|
310,597
|
|
|
|
129,049
|
|
Preferred stock A, $0.001 par value, 2,397.131 and 2,469.131 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively. Convertible to common stock at a 1:33,000 ratio.
|
|
|
|
|
2
|
|
|
|
2
|
|
Preferred stock B, 100,000 shares authorized, Nil and 100,000 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively. Convertible to common stock at a 1:1000 ratio.
|
|
|
|
|
-
|
|
|
|
100
|
|
Preferred stock C, $0.001 par value, Nil issued and outstanding as of June 30, 2019 and December 31, 2018, respectively. Convertible to common stock at a 1:1000 ratio.
|
|
|
|
|
-
|
|
|
|
-
|
|
Additional Paid in Capital
|
|
|
|
|
14,924,725
|
|
|
|
5,174,269
|
|
Total Shareholders’ deficit
|
|
|
|
|
(23,850,777
|
)
|
|
|
(22,299,570
|
)
|
Accumulated other comprehensive loss
|
|
|
|
|
67,465
|
|
|
|
(337,125
|
)
|
TOTAL EQUITY/(DEFICIT)
|
|
|
|
|
(8,547,988
|
)
|
|
|
(17,333,274
|
)
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND MEMBERS’ DEFICIT
|
|
|
|
|
1,217,300
|
|
|
|
1,642,364
|
|
The
accompanying notes are an integral part of these consolidated financial statements
NATUR
INTERNATIONAL CORP.
UNAUDITED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
For the Three Months
|
|
|
For the Six Months
|
|
|
|
June 30,
2019
|
|
|
June 30,
2018
|
|
|
June 30,
2019
|
|
|
June 30,
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REVENUE
|
|
|
8,134
|
|
|
|
414,716
|
|
|
|
72,553
|
|
|
|
942,433
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COST OF GOODS SOLD - RELATED PARTY
|
|
|
2,679
|
|
|
|
224,682
|
|
|
|
33,560
|
|
|
|
425,036
|
|
COST OF GOODS SOLD
|
|
|
2,240
|
|
|
|
58,718
|
|
|
|
66,136
|
|
|
|
132,116
|
|
|
|
|
4,919
|
|
|
|
283,400
|
|
|
|
99,696
|
|
|
|
557,152
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GROSS MARGIN
|
|
|
3,215
|
|
|
|
131,316
|
|
|
|
(27,143
|
)
|
|
|
385,281
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Wages & Salaries
|
|
|
108,335
|
|
|
|
349,298
|
|
|
|
373,064
|
|
|
|
792,679
|
|
Selling, General & Administrative
|
|
|
1,243,061
|
|
|
|
904,599
|
|
|
|
2,645,471
|
|
|
|
2,019,466
|
|
Amortization , depreciation and impairment
|
|
|
3,609
|
|
|
|
30,268
|
|
|
|
275,798
|
|
|
|
83,584
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
1,355,005
|
|
|
|
1,284,165
|
|
|
|
3,294,333
|
|
|
|
2,895,729
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS
|
|
|
(1,351,790
|
)
|
|
|
(1,152,849
|
)
|
|
|
(3,321,476
|
)
|
|
|
(2,510,448
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
862
|
|
|
|
34,413
|
|
|
|
40,095
|
|
|
|
63,261
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
|
|
|
(1,352,652
|
)
|
|
|
(1,187,262
|
)
|
|
|
(3,361,571
|
)
|
|
|
(2,573,709
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INCOME FROM CONTINUING OPERATIONS
|
|
|
(1,352,652
|
)
|
|
|
(1,187,262
|
)
|
|
|
(3,361,571
|
)
|
|
|
(2,573,709
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued operations (NOTE 13)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain (loss) on disposal of subsidiary
|
|
|
1,591,187
|
|
|
|
-
|
|
|
|
1,891,985
|
|
|
|
-
|
|
Loss from operations of discontinued Component
|
|
|
(42,211
|
)
|
|
|
(302,964
|
)
|
|
|
(81,621
|
)
|
|
|
(1,095,701
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET PROFIT (LOSS) AVAILABLE/ATTRIBUTE TO MEMBERS
|
|
|
196,324
|
|
|
|
(1,490,226
|
)
|
|
|
(1,551,207
|
)
|
|
|
(3,669,410
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings/(loss) per share
|
|
|
0.00
|
|
|
|
(0.01
|
)
|
|
|
(0.00
|
)
|
|
|
(0.03
|
)
|
Diluted earnings/(loss) per share
|
|
|
0.00
|
|
|
|
(0.01
|
)
|
|
|
(0.00
|
)
|
|
|
(0.03
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Profit (Loss)
|
|
|
196,324
|
|
|
|
(1,490,226
|
)
|
|
|
(1,551,207
|
)
|
|
|
(3,669,410
|
)
|
Other comprehensive income
|
|
|
50,677
|
|
|
|
-
|
|
|
|
404,590
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE PROFIT (LOSS)
|
|
|
247,001
|
|
|
|
(1,490,226
|
)
|
|
|
(1,146,617
|
)
|
|
|
(3,669,410
|
)
|
The
accompanying notes are an integral part of these consolidated financial statements
NATUR
INTERNATIONAL CORP.
UNAUDITED
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ DEFICIT
|
|
Common Stock
|
|
|
Preferred stock A
|
|
|
Preferred stock B
|
|
|
Preferred stock C
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount ($.001 par)
|
|
|
Number of Shares
|
|
|
Amount ($.001 par)
|
|
|
Number of Shares
|
|
|
Amount ($.001 par)
|
|
|
Number of Shares
|
|
|
Amount ($.001 par)
|
|
|
Number of Shares
|
|
|
Other Paid in Capital
|
|
|
Retained deficit
|
|
|
Accumulated OCI
|
|
|
Total
|
|
Balance at December 31, 2018
|
|
|
129,049
|
|
|
|
129,049,192
|
|
|
|
2
|
|
|
|
2,469.131
|
|
|
|
100
|
|
|
|
100,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5,174,269
|
|
|
|
(22,299,570
|
)
|
|
|
(337,125
|
)
|
|
|
(17,333,275
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,747,531
|
)
|
|
|
|
|
|
|
(1,747,531
|
)
|
Share-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
403,162
|
|
|
|
|
|
|
|
|
|
|
|
403,162
|
|
Conversion of Preferred A to Common Stock
|
|
|
2,376
|
|
|
|
2,376,002
|
|
|
|
(-)
|
|
|
|
(72
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,376
|
)
|
|
|
|
|
|
|
|
|
|
|
(-)
|
|
Accumulated other comprehensive gain/(loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
353,913
|
|
|
|
353,913
|
|
Balance at March 31, 2019
|
|
|
131,425
|
|
|
|
131,425,194
|
|
|
|
2
|
|
|
|
2,397.131
|
|
|
|
100
|
|
|
|
100,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5,575,055
|
|
|
|
(24,047,101
|
)
|
|
|
16,788
|
|
|
|
(18,323,731
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Net Profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
196,324
|
|
|
|
|
|
|
|
196,324
|
|
Share-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
685,044
|
|
|
|
|
|
|
|
|
|
|
|
685,044
|
|
Debt Converted to Common Stock
|
|
|
340
|
|
|
|
340,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,218
|
|
|
|
|
|
|
|
|
|
|
|
13,558
|
|
Conversion of Preferred B to Common Stock
|
|
|
100,000
|
|
|
|
100,000,000
|
|
|
|
|
|
|
|
|
|
|
|
(100
|
)
|
|
|
(100,000
|
)
|
|
|
|
|
|
|
|
|
|
|
(99,900
|
)
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of Preferred C Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
79
|
|
|
|
78,832
|
|
|
|
8,830,061
|
|
|
|
|
|
|
|
|
|
|
|
8,830,140
|
|
Conversion of Preferred C to Common Stock
|
|
|
78,832
|
|
|
|
78,832,399
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(79
|
)
|
|
|
(78,832
|
)
|
|
|
(78,753
|
)
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Accumulated other comprehensive gain/(loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,677
|
|
|
|
50,677
|
|
Balance at June 30, 2019
|
|
|
310,597
|
|
|
|
310,597,593
|
|
|
|
2
|
|
|
|
2,397
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
14,924,725
|
|
|
|
(23,850,777
|
)
|
|
|
67,465
|
|
|
|
(8,547,988
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
Preferred
stock A
|
|
|
Preferred
stock B
|
|
|
Preferred
stock C
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount ($.001 par)
|
|
|
Number of Shares
|
|
|
Amount ($.001 par)
|
|
|
Number of Shares
|
|
|
Amount ($.001 par)
|
|
|
Number of Shares
|
|
|
Amount ($.001 par)
|
|
|
Number of Shares
|
|
|
Other Paid in Capital
|
|
|
Retained deficit
|
|
|
Accumulated OCI
|
|
|
Total
|
|
Balance at December 31, 2017
|
|
|
115,760
|
|
|
|
115,759,999
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,316,560
|
|
|
|
(15,250,748
|
)
|
|
|
(1,114,812
|
)
|
|
|
(12,933.240
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,179,184
|
)
|
|
|
|
|
|
|
(2,179,184
|
)
|
Accumulated other comprehensive gain/(loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
Balance at March 31, 2018
|
|
|
115,760
|
|
|
|
115,759,999
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,316,560
|
|
|
|
(17,429,932
|
)
|
|
|
(1,114,812
|
)
|
|
|
(15,112,424
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Net Profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,490,226
|
)
|
|
|
|
|
|
|
(1,490,226
|
)
|
Accumulated other comprehensive gain/(loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
Balance at June 30, 2018
|
|
|
115,760
|
|
|
|
115,759,999
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,316,560
|
|
|
|
(18,920,158
|
)
|
|
|
(1,114,812
|
)
|
|
|
(16,602,650
|
|
The
accompanying notes are an integral part of these consolidated financial statements
NATUR
INTERNATIONAL CORP.
UNAUDITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
For the Six Months
|
|
|
|
June 30,
2019
|
|
|
June 30,
2018
|
|
CASH FLOW FROM OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
(1,551,207
|
)
|
|
|
(3,669,410
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities
|
|
|
|
|
|
|
|
|
Amortization, depreciation and impairment
|
|
|
275,798
|
|
|
|
32,015
|
|
Share Based Compensation
|
|
|
1,088,206
|
|
|
|
-
|
|
Gain on Disposal of Subsidiaries
|
|
|
(1,891,985
|
)
|
|
|
|
|
Changes in:
|
|
|
|
|
|
|
|
|
- Accounts receivable
|
|
|
37,592
|
|
|
|
(252,278
|
)
|
- Related party receivable
|
|
|
24
|
|
|
|
(20,802
|
)
|
- Inventories
|
|
|
44,516
|
|
|
|
(436,965
|
)
|
- Other current assets
|
|
|
(1,124
|
)
|
|
|
33,911
|
|
- Accounts payable
|
|
|
(23,411
|
)
|
|
|
1,951,766
|
|
- Accrued expenses
|
|
|
(178,008
|
)
|
|
|
(416,304
|
)
|
- Accrued expenses - related parties
|
|
|
110,391
|
|
|
|
(124,643
|
)
|
Net cash used in operating activities
|
|
|
(2,089,208
|
)
|
|
|
(2,902,710
|
)
|
Net cash (used in) from operating activities - Discontinued operations
|
|
|
-
|
|
|
|
210,652
|
|
|
|
|
|
|
|
|
|
|
CASH FLOW FROM INVESTING ACTIVITIES
|
|
|
|
|
|
|
|
|
Cash paid for purchase of fixed assets
|
|
|
-
|
|
|
|
-
|
|
Cash received for sale of property and equipment
|
|
|
-
|
|
|
|
-
|
|
Net cash used in investing activities
|
|
|
-
|
|
|
|
-
|
|
Net cash used in investing activities – Discontinued operations
|
|
|
51,165
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
CASH FLOW FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
Related party loan additions
|
|
|
-
|
|
|
|
1,799,213
|
|
Related party loan repayments
|
|
|
-
|
|
|
|
(240,503
|
)
|
Cash received from subscription of Preferred Stock
|
|
|
2,064,736
|
|
|
|
|
|
Third party convertible note additions
|
|
|
560,915
|
|
|
|
52,266
|
|
Related party convertible loan additions
|
|
|
-
|
|
|
|
-
|
|
Net cash provided from financing activities
|
|
|
2,625,651
|
|
|
|
1,610,976
|
|
Net cash from financing activities - Discontinued Operations
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Effect of foreign exchange rate changes on cash and cash equivalents
|
|
|
312,905
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
|
|
900,513
|
|
|
|
(1,081,082
|
)
|
|
|
|
|
|
|
|
|
|
CASH AND CASH EQUIVALENTS beginning of period
|
|
|
128,364
|
|
|
|
1,082,734
|
|
CASH AND CASH EQUIVALENTS end of period
|
|
|
1,028,877
|
|
|
|
1,652
|
|
|
|
|
|
|
|
|
|
|
NON-CASH TRANSACTIONS
|
|
|
|
|
|
|
|
|
Preferred stock C issued for debt conversion
|
|
|
79
|
|
|
|
|
|
Common stock issued for debt conversion
|
|
|
340
|
|
|
|
|
|
Preferred stock A conversion
|
|
|
2,376
|
|
|
|
|
|
Preferred stock C conversion
|
|
|
78,832
|
|
|
|
|
|
Preferred stock B conversion
|
|
|
100,000
|
|
|
|
|
|
Debt transferred from RP other liabilities to RP other notes payable
|
|
|
672,370
|
|
|
|
|
|
The
accompanying notes are an integral part of these consolidated financial statements
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – ORGANIZATION AND NATURE OF BUSINESS
Natur
International Corp. was formerly named Future Healthcare of America. In November 2018, Natur Holding B.V. was acquired to continue
the company as a provider of cold pressed juice beverages and healthy snacks. The original business of Future Healthcare of America,
founded in 2012, was as a provider of home healthcare services, which had declined and is expected to be fully closed and liquidated
in the third quarter of 2019.
The
current name of the company is Natur International Corp., which was effected on January 7, 2019. The trading symbol for our common
stock became NTRU as of that date and trades on The OTC Market.
Natur
International Corp., is a Wyoming corporation, and operates its beverage business through a number of direct and indirect subsidiaries,
of which the current principal one is Natur BPS B.V. (known by the trade name Natur Functionals), and is the successor to the
business of Natur Holding B.V. (“we”, “our”, “the Company” or “Natur”). Our beverage
business commenced in late 2015, with product distribution in Northern Europe. Currently, our operational headquarters is in Amsterdam,
the Netherlands.
At
the onset of 2019, our product line up centered on a range of cold pressed juices and healthy snacks. These products were sold
either directly or through distribution partners in the Netherlands and the United Kingdom. Beginning in the fourth quarter of
2018, and throughout the first half of 2019, the Company focus shifted from dependence on the legacy fruit and vegetable juices
and snacks toward innovating a new line of hemp-derived natural food and beverage products. The Company product value proposition
is to provide affordable, culturally relevant, authentic, fresh fruit, vegetable and hemp-derived supplemented consumer products
to democratize clean, healthy, eating and drinking, with plans to address the growing needs for products that address other personal
needs in health, wellness and beauty care.
Through
third party contract manufacturers, we apply patented technology to proprietary nutrient dense blends of fruit and vegetables,
adding hemp-derived supplements. These are bottled or packed with technically advanced food and product safety measures and in
some cases cold high-pressure processing to bring fresh tasting fruit, vegetable and hemp-derived supplemented blends to market
through more than fifteen product types. These newly innovated products are brought to market, in Europe, through Natur’s
distribution channels of direct-to-business, direct-to-consumer and through select distributors.
Natur
operated as a private enterprise in the Netherlands from its founding in 2015 through November 13, 2018, when it was acquired
as a wholly owned subsidiary in a share exchange transaction by Future Healthcare of America, pursuant to that certain Share Exchange
Agreement, among the Company and the former shareholders of Natur Holding, B.V. (the “Share Exchange Transaction”).
In connection with the Share Exchange Transaction, the former shareholders of Natur received the equivalent of 215,759,999 shares
of the Common Stock (the “Common Stock”), which was issued in part as 115,760,000 shares of Common Stock and in part
as 100,000 shares of voting, convertible Series B Preferred Stock (the “Series B Preferred Stock”) representing 100,000,000
shares of Common Stock upon conversion. The Share Exchange Transaction was accounted for as a reverse capitalization with Natur
Holding B.V. being treated as the accounting acquirer. As such, the historical information for all periods presented prior to
the merger date relate to Natur Holding B.V. Subsequent to the Share Exchange Transaction consummation date, the information in
this report relates to the consolidated entities of Natur, including Natur Holding B.V. and successor subsidiary and the former
subsidiaries of Future Healthcare of America, the latter of which are currently in the process of being wound down and presented
as discontinued operations.
In
connection with the Share Exchange Transaction, net cash received was $2,000,000 and costs incurred were $399,381 including professional
fees for legal, accounting services and finance commission. Immediately after the Share Exchange Transaction, the former Natur
shareholders collectively owned the controlling position among the shareholders of the Company.
On
May 1, 2019, Natur Holding B.V. filed a Petition in the Netherlands Court for the District of Amsterdam (“Petition”)
for the liquidation of the company and the transfer of certain assets and retained liabilities to Natur BPS B.V., a wholly owned
subsidiary of Natur International Corp., which operates under the trade name Natur Functionals. This court process allowed the
historical business of the Company’s beverage business to be continued and eliminates a substantial amount of the liabilities
of the Company. The Petition permits the Company to focus on activities that will drive growth and future profits. As a result
of the Petition the control of Natur International Corp. over Natur Holding B.V. is compromised for financial reporting purposes,
and its investment in it will be deconsolidated as of May 1, 2019.
The
Series B Preferred Stock was automatically converted upon the Company increasing the number of shares of Common Stock of its authorized
capital, which happened on June 26, 2019. At the same time the Series C Preferred Stock was automatically converted to 78,832,399
shares of Common Stock. As of June 30, 2019, the total number of outstanding shares amounted to 310,597,593 shares of Common Stock
with an authorized share capital of 750,000,000 shares of common Stock.
During
the first half of the 2019 fiscal year, in addition to pursuing the Petition to reorganize certain of its liabilities, the Company
successfully has negotiated to convert a further $6,114,790 of debt into 149,516,865 shares of common stock to be issued in due
course. More importantly, it has been conducting substantial fund-raising activities. It has obtained new funding through a series
of securities purchase agreements that have been funded in the amount of $2,064,736 or are subject to signed commitments for funding
in the amount of $3,283,904 that is expected to be completed during the third fiscal quarter of 2019. The securities to be sold
will be a mix of several new series of preferred stock convertible into up to 96,289,473 shares of Common Stock and warrants exercisable
for up to 177,404,377 shares of Common Stock.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – ORGANIZATION AND NATURE OF BUSINESS - continued
On
June 30, 2019, the Company expressed its interest in pursuing a transaction with Share International Holding B.V. on a binding
basis. The contemplated transaction would be an acquisition of Share International Holding B.V. (“SIH”) and related
assets for the operation of its business by the issuance of shares of Natur. The terms of this potential acquisition have yet
to be negotiated and finalized, and the overall transaction is subject to conditions precedent at this time. At the same time
as the Company entered into the letter of intent, it lent to SIH the sum $250,000 under a promissory note, due January 4, 2020.
The note bears interest at the rate of 10%. The repayment obligation under the Note will be cancelled if no business arrangement
is concluded due to a breach by the Company of any agreement for the business arrangement that is concluded in the future, either
party to the note experiences a material adverse change, or the business arrangement is not approved by the shareholders or owners
of the respective parties to the extent that approval is required. The note also has other standard default provisions under which
the Company may declare a default. Also, at the same time as the foregoing letter of intent and loan were concluded, the board
of directors of the Company appointed Mr. Paul Bartley as the Chief Executive Officer of the Company; Mr. Bartley is a principal
of SIH.
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of presentation. The Company prepares its financial statements using the accrual basis of accounting in accordance with United
States generally accepted accounting principles (“US GAAP”).
Consolidation
- The financial statements presented reflect the accounts of Natur International Corp and its direct and indirect subsidiaries.
All inter-company transactions have been eliminated in consolidation.
Use
of Estimates in Financial Statement Preparation. The preparation of financial statements in conformity with US GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent
assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
Cash
and Cash Equivalents. Cash equivalents include all highly liquid investments with original maturities of three months or less.
Accounts
Receivable. Accounts receivable are comprised of unsecured amounts due from customers. The Company carries its accounts receivable
at their face amounts less an allowance for bad debts. The allowance for bad debts is recognized based on management’s estimate
of likely losses per year, based on past experience and review of customer profiles and the aging of receivable balances.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
Inventory.
Inventory, consisting of raw materials, work in progress and finished goods, is valued at the lower of the inventory’s
costs or net realizable value, using the first in, first out method to determine the cost. Management compares the cost of inventory
with its net realizable value and an allowance is made to write down inventory to net realizable value, if lower.
Property
and Equipment. Property and equipment are valued at cost. Additions are capitalized and maintenance and repairs are charged
to expense as incurred. Gains and losses on dispositions of equipment are reflected in operations. Depreciation is provided using
the straight-line method over the estimated useful lives of the assets as follows:
Category
|
|
Estimated
Useful lives
|
Building and improvements
|
|
5
years
|
Machines and installations
|
|
5 years
|
Furniture and fixtures
|
|
7 years
|
Hardware and software
|
|
3 years
|
Intangible
Assets and Long-Lived Assets. The Company recognizes an acquired intangible asset apart from goodwill whenever the intangible
asset arises from contractual or other legal rights, or when it can be separated or divided from the acquired entity and sold,
transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability.
Such intangibles are amortized over their useful lives. Impairment losses are recognized if the carrying amount of an intangible
asset subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.
The
Company’s long-lived assets, including intangibles, are reviewed for impairment whenever events or changes in circumstances
indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability
of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the
carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An
impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Long lived
assets are evaluated on a yearly basis and no impairment losses were incurred during the six months ended June 30, 2019.
Related
Party Transactions. The Board of Directors has adopted a Related Party Transaction Policy for the review of related person
transactions. Under these policies and procedures, the management reviews related person transactions in which we are or will
be a participant to determine if they are fair and beneficial to the Company. Financial transactions, arrangements, relationships
or any series of similar transactions, arrangements or relationships in which a related person has or will have a material interest
and that exceeds the lesser of: (i) $10,000, and (ii) one percent of the average of the Company’s total assets at year-end
for the last two completed fiscal years, in the aggregate per year are subject to the boards review. Any member of the board who
is a related person with respect to a transaction under review may not participate in the deliberation or vote requesting approval
or ratification of the transaction. Transactions that are subject to the policy include any transaction, arrangement or relationship
(including indebtedness or guarantees of indebtedness) in which the Company is a participant with a related person. The related
person may have a direct or indirect material interest in the transaction. It is Company policy that the board shall approve any
related party transaction before the commencement of the transaction. However, if the transaction is not identified before commencement,
it must still be presented to the board for their review and ratification.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
Revenue
Recognition. Beginning on January 1, 2018, the Company recognizes revenue under ASC 606, Revenue from Contracts with Customers.
The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods
or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange
for those goods or services. The Company only applies the five-step model to contracts when it is probable that the Company will
collect the consideration it is entitled to in exchange for the goods and services transferred to the customer. The following
five steps are applied to achieve that core principle:
Step
1: Identify the contract with the customer
Step
2: Identify the performance obligations in the contract
Step
3: Determine the transaction price
Step
4: Allocate the transaction price to the performance obligations in the contract
Step
5: Recognize revenue when the company satisfies a performance obligation
The
Company’s performance obligations are satisfied at the point in time when products are received by the customer, which is
when the customer has title and the significant risks and rewards of ownership. Therefore, the Company’s contracts have
a single performance obligation (shipment of product). The Company primarily receives fixed consideration for sales of product.
The
Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers
contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities
are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised
service to the customer. Revenue and costs of sales are recognized when control of the products transfers to our customer, which
generally occurs upon delivery to the customer. The Company’s performance obligations are satisfied at that time.
Share-Based
Payment Arrangements. The Company measures the cost of employee services received in exchange for an award of equity instruments
(share-based payments, or SBP) based on the grant-date fair value of the award. That cost is recognized over the period during
which an employee is required to provide service in exchange for the SBP award—the requisite service period (vesting period).
For SBP awards subject to conditions, compensation is not recognized until the performance condition is probable of occurrence.
The grant-date fair value of share options is estimated using the Black-Scholes-Merton option-pricing model. The Company adopted
ASU 2018-07 in the first quarter of 2019 which aligns the accounting for share-based payment awards issued to employees and non-employees.
The
fair value of each option granted during the period ended June 30, 2019 was estimated on the date of grant using the Black-Scholes-Merton
option-pricing model with the weighted average assumptions in the following table:
|
|
2019
|
|
|
2018
|
|
Expected dividend yield
|
|
|
0
|
%
|
|
|
-
|
|
Expected option term (years)
|
|
|
6
|
|
|
|
-
|
|
Expected volatility
|
|
|
382
|
%
|
|
|
-
|
|
Risk-free interest rate
|
|
|
3
|
%
|
|
|
-
|
|
The
expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected
volatility was based on the volatility in the trading of the Company’s common stock. The assumed discount rate was the default
risk-free six-year interest rate in the Netherlands.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
Revenues
do not include sales or other taxes collected from customers.
The
Company’s products are sold and distributed through various channels, which include selling directly to retail stores and
other outlets such as food markets, institutional accounts and independent outlets. The Company typically collects payment from
customers within 30 days from the date of sale. The following table presents our continued revenues disaggregated by geographical
region for the six-month period ended June 30, 2019:
|
|
June 30,
2019
|
|
|
June 30,
2018
|
|
Netherlands
|
|
|
72,553
|
|
|
|
942,433
|
|
France
|
|
|
-
|
|
|
|
-
|
|
Iceland
|
|
|
-
|
|
|
|
-
|
|
Total
|
|
|
72,553
|
|
|
|
942,433
|
|
The
Company sells its products and extends credit, generally without requiring collateral, based on an ongoing evaluation of the customer’s
business prospects and financial condition. The Company evaluates the collectability of its trade accounts receivable based on
a number of factors, including the Company’s historic collections pattern and changes to a specific customer’s ability
to meet its financial obligations. The Company has established an allowance for doubtful accounts to adjust the recorded receivable
to the estimated amount the Company believes will ultimately be collected.
The
nature of the Company’s contracts does not give rise to variable consideration, such as prospective and retrospective rebates.
The
Company experiences customer returns primarily as a result of damaged or out-of-date product. At any given time, the Company estimates
less than 1% of sales could be at risk for return by customers. As the company do not deem this amount to be material no provision
was recorded for the period ended 30 June, 2019. Returned product is recognized as a reduction of net sales.
Recent
Accounting Pronouncements
Compensation—Stock
Compensation: On June 20, 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718) - Improvements
to Nonemployee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to employees
and nonemployees. Under ASU No. 2018-07, the existing employee guidance will apply to nonemployee share-based transactions (as
long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution
of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods
or services. In addition, the contractual term will be able to be used in lieu of an expected term in the option-pricing model
for nonemployee awards. The adoption had no impact on the Company’s historic financial statements.
Leases:
In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. This update requires the recognition
of lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous guidance.
The accounting for finance leases (capital leases) was substantially unchanged. The original guidance required application on
a modified retrospective basis with adjustments to the earliest comparative period presented. In August 2018, the FASB issued
ASU No. 2018-11, “Targeted Improvements to ASC 842,” which included an option to not restate comparative periods in
transition and elect to use the effective date of ASU No. 2016-02 as the date of initial application, which the Company elected.
As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, and continues to be reported under previous
guidance that did not require the recognition of operating lease liabilities and corresponding lease assets on the consolidated
balance sheet. As a result of the adoption of ASU No. 2016-02 on January 1, 2019, the Company recorded operating lease right-of-use
assets of $580,310 and operating lease liabilities of $578,007.
Foreign
Currency Translation. The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section
830-10-45”) for foreign currency translation to translate the financial statements from the functional currency, generally
the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the
functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books
of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities,
and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional
currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the
environment, or local currency, in which an entity primarily generates and expends cash.
The
financial records of the Company are maintained in its local currency, the euro (“EUR”), which is the functional currency.
Assets and liabilities are translated from the local currency into the reporting currency, U.S. dollars, at the exchange rate
prevailing at the balance sheet date. Revenues and expenses are translated at weighted average exchange rates for the period to
approximate translation at the exchange rates prevailing at the dates those elements are recognized in the consolidated financial
statements. Foreign currency translation gain (loss) resulting from the process of translating the local currency financial statements
into U.S. dollars are included in determining accumulated other comprehensive income in the consolidated statement of stockholders’
equity.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
Unless
otherwise noted, the rate presented below per U.S. $1.00 was the midpoint of the interbank rate as quoted by OANDA Corporation
(www.oanda.com) contained in its consolidated financial statements. Translation of amounts from EUR into U.S. dollars has been
made at the following exchange rates for the respective periods:
|
|
June 30,
2019
|
|
|
December 31,
2018
|
|
Balance Sheets
|
|
|
0.8849
|
|
|
|
0.8734
|
|
Statements of operations and comprehensive income (loss)
|
|
|
0.8895
|
|
|
|
0.8464
|
|
Equity
|
|
|
0.9037
|
|
|
|
0.9037
|
|
Cost
of Revenues. Cost of revenue includes all direct expenses incurred to produce the revenue for the period. This includes, but
is not limited to, costs for finished products, pick packing costs, storage costs and transportation costs. Cost of revenues are
recorded in the same period as the resulting revenue.
Employee
Benefits. Wages, salaries, bonuses and social security contributions are recognized as an expense in the year in which the
associated services are rendered by employees. For any unused portion of vacation leave, an accrual is recorded for carry over
to the following year.
Income
Taxes. The Company is subject to US corporation tax. The US combined federal and state corporate tax rate is 23%. The company’s
United States net operating losses totaled $3,483,928 as of December 31, 2017 and begin to expire in tax years 2032 and following.
Net losses from US operating totaled $157,386 for 2018 and may be carried forward indefinitely. The company is subject to US Internal
Revenue Code rules limiting the use of US net operating losses after the merger with Future Health Care of America during 2018
(described in Note 17). This limitation has no effect on the Company’s financial statements because the Company has recognized
no deferred tax asset with respect to its net operating loss carryforwards. The NOLs are the cumulative NOL’s per the Company’s
2017 federal income tax return. The 382 limit will not be factored in until the company has income and the limit is therefore
applicable.
Natur
BPS B.V., the Dutch subsidiary of Natur International Corp is structured as a Dutch limited liability company. Tax on the result
is calculated based on the result before tax in the profit and loss account, considering losses available for set-off from previous
years (to the extent that they have not already been included in the deferred tax assets) and exempt profit components and after
the addition of non-deductible costs. Due account is also taken of changes which occur in the deferred tax assets and deferred
tax liabilities in respect of changes in the applicable tax rate.
The
corporate tax rate for profits above $238,812 (or €200,000) amounts to 25%. Below that amount the rate is 20%. Future profits
can be carried back to prior year losses for a maximum of 9 years for the full amount of losses incurred.
In
the financial statements of group companies, a tax charge is calculated on the basis of the accounting result. The corporate income
tax that is due by these group companies is charged into the current accounts of the company.
Because
of the compensable losses no deferred taxes are included in the financial statements. From incorporation of the company only the
Corporation Tax return of 2015/2016 has been filed. All years are still subject to examination.
Fair
Value of Financial Instruments. The carrying value of short-term instruments, including cash, accounts payable and accrued
expenses, and short-term notes approximate fair value due to the relatively short period to maturity for these instruments. The
long-term debt approximate fair value since the related rates of interest approximate current market rates.
Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on
the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use
of unobservable inputs.
The
Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.
Income
/(Loss) Per Share - The Company computes income (loss) per share in accordance with Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”) Topic 260 Earnings Per Share, which requires the Company to present basic
earnings per share and diluted earnings per share when the effect is dilutive (see Note 12).
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
3 – GOING CONCERN
The
Company considered its going concern disclosure requirements in accordance with ASC 240-40-50. We have had material operating
losses, working capital deficit and have not yet created positive cash flows. These factors raise substantial doubt as to our
ability to continue as a going concern. The Company concluded, in spite of the decreased cash flow from operations, both the elimination
of certain debt and the successful raising of new capital and obtaining new capital commitments during the second quarter of 2019,
that it has materially improved its capital so as to continue as going concern. The Company implemented a plan in the second quarter
of 2019 to further structurally improve the conditions for its continuing as a going concern; (i) the Company implemented certain
cost savings, primarily to its overhead requirements, (ii) the Company will continue to generate additional revenue (and positive
cash flows from operations) partly related to the Company’s expansion into new product lines during 2019 and partly related
to the Company sales initiatives already implemented; and (iii) undertook a reorganization and restructuring program to reduce
its debt that has now been completed. The corporate restructuring through the Petition in May 2019 is further disclosed in Note
13 to these financial statements. These actions have had an overall positive impact on the cost-basis of the organization. Notwithstanding
the foregoing, the Company will continue to need additional capital from investors to fund its larger business plan and maintain
the continuity and growth of its current operations. The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.
NOTE
4 – FIXED ASSETS
Property,
equipment and intangible assets at June 30, 2019, and December 31, 2018, consisted of the following:
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2019
|
|
|
2018
|
|
Building and improvements
|
|
|
-
|
|
|
|
491,847
|
|
Machines and installations
|
|
|
-
|
|
|
|
65,886
|
|
Furniture and fixtures
|
|
|
60,117
|
|
|
|
200,508
|
|
Hardware and software
|
|
|
-
|
|
|
|
80,163
|
|
|
|
|
60,117
|
|
|
|
838,404
|
|
|
|
|
|
|
|
|
|
|
Less: Accumulated Depreciation & Amortization
|
|
|
(1,432
|
)
|
|
|
(314,894
|
)
|
|
|
|
58,685
|
|
|
|
523,510
|
|
NOTE
5 – OTHER CURRENT ASSETS
Other
current assets at June 30, 2019 and December 31, 2018 consisted of the following:
|
|
June 30,
2019
|
|
|
December 31, 2018
|
|
|
|
|
|
|
|
|
Value Added Tax receivable
|
|
|
34,878
|
|
|
|
67,388
|
|
Prepaid expenses
|
|
|
25,396
|
|
|
|
32,054
|
|
Other Receivables
|
|
|
-
|
|
|
|
93
|
|
|
|
|
60,274
|
|
|
|
99,535
|
|
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
6 – ACCRUED EXPENSES & OTHER CONTINGENT LIABILITIES
Accrued
expenses & other contingent liabilities at June 30, 2019 and December 31, 2018 consisted of the following:
|
|
June 30,
2019
|
|
|
December 31, 2018
|
|
|
|
|
|
|
|
|
Taxes payable
|
|
|
21,628
|
|
|
|
352,423
|
|
Invoices to be received
|
|
|
26,018
|
|
|
|
3,972
|
|
Holiday Allowance Payable
|
|
|
2,558
|
|
|
|
24,642
|
|
Other accrued expenses & other contingent liabilities
|
|
|
56,183
|
|
|
|
202,124
|
|
|
|
|
106,387
|
|
|
|
583,161
|
|
NOTE
7 – RELATED PARTY OTHER LIABILITIES
Related
party other liabilities at June 30, 2019 and December 31, 2018 consisted of the following:
|
|
June 30,
2019
|
|
|
December 31, 2018
|
|
|
|
|
|
|
|
|
NL Life Sciences B.V.
|
|
|
2,088,917
|
|
|
|
563,118
|
|
STB Family Offices SARL
|
|
|
227,323
|
|
|
|
200,234
|
|
STB Family Offices B.V.
|
|
|
-
|
|
|
|
661,432
|
|
Stichting Thank You Nature
|
|
|
-
|
|
|
|
16,913
|
|
Flare Media B.V.
|
|
|
-
|
|
|
|
25,458
|
|
AMC
|
|
|
193,632
|
|
|
|
325,382
|
|
Management & Board Fees
|
|
|
278,092
|
|
|
|
142,154
|
|
Yoomoo Limited
|
|
|
-
|
|
|
|
98,014
|
|
TriDutch Holding B.V.
|
|
|
21,975
|
|
|
|
-
|
|
|
|
|
2,809,939
|
|
|
|
2,032,705
|
|
For
the outstanding amount relating to AMC this transaction relates to the purchase of bottled juices for resale. Total purchases
relating to goods sold for the six-month period ended June 30, 2019 and the six-month period ended June 30, 2018 was $41,130,
and $797,770, respectively.
For
the related party balance liability held from NL Life Sciences, STB Family Offices SARL and TriDutch Holding B.V there is no repayment
schedule in place. No interest is being charged. For the related party liability held with Flare Media B.V., STB Family Office
B.V. in May 2019 the debt was fully transferred to NL Life Sciences B.V. as part of a debt restructuring. This balance will be
converted into equity in the third quarter of 2019.
The
other loans consist of the procurement of goods and consulting fees for the management team that have accrued from previous periods.
No interest is being charged.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
8 – RELATED PARTY OTHER NOTES
Loan
from other related parties at June 30, 2019 and December 31, 2018 consisted of the following:
|
|
June 30,
2019
|
|
|
December 31, 2018
|
|
|
|
|
|
|
|
|
Efficiency Life Fund
|
|
|
2,984,017
|
|
|
|
400,750
|
|
TriDutch Holding B.V.
|
|
|
-
|
|
|
|
672,099
|
|
|
|
|
2,984,017
|
|
|
|
1,072,849
|
|
For
the loan from TriDutch Holding B.V., in May 2019 the debt was fully transferred to NL Life Sciences B.V. as part of a debt restructuring.
For
the loan from Efficiency Life Fund there is a repayment schedule in place to repay the loan in 10 installments from July 2019
to April 2022 and the debt therefore transferred from a related party liability to a loan.
NOTE
9 – CONVERTIBLE NOTE PAYABLE
Convertible
loans payable at June 30, 2019 and December 31, 2018 consisted of the following:
|
|
June 30,
2019
|
|
|
December 31, 2018
|
|
|
|
|
|
|
|
|
Convertible loan 1
|
|
|
636,614
|
|
|
|
629,750
|
|
Convertible loan 2
|
|
|
-
|
|
|
|
970,960
|
|
Convertible loan 3
|
|
|
566,235
|
|
|
|
-
|
|
|
|
|
1,202,849
|
|
|
|
1,600,710
|
|
Convertible
Loan 1
Party
for loan 1 had granted a loan facility in the principle amount of $581,058 or €500,000 with the right, but not the obligation
to convert the outstanding loan amounts into shares in the capital of Natur at a company valuation of $17.4 million or €15
million for a term from December 19, 2017, till the maturity date of December 31, 2018, at an interest rate of 10% per annum.
In July 2019 the amount was fully converted to common stock of the company.
Convertible
Loan 2
On
October 20, 2017, an amount of $929,692 or €800,000 was advanced to the Company for a loan agreement that was drafted but
never signed. An interest rate of 5% per annum is calculated and the loan has a maturity date of February 28, 2018. Repeated attempts
at correspondence was made between the Company and the lender’s attorney in April and May 2019 to discuss converting the
balance to Common Stock of the Company on the bankruptcy of Natur Holding B.V. as no response was received the amount remains
in Natur Holding B.V. who’s estate is being managed independently by a court issued Curator.
Convertible
Loan 3
Natur
Holding B.V., the principle subsidiary of Natur International Corp, entered into a loan agreement with Dam! Holding B.V., under
which Natur Holding may borrow up to US$560,915 or €500,000. The final terms of the agreement were concluded on February
18, 2019.The full drawdown of US$560,915 was made in three tranches throughout January and February 2019. It is the company’s
intention to fully convert this to common stock in the third quarter of 2019.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
10 – RELATED PARTY CONVERTIBLE NOTE PAYABLE
Related
party convertible note payable at June 30, 2019 and December 31, 2018 consisted of the following:
|
|
June 30,
2019
|
|
|
December 31, 2018
|
|
|
|
|
|
|
|
|
Convertible loan Efficiency Life Fund
|
|
|
-
|
|
|
|
11,671,743
|
|
As
at June 26, 2019 $8,830,140 of the balance was converted Into Series Preferred C stock, this stock then converted to Common
stock after the increase in authorized share capital of NTRU . The remainder of the balance is currently being held as loan
with the company as described and shown in note 8.
NOTE
11 – OPTIONS & WARRANTS
On
November 13, 2018, the Company closed a subscription agreement and debt conversion agreement with Alpha Capital Anstalt wherein
the Company granted the following warrants to purchase:
-
|
A total of 33,000,000 shares of common stock,
at $0.0606060 per share, exercisable for four years.
|
-
|
A total of 6,000,000 shares of common stock,
at $0.15 per share, exercisable for four years.
|
A
summary of the status of the warrants granted is presented below for the three months ended:
|
|
June 30, 2019
|
|
|
December 31, 2018
|
|
|
|
Shares
|
|
|
Weighted
Average
Exercise Price
|
|
|
Shares
|
|
|
Weighted
Average
Exercise Price
|
|
Outstanding at beginning of period
|
|
|
39,000,000
|
|
|
$
|
0.074
|
|
|
|
-
|
|
|
$
|
-
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
|
|
39,000,000
|
|
|
|
0.074
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Expired
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Outstanding at end of period
|
|
|
39,000,000
|
|
|
$
|
0.074
|
|
|
|
39,000,000
|
|
|
$
|
0.074
|
|
On
January 16, 2019, the Company completed compensatory arrangements with three board members of Natur International Corp. with the
following terms:
Mr.
Anthony Joel Bay, through La Bay Ventures Inc., will be issued a six-year option to purchase an aggregate of 7,319,321 shares
of common stock of the Company. The option granted by the Company provides for equal quarterly vesting of the shares commencing
March 31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any
time until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale
at the election of the Company. If the service agreement is terminated for a breach thereof, all vested and unvested options will
terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable
for the full term.
Mr.
Rudolf Derk Huisman, through Pas Beheer B.V., will be issued a six-year option to purchase an aggregate of 7,319,321 shares of
common stock of the Company. The option granted by the Company provides for equal quarterly vesting of the shares commencing March
31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time
until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at
the election of the Company If the service agreement is terminated for a breach thereof, all vested and unvested options will
terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable
for the full term.
Ms.
Ellen Berkers, through Montrose Executive Management, will be issued an aggregate of 5,800,000 share of options to purchase common
stock of the Company as part of her termination arrangement dated May 30, 2019. The option granted by the Company provides for
the right to exercise the shares at $.030303 per share at any time from April 1, 2022 until March 31, 2025. The option provides
for cashless exercise and may be registered for resale at the election of the Company.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
11 – OPTIONS & WARRANTS - continued
Mr.
Robert A. Paladino, through Cavalier Aire LLC., will be issued a six-year option to purchase an aggregate of 7,319,321 shares
of common stock of NTRU. The option granted by the Company provides for equal quarterly vesting of the shares commencing March
31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time
until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at
the election of the Company. If the service agreement is terminated for a breach thereof, all vested and unvested options will
terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable
for the full term.
A
summary of the status of the share options is presented below for the six months ended:
|
|
June 30, 2019
|
|
|
December 31, 2018
|
|
|
|
Shares
|
|
|
Weighted Average Fair Value
|
|
|
Shares
|
|
|
Weighted Average Fair Value
|
|
Outstanding at beginning of period
|
|
|
-
|
|
|
$
|
-
|
|
|
|
-
|
|
|
$
|
-
|
|
Vested
|
|
|
9,459,688
|
|
|
|
0.071
|
|
|
|
-
|
|
|
|
-
|
|
Unvested
|
|
|
18,298,275
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
|
0.071
|
|
|
|
-
|
|
|
|
-
|
|
Expired
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Outstanding at end of period
|
|
|
27,757,963
|
|
|
$
|
0.071
|
|
|
|
-
|
|
|
$
|
-
|
|
The
fair value of all stock options outstanding at 30 June, 2019 is $1,970,813 at a weighted average fair value of $0.071 per option.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
12 – LOSS PER SHARE
At
June 30, 2019, the Company had 310,597,593 shares issues and outstanding at a par value of $.001. The Company also has 2,397.130
preferred A shares issued and outstanding. Alpha Capital Anstalt has two outstanding warrants issued on November 13, 2018, each
with 4-year terms. The first warrant has an exercise price of $0.060606 for 36,000,000 shares and the second warrant is exercisable
for 6,000,000 shares at a $0.15 exercise price. The Company has reserved 16,240,000 shares of Common Stock for management
incentive awards. At December 31, 2018, the Company had 129,049,192 shares of common stock issued and outstanding.
NOTE
13 – DISCONTINUED OPERATIONS AND ASSETS/LIABILITIES HELD FOR DISPOSAL
Effective
November 30, 2018, the Company closed the London office and shops as part of the restructuring plan. Functionally the operations
were shut down before December 31, 2018, and therefore we have qualified it as discontinued operations the sale of assets is in
process. The existing support functions were transferred to the headquarters in Amsterdam as part of the centralization of support
staff initiative.
As
of March 22, 2019, the company Naturalicious UK Limited was put into liquidation and the matters are being dealt with by a qualified
administration firm in the United Kingdom. A board meeting was held on March 22, 2019, and it was agreed to liquidate the company.
Currently the rights and obligations of the company are handled by the administration firm and the legal obligation over the liabilities
are extinguished. As we no longer have any rights or obligations to the indirect subsidiary, it has been removed from the consolidation
and the net liability position of the company is released and recognized as a gain on disposal.
Effective
August 31, 2018, the Company offices in Casper, Wyoming were closed at the termination of its health care operations.. The increase
in costs coupled with a decrease in business activity, led to the decision to close the Casper, Wyoming operations. In closing
the office, the Company transitioned its clients to new service providers, and terminated employees as the transition happened.
The month to month lease was terminated with the landlord on August 31, 2018.
In
line with the objective to secure the continuity of the Company, it was decided late 2018 to extend the product line with added
functional extracts (Nutrigenomics, hemp-derived extracts). For this, the Company established Natur BPS B.V. (formerly Natur CBD
B.V.) as a sister company of Natur Holding B.V. at March 13, 2019, wholly owned by Natur International Corp. Based on global developments
and following the success of companies in the USA and Canada, the Company defined new growth objectives with complementary products
based on hemp-derived extracts as a new revenue model. Additional funding was sought in the market, but it became apparent that
the willingness of new investors to provide the company with funding in debt or equity was dependent on the restructuring of the
existing debt on the balance sheet of the Company. As most of this debt is held on the balance sheet of Natur Holding B.V., it
was decided to develop a restructuring plan to:
|
A.
|
Establish
an asset transfer from Natur Holding B.V. to Natur CBD B.V., optimizing the proceeds for these assets and subsequently liquidate
Natur Holding B.V.;
|
|
B.
|
Continue
the business in Natur CBD B.V. with an extended portfolio of functional products, including food and beverages infused with hemp-derived
extracts and deliver the objectives as set by the Board
|
|
C.
|
Expeditiously
seek new funding in the form of (long-term) or convertible debt or equity. Discussions with Third parties are on-going.
|
In
May 2019 we reached agreements with most of the debtholders to convert their debt to equity and effective from May 1, 2019, the
asset transfer between Natur Holding B.V. and its sister company Natur BPS B.V was executed and Natur Holding B.V. and its wholly
owned subsidiaries were declared bankrupt by the Court in Amsterdam, the Netherlands. The total debt that was converted to shares
of common stock to be issued is $ 6,754,575.
In
June we reached agreement with private investors for the sale of preferred stock and warrants. At June 30, 2019, agreements were
signed for a total of $2,064,756 against 65,621.283 of to be issued shares of several series of preferred stock.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
13 – DISCONTINUED OPERATIONS AND ASSETS/LIABILITIES HELD FOR DISPOSAL - continued
The
following table presents the carrying amounts of the major classes of assets and liabilities included in our discontinued operations
as presented on our Unaudited Consolidated Balance Sheet as of June 30, 2019.
NATUR
INTERNATIONAL CORP
UNAUDITED
BALANCE SHEET OF DISCONTINUED OPERATIONS
|
|
For the Six Months
|
|
|
December 31, 2018
|
|
Current assets
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
-
|
|
|
|
-
|
|
Related party receivable
|
|
|
-
|
|
|
|
201,907
|
|
Accounts receivable
|
|
|
-
|
|
|
|
124,016
|
|
Inventories
|
|
|
-
|
|
|
|
-
|
|
Other current assets
|
|
|
-
|
|
|
|
51,705
|
|
Total current assets
|
|
|
-
|
|
|
|
377,628
|
|
|
|
|
|
|
|
|
|
|
Fixed Assets
|
|
|
|
|
|
|
|
|
Tangible fixed assets
|
|
|
-
|
|
|
|
27,547
|
|
Financial Fixed Assets
|
|
|
-
|
|
|
|
23,618
|
|
Total fixed assets
|
|
|
-
|
|
|
|
51,165
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
|
-
|
|
|
|
428,793
|
|
|
|
|
|
|
|
|
|
|
Short term debt
|
|
|
|
|
|
|
|
|
Accounts Payable
|
|
|
36,894
|
|
|
|
643,616
|
|
Accrued expenses & other contingent liabilities
|
|
|
133,575
|
|
|
|
243,510
|
|
Total short-term debt
|
|
|
170,469
|
|
|
|
887,126
|
|
NATUR
INTERNATIONAL CORP
UNAUDITED
INCOME STATEMENT OF DISCONTINUED OPERATIONS
|
|
For the Three Months
|
|
|
For the Six Months
|
|
|
|
For the Six Months
|
|
|
December 31, 2018
|
|
|
|
|
|
|
|
|
REVENUE
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
COST OF GOODS SOLD
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
GROSS MARGIN
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES
|
|
|
|
|
|
|
|
|
Wages & Salaries
|
|
|
-
|
|
|
|
-
|
|
Selling, General & Administrative
|
|
|
(42,211
|
)
|
|
|
(81,621
|
)
|
Amortization & depreciation
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
(42,211
|
)
|
|
|
(81,621
|
)
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS
|
|
|
42,211
|
|
|
|
81,621
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM DISCONTINUED OPERATIONS
|
|
|
42,211
|
|
|
|
81,621
|
|
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
14 – SUBSEQUENT EVENTS
In
July 2019 the Company reached agreement with certain non-US private investors to invest in total $1,765,605 to acquire 46,947.368
of the Series G Preferred Stock. These preferred shares have registration rights.
On
July 25, 2019 the Company entered into a Purchase and Recapitalization Agreement (“Recapitalization Agreement”) with
DRBG Holdco, LLC, a Delaware limited liability company, Temple Turmeric, Inc., a Delaware corporation, Daniel Sullivan, Tim Quick,
and TQ Holdings LLC, a New Hampshire limited liability company to acquire the business of Temple. Under the Recapitalization Agreement
the Company acquired 15,121,984 shares of Series A Preferred Stock of Temple from DRBG for a nominal amount and acquired from
TQH a promissory note in the principal amount of $100,000, plus all accrued and unpaid interest. As part of the transaction Temple
issued to DRBG a warrant to acquire a percentage of the Temple equity. The Temple board of directors will have three of the five
directors appointed by the Company pursuant to the terms of the Series A Shares. The Series A Shares represent an approximate
52% of the equity of Temple, on a fully diluted basis.
Under
the Recapitalization Agreement the Company will provide working capital to Temple in the amount of not less than $150,000 but
up to $250,000. The Company will acquire additional equity ownership of Temple for this investment based on a valuation of Temple
of $1,000,000. This further investment will increase the controlling position of the Company in combination with its ownership
of the Series A Shares.
The
Temple warrant is exercisable for the greater of 1,493,735 shares of common stock of Temple or 2.5% of the equity of Temple on
a fully diluted basis. The exercise price per share is the par value of the common stock to be acquired upon exercise of the Temple
warrant. The exercise period is ten years, but not later than the earlier of the consummation of the initial public offering by
Temple or a sale transaction of Temple, as defined in the Warrant. The Temple warrant has a cashless conversion right and has
typical anti-dilution rights for dividends, reverse splits and changes in the capitalization of Temple.
On
July 19, 2019, the board of directors of the Company appointed Mr. Paul Bartley as the Chief Executive Officer of the Company
and appointed him to be a director of the Company, filling one of the existing vacancies on the Board of Directors. On June 30,
2019, the Company lent to Share International Holding B.V. a company of which Mr. Bartley is a principal, the sum $250,000 under
a promissory note, due January 4, 2020. The note bears interest at the rate of 10%. SIH requested the loan to finance the costs
relating to the conclusion of the merger such as extensive travel, third party consultancy fees and legal costs. Natur International
Corp. was willing to provide the loan pending the outcome of the merger discussions.
The
repayment obligation under the note will be cancelled if no business arrangement is concluded due to a breach by the Company of
any agreement for the business arrangement that is concluded in the future, either party to the note experiences a material adverse
change, or the business arrangement is not approved by the shareholders or owners of the respective parties to the extent that
approval is required. The note also has other standard default provisions under which the Company may declare a default.
On
July 29, 2019, $639,784 of an outstanding loan facility in the principle amount of $581,058 or €500,000 plus accrued interest,
at an interest rate of 10% per annum, was converted to common stock of the company. On this date the debt was converted and 11,632,445
of common stock was issued to the borrower.
NATUR
INTERNATIONAL CORP.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
15 – RECAPITALIZATION
As
discussed in Note 1 – Organization and nature of business, effective November 13, 2018, Future Healthcare of America entered
into a reverse capitalization transaction with Natur Holding B.V. In conjunction with the transaction the Company was recapitalized,
resulting in the capital structure outlined below. The main purpose of the transaction was to raise additional capital for the
purposes of growth. The historical number of common shares of Nature Holding B.V. presented in our financial statements were converted
to post-acquisition shares on a 1 to 112 basis.
The
following shares of common stock were issued in connection with the reverse capitalization transaction. Natur shareholders had
a controlling voting percentage of 94% subsequent to the transaction:
-
|
115,759,999 shares of common stock were issued
to the Natur shareholders.
|
-
|
2,023,562 shares of common stock were issued
to two of the former management of the Company for their cancellation and release of accrued salaries
|
-
|
2,469,131 shares of Series A Preferred Stock
were issued for a cash capital investment of $2,000,000 and debt forgiveness of $469,131. The shares of Series A Preferred
Stock will convert at a ratio of 1 share to 33,000 common shares.
|
-
|
100,000 shares of Series B Preferred Stock were
issued to the Natur Holding B.V. shareholders. These shares convert at a ratio of 1 share to 1,000 common shares.
|
NOTE
16 – STOCKHOLDERS’ DEFICIT
On
November 13, 2018, Future Healthcare of America completed a transactions pursuant to the Share Exchange Agreement discussed in
Note 1. In connection with the Share Exchange Transaction, the Company issued the equivalent of 215,759,999 shares of the Common
Stock to the former shareholders of Nature Holding B.V., which was issued in part as 115,760,000 shares of Common Stock and in
part as 100,000 shares of voting, convertible Series B Preferred Stock (the “Series B Preferred Stock”) representing
100,000,000 shares of Common Stock upon conversion. The Series B Preferred Stock converted automatically into the Common Stock
on June 26, 2019, when the Company increased its authorized capital in sufficient amount to permit the conversion of the Series
B Preferred Stock. At closing the number of common shares, issued and outstanding was 322,230,038. Per the OTC listing the
shares were officially converted on the July 2, 2019.
On
September 21, 2018, Parent Company also executed a Securities Purchase Agreement (the “SPA”) by which it agreed to
privately issue and sell to Alpha Capital Anstalt (the “Alpha”) 2,469.131 shares of non-voting, convertible Series
A Preferred Stock, each share convertible into approximately 33,000 shares of Common Stock, based on a per common share conversion
rate of $.030303. Alpha also purchased two warrants, one pursuant to the SPA that is exercisable for 33,000,000 shares of Common
Stock at $.060606 per share and another one pursuant to a debt cancellation agreement exercisable for 6,000,000 shares of Common
Stock at $.15 per share. The aggregate purchase price for the Series A Preferred Stock and the warrant for 33,333,000 shares of
common stock was $2,000,000 in cash and conversion of $469,131 of outstanding debt. The other warrant was issued for conversion
of outstanding interest due Alpha under a prior loan agreement to Future Healthcare of America. Prior to the acquisition of Natur
Holding, B.V., Alpha also had cancelled approximately $651,000 of debt principle and interest due from the Company. These transactions
eliminated $1,420,000 of debt principle and interest of the Company and improved its balance sheet. As part of the SPA transaction,
Alpha has also agreed to reimburse up to $100,000 of the liabilities of Parent Company existing at the closing date, which has
not yet been paid.
On
March 19, 2019, the holder of the Series A Preferred Stock converted 72 of such shares with a stated value of $72,000 for 2,376,002
shares of common stock. The applicable conversion price per common share was $0.030303. The Company did not receive any payment
on this conversion, having received the consideration for the Series A Preferred Shares on November 12, 2018. There are remaining
an aggregate of 2,397.131 shares of Series A Preferred Stock issued and outstanding. The shares of common stock issued on conversion
are registered for resale by the holder.
On
April 4, 2019, the Company filed an Articles of Amendment in the State of Wyoming to create a new class of Series C Preferred
Stock, which was returned as of April 9, 2019. The Series C Preferred Stock was converted into 78,832,399 shares of Common Stock
on June 26, 2019. Per the OTC listing the shares were officially converted on the July 2, 2019.
In
June 2019, the Company has entered into a series of agreements under which it will be required to issue the following different
series of preferred stock, subject to certain conditions precedent.
|
●
|
Series Preferred Stock D: 15,789.473 preferred
shares, conversion to common shares at a ratio of 1:1,000. price per share of $31.70, no voting rights and a warrant reflecting
the right to buy 20,000,000 shares at an exercise price of $0.06
|
|
●
|
Series Preferred Stock E: 56,443.551 preferred
shares, conversion to common shares at a ratio of 1:1,000, price per share of $30,40, no voting rights and a warrant reflecting
the right to buy 56,443,551 shares at an exercise price of $0.0304
|
|
●
|
Series Preferred Sock F: 49,342.105 preferred
shares, conversion to common shares at a ratio of 1:1,000, price per share $0.0304, registration rights, and warrant reflecting
the right to buy 740,130,158 shares at an exercise price of $0.0304.
|
|
●
|
Series Preferred Sock G: 46,947.368 preferred
shares, conversion to common shares at a ratio of 1:1,000, price per share of $0.038, registration rights and a warrant reflecting
the right to buy 46,947,368 shares at an exercise price of $0.076.
|
F-39
Natur (CE) (USOTC:NTRU)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Natur (CE) (USOTC:NTRU)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025